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Abstract 
 
Background 
Biomarkers are powerful tools for interrogating the basic science of disease processes, in the clinical 
detection of disease states, and as both targets and endpoints in therapeutic strategy. Amyloid beta 
(Aβ) is a core biomarker for Alzheimer’s disease (AD), but measurement variation between sites and 
experiments limits its potential. Furthermore, although the role of brain Aβ accumulation early in AD 
is extremely well attested, the biological mechanisms underlying this remain poorly understood. 
 
Methods 
To contribute to the development of treatments for AD patients and those at risk, this thesis set out 
to identify important pre-analytical confounding factors in Aβ measurement, strategies to mitigate 
them, and identify disease relevant patterns of Aβ peptide production in human CSF and an induced 
pluripotent stem cell-derived cortical neuron model of familial AD (fAD).  
 
Results 
A series of experiments demonstrated the importance of sample surface exposure to the 
measurement of Aβ peptides and tau. The volume at which samples are stored and iterative contact 
with fresh surfaces had profound effect on Aβ, but not tau, with greater surface exposure resulting 
in depletion of Aβ concentration. The mechanism was demonstrated to be protein surface 
adsorption. Importantly, the different Aβ peptides did not absorb to polypropylene to the same 
extent; Aβ42 concentration decreased proportionally more with surface exposure treatment than 
Aβ40 and Aβ38.  
 
It was observed that the addition of a non-ionic surfactant (Tween 20) to samples significantly 
mitigated the effect of surface exposure treatments on Aβ peptides and tau. However, the use of 
this additive did not meaningfully improve variability when sample storage conditions were 
standardised. Furthermore, variances in clinic to laboratory temperature and time interval did not 
significantly affect Aβ or tau concentration. 
 
Validation of an in vitro model of fAD was conducted. Experiment identified the use of Aβ ratios as a 
robust method for normalising data variability between and within cell lines over extended time 
periods. Furthermore, comparison of paired CSF, cell media, cell lysates, and post-mortem cortical 
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tissue from the same individual demonstrated physiologically consistent patterns of Aβ ratios across 
sample types. 
Finally, comparison of multiple fAD mutation and control cell lines demonstrated quantitative and 
qualitative differences in secreted Aβ. APP V717I neurons increased secretion of Aβ42 and Aβ38 
relative to Aβ43 and Aβ40. PSEN1 mutations increased secretion of longer Aβ peptides relative to 
shorter Aβ peptides, with mutation specific differences such as greatly increased Aβ43 in PSEN1 
R278I.   
 
Conclusions 
This work demonstrated several novel considerations in the use of Aβ peptides as biomarkers for 
AD. Data principally highlight the importance of Aβ ratios to AD biomarker research, the necessity of 
controlling pre-analytical sample surface exposure intended for the measurement of ‘sticky’ protein 
biomarkers such as Aβ peptides, and the validity of iPSC-derived neuronal models for exploring the 
production of Aβ in AD and health. 
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Impact statement 
This work formed part of an ongoing movement to improve the quality and reliability of biomarker 
data in the field of Alzheimer’s research. Contribution was to two main areas: the effect of sample 
surface exposure on the Aβ content of CSF, and the production of Aβ peptides in fAD patient 
neurons. Concerning the former, experiments identified and characterised a number of previously 
under-appreciated aspects of CSF and cell media storage and handling (storage volume, consecutive 
aliquoting, the effect of using a manometer), which inspired investigations by other groups and 
contributed to proposals for “gold standard” CSF collection protocols. Furthermore, data highlighted 
the potential of sample additives (Tween 20) to mitigate surface adsorption of vulnerable proteins 
such as Aβ peptides. This generated a certain amount of interest from ELISA manufacturing 
companies. Concerning Aβ production in vitro, different fAD genotypes were shown to produce 
distinct ratios of Aβ peptides, supporting a growing understanding of APP proteolysis mechanisms 
that will inform understanding of past drug failure and future drug development. Additionally, the 
notion of Aβ as a biomarker was expanded with presentation of the concept of Aβ peptide ratios as 
biomarkers for γ-secretase activity. This thesis also represents one of only two studies to compare 
iPSC-derived neurons with tissues from the same individual, in this case brain tissue homogenate 
and CSF in an individual with an APP V717I mutation. Finally, work culminated in six original 
publications to Clinical Chemistry and Laboratory Medicine, Alzheimer’s & Dementia, Alzheimer’s 
Research & Therapy, and the Journal of Alzheimer’s disease, with a seventh under revision at 
Molecular Psychiatry. 
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1 Background 
 
1.1 Project Aims 
The aim of this work is to expand understanding of Alzheimer’s disease (AD) through improved 
characterisation of amyloid beta (Aβ) peptide as a biomarker for the disease. Work was conducted in 
two phases – the first providing data to help guide standardisation strategies in a diagnostic context, 
and the second exploring production in in vitro cell models to better understand what Aβ is a 
biomarker of. 
 
The specific aims of this project are: 
I. Identify novel confounding factors in the storage and handling of CSF and cell culture media 
that may artificially alter detectable Aβ peptides. Factors studied include: 
 Effect of sample storage volume,  
 Effect of sample transfer between tubes, 
 Effect of Tween 20 on sample measurement variation, 
 Effect of using a spinal manometer, 
 Effect of sample transportation time and temperature in clinical context, 
II. Investigate the physiological relevance of iPSC-neurons by comparing A peptide profiles in 
cell culture, CSF, and brain homogenate from a single patient with the APP V717I mutation. 
III. Investigate the full spectrum of A peptides produced by glutamatergic cortical neurons 
from six different fAD lines (APP V717I, PSEN1 int4del, PSEN1 Y115H, PSEN1 M139V, PSEN1 
M146I, and PSEN1 R278I) and five non-neurodegenerative controls. 
 
1.2 Alzheimer’s disease research in context 
On the 3rd of November 1906, Aloysius ‘Alois’ Alzheimer described a “peculiar severe disease 
process of the cerebral cortex” to the 37th meeting of the Southwest German Psychiatrists in 
Tübingen (Alzheimer, 1907). His work highlighted the presence of insoluble extracellular and 
intracellular proteinaceous deposits in the brain of his patient, Auguste Deter, who displayed 
symptoms of dementia. The condition was later coined ‘Alzheimer’s disease’ by Alzheimer’s 
distinguished employer, Emil Kraepelin, in the eighth edition of Psychiatrie 1910 (Hippius and 
Neundörfer, 2003). AD received, at best, modest attention until 1976, when Robert Katzman 
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catapulted it onto the mainstream medical radar by arguing the equivalence of AD and ‘senile 
dementia’ and identified the disease process as a leading cause of death in the USA (Katzman, 1976). 
 
In 1984 Glenner and Wong identified Aβ from cerebro-vascular amyloid fibril deposits using 
Sephadex G-100 column chromatography and high performance liquid chromatography  (Glenner 
and Wong, 1984a). Work by Masters and colleagues in 1985 confirmed Aβ, in particular Aβ1-42 
peptide, as the major constituent of Alzheimer’s extracellular plaques, and furthermore that the 
protein is prone to self-aggregate into oligomer and fibrillary complexes (Masters et al., 1985). The 
gene encoding the amyloid precursor protein (APP) was first identified by the independent efforts of 
Kang et al. and Tanzi et al. in 1987 (Kang et al., 1987; Tanzi et al., 1987), through genetic linkage 
mapping of Aβ to the APP gene located at 21q21.3. Tau had been identified as the primary protein 
constituting intra-cellular tangles in 1986 (Wood et al., 1986).  
 
A milestone that placed genetics close the pulse of ongoing AD research came in 1991, when Goate 
et al. identified a valine to isoleucine point mutation near the C-terminal of the APP gene (APP V717I, 
the London mutation) in families from the UK and USA (Goate et al., 1991). Fitting the pieces of the 
puzzle together, in 1992 Hardy and Higgins proposed the ‘amyloid cascade hypothesis’, stipulating 
that Aβ accumulation is the driving factor of subsequent pathological processes and which remains 
the dominant theory of AD biology to the current time (Hardy and Higgins, 1992). Sherrington et al. 
quickly followed this up by identifying the link between AD and presenilin mutations in 1995 
(Sherrington et al., 1995), a year which also saw the generation of the first transgenic mouse model 
(Games et al., 1995). Alongside the discovery of high penetrance autosomal dominant mutations, 
work had also begun highlighting the role of genetic risk factors, such as the APOE-e4 allele (Corder 
et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993). By the 2010s technological 
sophistication and international collaborations had enabled sequencing of large cohorts and meta-
analysis of genome wide association studies (GWAS) led to the identification of AD-genic TREM2 
mutations (Guerreiro et al., 2013) and 21 risk factor genes (Van Cauwenberghe et al., 2016; Naj and 
Schellenberg, 2017)  
 
Despite increasing energy for AD research, output from the field in terms of therapeutics has been 
noticeably low. Memantine was approved for AD treatment in Germany in 1989, and in 1993 tacrine 
became the first FDA approved drug for AD, although it was discontinued in 2013 due to safety 
concerns (liver toxicity). Four more drugs, all targeting aspects of the cholinergic system (after the 
first hypothesis of AD aetiology), were approved over next decade (Table 1). A combination of 
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donepezil and memantine has been the only ‘new’ therapy approved since 2003, out of the 188 
phase III trials currently listed as suspended, terminated, completed, or withdrawn on 
clinicaltrials.gov (National Institute of Health, 2018).  
 
Table 1: List of FDA approved AD therapeutics 
Drug Developer Type 
Date 
Approved 
Approved 
for 
Reference 
Donepezil 
hydrochloride 
(Aricept) 
Eisai/Pfizer 
Cholinesterase 
inhibitor 
1996 AD 
(Dooley and 
Lamb, 
2000) 
Galantamine 
(Razadyne) 
Jansen 
Cholinesterase 
inhibitor and allosteric 
potentiator of both 
nicotinic and 
muscarinic 
acetylcholine 
receptors 
2000 
Mild to 
moderate 
AD 
(Scott and 
Goa, 2000) 
Mementine 
(Akatinol) 
Forest 
Laboratories/Merz 
Pharma 
NMDAr antagonist 
2003 
(1989) 
AD 
(Robinson 
and 
Keating, 
2006) 
Rivastagmine 
(Exelon) 
Novartis 
Cholinesterase and 
butyrylcholinesterase 
inhibitor 
1997 
Mild to 
moderate 
AD 
(Birks et al., 
2015) 
Tacrine 
(Cognex) 
Pfizer, Shionogi 
Pharma 
Cholinesterase 
inhibitor 
1993-2013 Discontinued 
(Giacobini, 
1998) 
The need for better diagnostic accuracy and more detailed understanding of the underlying disease 
biology have been driving forces behind development of measurement techniques, with an emphasis 
on probing ever earlier into the disease course. The longstanding tradition of immunohistochemistry 
still utilises Congo red and thioflavin S to stain amyloid structures, alongside more modern antibody-
based techniques. Immunoassay has dominated quantitation of biofluid proteins, yielding 
increasingly sensitive approaches that presently culminate in the femtolitre detection ranges that 
hold promise for developing blood-based tests (Zetterberg et al., 2013). Beyond immunological 
methods, mass spectrometry has become increasingly accessible and utilised for screening large 
Table 1: Showing information for the five small molecule drugs that have been approved for the treatment of AD. 
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numbers of proteins without necessarily requiring antibody development. However, techniques 
aimed at exploring protein conformation (qualitative) rather than concentration (quantitative) 
remain relatively underdeveloped. Finally, brain imaging has undergone rapid growth with the 
adoption of computer tomography (CT), magnetic resonance imaging (MRI) and positron emission 
tomography (PET). The development of Pittsburgh Compound B in 2004 in particular has had 
considerable impact on this area (Klunk et al., 2004).  
 
In summary, over the last 100 years AD has moved from relative obscurity to a centre-stage world 
health crisis. Research into the proteomic and genetic biology of the disease snowballed in the latter 
decades of the 20th century, but translating these gains to clinical therapeutics has proved 
frustratingly difficult. The field awaits a breakthrough, and the amyloid cascade hypothesis is yet to 
be conclusively vindicated.  
 
1.3 Alzheimer’s disease 
AD is a progressive neurodegenerative disease, characterised histologically by extra-cellular plaques 
(primarily composed of aggregated Aβ peptides) and intra-cellular neurofibrillary tangles (primarily 
of aggregated, hyper-phosphorylated tau), alongside atrophy of the cortex (Perl, 2010). Clinically, AD 
presents as insidious loss of cognitive function, progressive impairment of memory encoding and 
recall, and the attendant inability to maintain an independent lifestyle (Burns and Iliffe, 2009). 
Diagnosis of AD is dependent on histological identification of Aβ and tau deposition post-mortem, in 
the context of symptoms having been clinically documented in life (McKhann et al., 2011). Though 
histopathology is seen as the ‘gold standard’ in AD diagnosis, and not without dispute (Scheltens and 
Rockwood, 2011), biological assay and imaging techniques are becoming increasingly powerful tools 
in clinical diagnostics and predictive diagnosis (Dubois et al., 2014).  
 
Various models of AD aetiology have been proposed (Table 2), though the cause is ultimately 
unknown. The leading theory, formalised as the ‘amyloid cascade hypothesis’, posits that Aβ 
accumulation in the brain following dysregulated production and/or clearance is the trigger for 
neurodegenerative changes that lead to AD (Hardy, 2006, 2009; Hardy and Higgins, 1992). 
Alterations in production, clearance and deposition of Aβ, as well as other proteins such as tau, over 
time become consequential at a cellular and eventually systemic level.  
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Table 2: Alternative hypotheses for AD genesis 
Hypothesis Description Key References 
Amyloid cascade 
hypothesis 
Aβ dyshomeostasis in the brain leads to the retention of Aβ in the brain and formation 
of amyloid structures that disrupt many aspects of brain physiology. Cascading effects 
of this cause neurodegeneration and eventually manifest as AD 
Original: (Hardy and 
Allsop, 1991) 
Update: (Selkoe and 
Hardy, 2016) 
 
Calcium homeostasis 
hypothesis 
Proposes that there is a bidirectional relationship between Ca2+ signalling and the 
amyloidogenic pathway. A dyshomeostasis can disrupt Ca2+ signalling, which in turn 
can promote amyloidogenic APP metabolism. 
Original: 
(Khachaturian, 1989) 
Updates: (Berridge, 
2010; LaFerla, 2002) 
Cholinergic hypothesis 
The clinical manifestations of AD are driven by the downregulation of cholinergic 
markers, such as acetyltransferase and acetylcholinesterase, and loss of cholinergic 
neurons in the basal forebrain (nucleus basalis of Meynert, and medial septum), 
hippocampus, frontal cortex, and amygdala 
Original: (Bartus et 
al., 1982) 
Updates: (Craig et al., 
2011; Sanabria-Castro 
et al., 2017) 
GM1 ganglioside 
hypothesis 
A peptides bind to the surface bound GM1 ganglioside. Binding at Lys28 results in 
conformational changes in the C-terminal region that expose the hydrophobic domain 
and readily recruit other amyloid beta peptides in a beta sheet. This forms the seed for 
fibril formation 
Original: (Yanagisawa 
et al., 1995) 
Update: (Yanagisawa, 
2015) 
Infection hypothesis 
The majority of people who reach old age are infected with HSV-1. Compromise of the 
immune system by aging processes, stress etc. can assist the spread of this virus to the 
brain. This can occur through the olfactory system, which is among the first to fail in a 
number of neurodegenerative conditions including AD. Here it triggers 
neuroinflammation and plaque deposition, and HSV-1 DNA has been found in amyloid 
plaques. Other microorganisms such as CMV, HIV, measles, spirochaete, and Chlamydia 
pneumonia have also been implicated, as well as prion-like proteins. 
Original: (Itzhaki et 
al., 2016) 
Update: (Fulop et al., 
2018) 
Inflammatory 
hypothesis 
Degeneration of the blood–brain barrier and decreased cerebral blood flow disrupt 
energy metabolism, facilitate protein misfolding, oxidative stress and inflammation, 
leading to neurodegeneration that eventually manifests as AD. Inflammation is the 
triggering factor as the limited neurotoxicity of Aβ is exacerbated by the activation of 
the complement system. 
Original: (Rogers et 
al., 1992) 
Update: (McGeer and 
McGeer, 2013)  
Lipid metabolism 
hypothesis 
Abnormal lipid synthesis, modification, trafficking, and degradation leads to altered Aβ 
production, synaptic dysfunction, abnormal tau phosphorylation, and inflammation. 
Cascading effects of this eventually manifest as AD 
Original: (Liu and 
Zhang, 2014)  
Update: (Drolle et al., 
2017) 
Metal hypothesis 
Aβ is central to Alzheimer’s disease pathobiology, but neurotoxicity is driven by 
interaction with Zn2+ and Cu2+ metal ions. Zn and Cu bind to the Aβ 6-14aa domain and 
catalyse rapid aggregation proximal to synapses, reducing NMDA receptor activity. It is 
suggested that increased concentrations of Zn2+ and Cu2+ and/or decreased 
antagonists such as metallothionein-3 are found in the AD and Down’s syndrome brain. 
Cascading effects of this cause neurodegeneration and eventually manifest as AD 
Original: (Armstrong 
et al., 1995; Bush et 
al., 1994) 
Updates: (Bush and 
Tanzi, 2008; Craddock 
et al., 2012) 
Oxidative stress 
hypothesis 
AD is caused by free radical damage to neurons, glia and mitochondria from various 
sources. Damage to tissue creates a cycle of free radical production that eventually 
overwhelms the body’s antioxidant reservoir 
Original: (Markesbery, 
1997) 
Updates: (Nunomura 
et al., 2001; Zhao and 
Zhao, 2013) 
Tau hypothesis 
Excessive or abnormal phosphorylation of tau results in formation of PHFs and NFTs, 
destabilising microtubules and disrupting cellular processes. Misfolded tau spreads 
through neural networks in a prion-like manner. Cascading effects of this cause 
neurodegeneration and eventually manifest as AD 
Original: (Mudher and 
Lovestone, 2002) 
Update: (Kametani 
and Hasegawa, 2018) 
Traumatic brain injury 
(TBI) hypothesis 
Brain trauma, caused by external force applied to the head in a variety of activities or 
accidents, can result in acute and potentially chronic death of neurons and glia, 
elevated protein (Aβ, tau, α-synuclein) concentrations, inflammation, damage to 
cerebral vasculature, as well as persistent cognitive changes. TBI severity is suggested to 
associate with dementia risk in late-life, especially in males. 
Original: (Mortimer et 
al., 1985) 
 
Update: (Kokiko-
Cochran and Godbout, 
2018) 
Vascular hypothesis 
Aging and the presence of vascular risk factors create a Critically Attained Threshold of 
Cerebral Hypoperfusion (CATCH) that disrupt many aspects of brain physiology. 
Cascading effects of this cause neurodegeneration and eventually manifest as AD 
Original: (De la Torre 
and Mussivand, 1993) 
Update: (de la Torre, 
2010) 
Table 2: A list of the main hypotheses for the pathogenesis of AD 
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The key evidence supporting the amyloid cascade hypothesis is the fact that all known genetic 
mutations that produce heritable forms of AD affect Aβ production (Selkoe and Hardy, 2016). 
Additionally, many if not most genetic risk factors affect cellular mechanisms for responding to or 
clearing accumulation of Aβ in the brain (Van Cauwenberghe et al., 2016). Furthermore, changes in 
Aβ clearance to CSF is the earliest and among the most reliable indicators of AD (Jack et al., 2013). 
That extensive Aβ plaque pathology is among the most consistent features of AD is also relevant, 
though arguably weaker evidence given the circular nature of typical AD diagnosis requiring plaque 
pathology, the fact that a-symptomatic individuals also demonstrate plaque deposition, and that 
plaque number does not correlate well with symptom severity (Sperling et al., 2009).  
 
The differences between the various hypotheses for AD are yet to be fully reconciled. It may be that 
the brain is limited in the ways in which it can respond to damage from unrelated causes. It may also 
be that the common, emergent themes of aberrant protein production / localisation / folding / 
clearance, excitotoxicity, oxidative stress, energy hypometabolism, lipid dysregulation, vascular 
pathology, and inflammation are parallel and reciprocal processes. The disruption of one feeding 
back into others, and under certain conditions reaching a state conducive to AD. The weight of 
evidence suggests Aβ is likely to be integral to this state.  
 
Epidemiologically, AD is thought to be the most prevalent form of dementia (Katzman, 1976), 
accounting for 60-80% of all dementia cases (Alzheimer’s Association, 2016). Prevalence increases 
with age, rising from one in 14 at age 65 years to one in six at age 80 years (Prince et al., 2014), with 
females disproportionately affected over the age of 80 years (Prince et al., 2014). Approximately 
850,000 dementia cases have been reported in the UK, 5.3 million in the USA, and 46.8 million 
worldwide (Martin Prince et al., 2015). In 2016 the UK Office for National Statistics announced AD as 
among the leading cause of death in England and Wales (Office for National Statistics, 2016), and it 
was recorded as the fifth leading cause of death (with other dementias) globally (World Health 
Organisation, 2016). Projections of the number of people affected by mid-century approximate 
131.5 million (Martin Prince et al., 2015). Persistent data suggests that incidence of new dementia 
cases has been falling each decade in Western Europe and the USA since the 1990s (Matthews et al., 
2013; Satizabal et al., 2016; Schrijvers et al., 2012) attributed cautiously to broad changes in lifestyle. 
However, prevalence is a balance of incidence and disease duration, the latter of which may increase 
as lifestyle and care improve (Prince et al., 2016). Additionally, trends in low and middle income 
areas, thought to contribute more than half of cases (Martin Prince et al., 2015), are yet unclear.  
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The combination of increased lifespan with an attendant decrease in autonomous capacity already 
constitutes a heavy social and economic burden in developed countries, and increasingly in low and 
middle income countries. Without substantial changes to therapeutic effectiveness and organisation 
of care, AD and dementia will be a limiting factor on global quality of life with mathematical 
inevitability. 
 
1.3.1 Alzheimer’s disease: Subcategories 
AD has been an intractable problem in neuroscience for the past century, and a considerable 
hindrance to its solvation is the heterogeneity of its manifestation. Familial AD (fAD) describes cases 
where manifestation of pathology can be linked to a heritable genetic mutation, most commonly in 
the amyloid beta precursor protein gene (APP, also known as A4) (Julia and Goate, 2017), presenilin-
1 (PSEN1) and presenilin-2 (PSEN2) genes (Cai et al., 2015; Kelleher and Shen, 2017), and triggering 
receptor expressed on myeloid cells 2 gene (TREM2) (Guerreiro et al., 2013). AD-like pathology also 
frequently accompanies the chromosomal disorder trisomy 21 (Down’s Syndrome) (Wiseman et al., 
2015). Sporadic AD (sAD) describes cases where a direct genetic cause cannot be determined, 
though genetic risk factors, for example apolipoprotein E (APOE) allele, may be present (reviewed in 
(Van Cauwenberghe et al., 2016)).  
 
AD may also be subcategorised into early onset (EOAD) and late onset (LOAD) (Naj and Schellenberg, 
2017). These categories are not different forms of AD, but describe whether the clinical symptoms 
manifest before or after 65 years of age. The distinction is largely a clinical convention, as certain 
patterns of AD progression have become associated with one or the other. For example, EOAD is 
more often associated with more aggressive pathology and atypical symptoms whilst LOAD more 
frequently presents alongside other age-related comorbidities (Van der Flier, 2016). Furthermore, 
there is considerable overlap with fAD and sAD. Typically, fAD cases have earlier age of onset than 
sAD cases. For example, no (pathological) APP mutation carrier has yet been reported unaffected 
beyond the age of 67 years (Holmes, 2002). Based on the strong link between fAD and EOAD, which 
account for 0.3-0.5% of all AD cases (Rocca et al., 1991), it is considered that sAD accounts for ~99% 
of cases.   
 
fAD and sAD both manifest with considerable heterogeneity in the phenotypic expression of 
cognitive features (Lam et al., 2013), non-cognitive features (Masters et al., 2015), age at disease 
onset (Tellechea et al., 2018), disease duration and rate of progression (Komarova and Thalhauser, 
2011), as well as distributions and conformations of pathologically misfolded protein and regions of 
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cortical atrophy (Lam et al., 2013). Grouping AD cases into typical and atypical forms provides some 
structure to this diversity, though comorbidities (Cermakova et al., 2015; Clodomiro et al., 2013; 
Duthie et al., 2011), pathological changes beyond the classic amyloid plaque and neurofibrillary 
tangle formations (Crutch et al., 2012; Dzamba et al., 2016; Jaunmuktane et al., 2015; Smith and 
Greenberg, 2009; Winkler et al., 2014), and fundamental gaps in our understanding of brain 
physiology make classification a matter of ongoing discussion. 
 
Typical or ‘memory-led’ AD begins with amyloid deposition in the basal temporal lobes and 
associative neocortex (Grothe et al., 2017; Thal et al., 2002). Individuals present with early mild 
episodic memory (autobiographical) and spatial (navigational) impairment, often with attendant 
confusion and anxiety. Deficits are subtle and overlap with the prodromal symptoms of other 
conditions of the central nervous system (CNS). Thus, a diagnosis of mild cognitive impairment (MCI) 
is commonly made at this stage (Albert et al., 2011; Petersen et al., 1999). As the disease progresses, 
amyloid deposits in the striatum and sub-cortical regions (Grothe et al., 2017; Thal et al., 2002), and 
tau accumulates in the neurons of the transentorhinal cortex, later spreading to the hippocampus 
and basal forebrain (Braak et al., 2006). Progressive impairment to recall, navigation, orientation, 
timekeeping, numeracy, spelling, linguistic abilities, and problem-solving gradually manifest. In the 
final stages, Aβ and tau pathology incorporate the hind brain and neocortex, and atrophy of the 
hippocampus and cortex is typically profound (Braak et al., 2006; Grothe et al., 2017; Thal et al., 
2002). The individual’s symptoms are often broadly incapacitating, with greatly reduced mobility, 
coordination, excretion control, and capacity for communication, eventually requiring full-time care. 
Individuals become increasingly susceptible to secondary infection, with aspirational pneumonia due 
to swallowing difficulties being the leading cause of death in severe cases, and heart disease and 
stroke in less severe or vascular associated cases (Kammoun et al., 2000; Kukull et al., 1994).  
 
Atypical AD variants are neurodegenerative conditions that share the same core pathology as typical 
AD (Aβ and tau accumulation), but differ in lesion distribution, neuron cell type loss, neuronal 
network disruption, and dominant symptoms (i.e. non-amnestic). Atypical variants are estimated to 
account for 6-14% of AD cases (Dubois et al., 2014). The most common variants are characterised by 
visual/biparietal posterior cortical atrophy (PCA) (Benson et al., 1988; Crutch et al., 2012)), linguistic 
logopenic variant primary aphasia (LPA) (Gorno-Tempini et al., 2011), and behavioural/dysexecutive 
(frontal) features (Ossenkoppele et al., 2015). Although prevalence of atypical cases is low, they are 
enriched in EOAD (Koedam et al., 2010; Paterson et al., 2015; Tellechea et al., 2018) and among 
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certain risk genotypes (e.g. APOE-ε4/ε4) (Balasa et al., 2011; Carrasquillo et al., 2014; Van Der Flier 
et al., 2006; Schott et al., 2006; Tellechea et al., 2018). 
 
Finally, it is important to acknowledge the role social environment and interpersonal relationships 
play in the clinical presentation and experience of affected individuals. Who a clinician sees, what 
disease stage they are at, what life-history is available, and capacity to engage with examination or 
respond to treatment will significantly colour diagnosis. There is some evidence to suggest that 
certain people are able to tolerate more AD-related pathology than others before reaching functional 
threshold, a concept known as cognitive reserve (Stern, 2012). Education level, occupational 
attainment, and stimulating leisure activities are associated with increase in this reserve (Stern, 
2012). Additionally, a supportive social network may compensate for declining capacities and mask 
the onset of symptoms that might be more recognisable in its absence. Alternatively, an attentive 
network may recognise symptoms earlier, or encourage an individual to seek medical attention 
earlier than one less connected. The size of social networks and quality of relationships are also likely 
to be meaningful in terms of co-prevalence with certain psychological features and comorbidities. By 
way of a simplistic example, AD is often associated with depression (Modrego, 2010) and 
cardiovascular disease (Stampfer, 2006). The extent to which such conditions influence, cause, or are 
caused by AD is unknown, but the role of an individual’s environment would seem relevant. 
 
In summary, Alzheimer’s disease is a complex neurodegenerative condition, with significant 
consequence to individual lives and global society. Biomarkers for the protein products of AD 
associated genes, downstream processes, and biological response to pharmacological and 
environmental factors represent powerful tools for disentangling this complexity. Better 
understanding of the role of Aβ in the disease process, and the accurate measurement of differences 
in Aβ profiles between cases, is crucial to the project of developing effective therapeutics. 
 
1.4 Amyloid beta biology 
This thesis concerns the study of Aβ peptides as biomarkers for AD. This section will discuss the 
current understanding of Aβ biology by introducing the substrate from which it is derived (APP), the 
enzymes which liberate A from APP, and then detail the properties of various A structures relevant 
to AD.  
 
First however, a brief overview of Aβ is desirable to set the scene. At the microscopic level, AD is 
characterised by the proteinaceous accumulations that Alzheimer first described. We now know the 
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“miliary foci” (amyloid plaques) he observed to consist primarily of aggregated Aβ (Masters et al., 
1985). Aβ exists as a series of low molecular weight peptides produced from the sequential cleavage 
of APP by a form of proteolysis known as secretase activity (De Strooper et al., 2010). Aβ peptides 
can be truncated both N- and C-terminally depending on the nature of secretase activity involved in 
their production, as well as by secondary degradation events (Saido and Leissring, 2012). These 
truncations are expressed as ‘Aβx-y’, where x is the number of the most N-terminal amino acid 
present, and y is the number of the most C-terminal amino acid present, relative to the Aβ domain 
sequence. For example, Aβ1-42 describes a peptide consisting of aspartic acid 1 through to alanine 
42 of the Aβ domain. This work will use the convention of only using the C-terminal amino acid when 
referring to peptides with an N-terminal beginning at aspartic acid 1 (e.g. Aβ1-42 becomes Aβ42). 
Peptides with N-terminal truncations will be directly specified.  
 
1.4.1 Amyloid Precursor Protein 
The genesis of Aβ peptides is a complex biological process involving the sequential cleavage of APP 
by an assortment of different enzymes. In order to properly engage with this process some 
discussion of APP is required. This section will introduce what is known of APP genetics, maturation, 
and function. 
 
1.4.1.1 Amyloid Precursor Protein Genetics 
APP is the pro-protein of which Aβ peptides are cleavage products. Mutations in or pertinent to the 
expression of the APP gene are among the most common causes of fAD and have formed the 
foundation for the present understanding of AD biology. There are currently 52 APP mutations that 
have been investigated in association with AD. Of these, 27 are pathogenic, 15 are not thought to be 
pathogenic, one is protective, and nine have uncertain pathogenicity (ALZFORUM, 2019a). 
Additionally, eight APP mutations have been linked to cerebral amyloid angiopathy (CAA). Of these 
six are pathogenic, one is not pathogenic, and one has unclear pathogenicity (ALZFORUM, 2019a). 
Finally, AD-like pathology with early onset is prevalent in Down’s syndrome (Glenner and Wong, 
1984b). Down’s syndrome is the result of a full or partial triplication in chromosome 21, the 
chromosome on which APP is located (Wilcock and Griffin, 2013). Compellingly, the few known cases 
where partial triplication of chromosome 21 did not include the APP gene did not develop AD for as 
long as they were observed (Doran et al., 2017; Wiseman et al., 2018). 
 
APP protein is one of a family of type I transmembrane glycoprotein homologues (Table 3) (Shariati 
and De Strooper, 2013). Only APP contains the Aβ domain. Evolutionarily, the APP gene is thought to 
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have emerged with the earliest functioning synapses (Shariati and De Strooper, 2013) and lipoprotein 
receptors (Dieckmann et al., 2010).  
 
 
1.4.1.2 Amyloid Precursor Protein Isoforms 
 
 
 
 
APP is located on chromosome 21 (21q21.3) and consists of 19 exons. The Aβ domain is encoded by 
exons 16 and 17 (Yoshikai et al., 1990). APP mRNA is found expressed in all human tissues, with 
Table 3: Amyloid precursor protein homologues 
Protein Documented Species 
APP H. sapiens, P. troglodytes, C. lupus familiaris, M. musculus, G. gallus, D. reiro, X. laevis 
APLP-1 H. sapiens, P. troglodytes, C. lupus familiaris, M. musculus, D. reiro, X. laevis 
APLP-2 H. sapiens, P. troglodytes, C. lupus familiaris, M. musculus, G. gallus, D. reiro, X. laevis 
APPL D. melanogaster 
ALP-1 C. elegans 
Table 3: Listing the homologue proteins for amyloid precursor protein and the species they have been observed in.  
Figure 1: Diagram depicting the structure of the three major isoforms of APP.   
Figure 1: APP primary structure 
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protein expression recorded in the cerebral cortex, hippocampus, caudate, cerebellum, appendix, 
gallbladder, pancreas, duodenum, colon, rectum, testis, prostate, epididymis, seminal vesicle, breast, 
endometrium, and placenta (The Human Protein Atlas, 2019). Humans produce eight canonical 
isoforms of APP, with permutations based on the alternative splicing of exons 7, 8, and 15: APP770, L-
APP752, APP751, L-APP733, APP714, L-APP696, APP695, L-APP677. APP isoforms lacking exon 15 were first 
identified in peripheral leukocytes and are designated L-APP (Sandbrink et al., 1994). A number of 
other APP isoforms have been reported, but are rare and poorly documented: APP639 (Tang et al., 
2003), APP563 (Perry et al., 1988), APP365 (Jacobsen et al., 1991), and APP305 (Chen et al., 2013)).  
 
Of the known isoforms, APP770, APP751, and APP695 are most prevalent (Figure 1). APP695 is the major 
isoform expressed by neurons (Nalivaeva and Turner, 2013; O’Brien and Wong, 2012; Puig and 
Combs, 2013; Sandbrink et al., 1996a; Tanaka et al., 1988), where mRNAs are reported to 
approximate a ratio of APP770/APP751/APP695 = 1:10:20 (Nalivaeva and Turner, 2013). Regional 
variation exists and APP695 is reported highest in the cerebral cortex, hippocampus, and areas 
proximal to the lateral ventricle (Golde et al., 1990). APP770/APP751/APP695 are expressed at a ratio of 
4:4:1 in HeLa cells (Golde et al., 1990) and APP770 and APP751 are also the primary forms expressed in 
glia (Matsui et al., 2007; De Silva et al., 1997; Simons et al., 1996). APP770 is sequentially similar to 
APLP-2, whilst APP695 is sequentially similar to APLP-1 as both lack the KPI domain (Nalivaeva and 
Turner, 2013). It may be that this contributes to the apparent functional redundancy between the 
protein homologues.  
 
1.4.1.3 Amyloid Precursor Protein translation and transport 
Diagrams of APP processing invariably show APP bisecting generic lipid bilayer, which students of 
neuroscience are guided to assume is the cell plasma membrane. Unfortunately, the dynamics of Aβ 
biology are nothing so simple. Integral to an understanding of Aβ production is an appreciation of 
where it is produced. Furthermore one of the most heated areas of discussion centres on the 
pathophysiological relevance of intracellular verses extra-cellular Aβ and how it gets to the 
respective location (Figure 2). Therefore, this section will outline the maturation and trafficking of 
APP and Aβ within a cell.  
 
In both polarised and non-polarised cells, APP is synthesised in the endoplasmic reticulum (ER), 
where it is folded, N-glycosylated, and may potentially be proteolysed by secretase activity during ER 
stress (Plácido et al., 2014), with implications for intracellular Aβ accumulation. From there APP can 
follow a constitutive secretion pathway through the golgi apparatus, where post-translational 
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modifications such as O- and N-link glycosylation, sialylation, phosphorylation, tyrosine motif 
sulphonation, and chondroitin sulfate/dermatan sulfate glycosaminoglycanation are applied (Kins et 
al., 2006; Plácido et al., 2014).  
 
 
 
 
Alternatively, overexpression models suggest some portion of APP may also be localised to 
mitochondrial associate membranes (MAM) of the ER (Del Prete et al., 2017). MAM are intracellular 
lipid-raft-like structures involved in mitochondrial lipid metabolism and Ca2+ homeostasis, and which 
constitute major sites of γ-secretase activity (Area-Gomez and Schon, 2016). Some study has been 
made of the localisation patterns of different APP isoforms. APP695 has been shown to possess 
different affinities for particular compartments compared to APP770 and APP751, such as the ER over 
the Golgi in circumstances of ER stress (Plácido et al., 2014), and the endosomal system versus the 
plasma membrane in the secretory pathway (Ben Khalifa et al., 2012). However, these experiments 
were conducted primarily in non-neuronal cell models, and it will be recalled that isoform expression 
Figure 2: APP is synthesised in the endoplasmic reticulum (ER) and transported to the Golgi network. From there it is rapidly 
trafficked to the cell plasma membrane. Recycling from the plasma membrane is facilitated by lipid rafts and clathrin mediated 
endocytosis. At the plasma membrane APP can be cleaved by non-amyloidogenic α-secretase activity (ADAM10). Alternatively, 
amyloidogenic cleavage can occur by β-secretase activity (BACE1) and then γ-secretase activity, which predominantly occurs in the 
early endosomes. From the endosome system, APP can be recycled to the Golgi and plasma membrane with the assistance of SORLA, 
or targeted to the lysosomes for degradation. Aβ peptides may also follow this pathway, or enter multivesicular bodies (MVBs) for 
exocytosis or degradation. Also depicted is tendency for Aβ to form aggregate structures (oligomers, fibrils, and plaques), and for 
these to bind to cell surface receptors, or be degraded by interstitial fluid enzymes. Full arrows represent well evidenced pathways, 
dashed arrows represent pathways for which there is less confidence.   
Figure 2: APP transportation and processing 
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patterns differ between cell types (i.e. APP695 is the predominant form in neurons) and so this data 
may have limited neurobiological relevance.   
 
To return to the secretory pathway, after maturation in the cis-Golgi APP enters the trans-Golgi 
network (TGN) and is sorted to different cellular destinations in coated vesicles. Work on HeLa cells 
has suggested adaptor protein complex 4 interacts with the C-terminal YKFFE sequence of APP to 
facilitate the recruitment of APP into certain of these transport vesicles (Burgos et al., 2010). The 
complexities of APP distribution are still dimly understood and much debated. Non-polarised and 
polarised cells (such as neurons) differ in the targeting and transport of APP to destination 
compartments. In neurons, anterograde axonal transport of APP occurs via kinesin-1-mediated fast 
transport. These vesicles move mono-directionally at speeds of up to 10μm/s (Kaether et al., 2000), 
which can be interpreted as high priority trafficking. There is contention over whether APP and its 
secretases co-localise in transport vesicles (Brunholz et al., 2012). However, recent work suggests co-
transportation of APP, ADAM10, and BACE1 can occur in at least some axonal transport vesicles (Das 
et al., 2015; Szodorai et al., 2009), but quantities may be dependent on certain cellular activity states 
(Das et al., 2013). Transcytosis of APP towards the dendritic compartment has not been well studied, 
although anterograde dendritic transport appears to utilise microtubules (Das et al., 2013), and can 
be stimulated by glycine-induced long-term potentiation (Tampellini et al., 2009). APP is also 
transported toward the soma. Retrograde axonal transport utilises the relatively slower cytoplasmic 
dynein transport method (Brunholz et al., 2012). Alternatively, APP can be retro-transported from 
the Golgi and TGN to the ER in COPI- or Rab6-coated vesicles.  
 
Following post-Golgi transport, APP is recruited to the cell plasma membrane where it has an affinity 
for cholesterol and sphingolipid enriched domains known as lipid rafts (Vetrivel and Thinakaran, 
2010). It is estimated that only ~10% of cellular APP is present at the plasma membrane at any given 
time, the bulk is retained within the Golgi and TGN (Haass et al., 2012). It should be noted that the 
precise location of APP delivery along the axon is not known (Haass et al., 2012) although the 
majority of Aβ peptide appears to be pre-synaptic. Whilst within plasma membrane, APP is 
predominantly processed by the non-amyloidogenic secretase pathway. Amyloidogenic processing is 
facilitated when APP associates with lipid rafts. The extent to which APP interacts with BACE1 and γ-
secretase within lipid rafts at the cell surface is unclear. However, clathrin-mediated endocytosis is 
essential to the bulk of Aβ production. Aside from the plasma membrane, non-glycosylated APP can 
localise to mitochondrial membranes, where it can interact with translocases of outer membrane 
(TOM) and translocases of inner membrane (TIM) import receptor isoforms (Devi and 
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Anandatheerthavarada, 2010). Whether APP gets to the mitochondria from the ER, TGN or multiple 
pathways is not clear.  
 
Consequent to endocytosis, APP enters the endosome system, where it is processed or recycled to 
and from the plasma membrane. From the endosomes, APP can be trafficked back to the TGN by 
SORLA (Schmidt et al., 2017), or be targeted to the lysosomes by N-linked glycosylation (and it is 
worth noting that this is impeded in the Swedish and London mutations of APP (Haass et al., 1992, 
2012; Lorenzen et al., 2010)). BACE1 is enriched in endosomes, where the low pH environment is 
favourable for its enzymatic activity (Yan et al., 2001a), and overexpression of mutant rab5 GTPase 
has shown that the bulk of amyloidogenic secretase activity occurs in the early endosomes 
(Rajendran et al., 2006). Studies in HeLa and N2a cells have revealed that Aβ peptides generated in 
the endosomes become localised to multivesicular bodies, where they become incorporated into 
intraluminal vesicles that either couple with lysosomes or are secreted as exosomes (Rajendran et 
al., 2006). Unilateral lesions of the perforant pathway, an axonal route connecting neurons in the 
entorhinal cortex to the dentate gyrus and other areas of the hippocampus, have demonstrated that 
axonally transported (thus pre-synaptic) APP likely originates the bulk of A peptides secreted to the 
extracellular space (Lazarov, 2005). Consistent with this view, synaptic activity has been shown to 
modulate levels of secreted Aβ (Cirrito et al., 2008), and exosomal markers (Alix and flotillin-1) have 
been observed associated with plaques (Rajendran et al., 2006). Pre-synaptic components identified 
in APP transport vesicles included synapsin-I, SNAP25, syntaxin-1B, VAMP2, Munc13-1, and RIM2, 
but not synaptophysin (Szodorai et al., 2009). 
 
1.4.1.4 Amyloid Precursor Protein Function 
The physiological role of APP and its various isoforms remains poorly understood despite 
considerable study. This is likely due to complex localisation and proteolysis, limited work in human 
neurons, and lack of a general theory to integrate the findings of disparate experiments. APP is 
expressed early in development. Isoforms APP770 and APP751 are present throughout each of the 
three germ layers, whilst APP695 predominates in neuroectoderm (Dawkins and Small, 2014; Kirazov 
et al., 2001). 
 
Numerous studies have shown APP to be required for correct migration of neural precursor cells 
(Rice et al., 2012; Young-Pearse et al., 2008) and regulation of synaptic architecture along with 
subsequent activity (Akaaboune et al., 2000; Jung and Herms, 2012; Kohli et al., 2012; Octave et al., 
2013; Tyan et al., 2012). This overlaps with apparent functions of Aβ peptides, and it is not 
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necessarily easy to disentangle the two. Additionally, a role as a cell adhesion molecule is postulated 
due to the presence of APP at the cell plasma membrane, and significant ectodomain with a 
sequence structure matches many recognised cell adhesion motifs (Sosa et al., 2017). 
 
Furthermore, recent work has indicated that different APP isoforms have unique interactomes. 
APP751 proteolysis is mediated by GAP45, which reduces amyloidogenic proteolysis. On the other 
hand APP695 has been found to have interactions enriched for mitochondrial function, as well as 
nuclear pore and nuclear transport proteins (Andrew et al., 2019). APP695 is also implicated in cell 
cycling of neural progenitor cells in conjunction with APP binding protein-1 (Joo et al., 2010) and 
inhibition of Wnt signalling (Zhou et al., 2012).  
 
As with Notch, APP has a cytosolic intracellular domain (NICD and AICD respectively) suggestive of a 
signalling function. This has variously been reported to include the role of a transcription factor in 
conjunction with Fe65 and Tip60 (Pardossi-Piquard and Checler, 2012; Sabo et al., 2001), signal 
transduction in association with Mint1/2/3 (Swistowski et al., 2009), homeostasis of calcium and ATP 
(Hamid et al., 2007), regulation of filamentous actin structures (Ward et al., 2010), and neuron-
specific apoptosis (Ohkawara et al., 2011) by promoting activation of p53 (Pardossi-Piquard and 
Checler, 2012) and GSK-3b (Chang et al., 2006). Potentially one of the most interesting suggested 
functions for AICD is that it regulates the promoter transactivation of neprilysin (Belyaev et al., 2009; 
Pardossi-Piquard et al., 2005, 2006). Neprilysin is an Aβ-degrading enzyme, depletion of which can 
be predicted to result in Aβ accumulation or tax other cellular mechanisms of clearance, therefore it 
may be that part of the function of APP is to act as a pro-protein for which certain products (AICD) 
regulate the activity of others (Aβ).  
 
In an important study, Heber et al. demonstrated that knock out (KO) of APP/APLP-1/APLP-2, 
APP/APLP-2, and APLP-1/APLP-2 had perinatal lethality in mice (Heber et al., 2000). Individually and 
in combination APP and APLP-1 KO reduce body weight, grip strength, and locomotor activity of mice 
(Heber et al., 2000; Li et al., 1996; Müller et al., 1994; Senechal et al., 2008; Zheng et al., 1995), 
produce age-associated memory deficit (Senechal et al., 2008), and increase vulnerability to epileptic 
seizures (Steinbach et al., 1998). Conversely, adding soluble human APP to mouse primary cultures 
protected neurons from glutamate-induced excitotoxicity (Mattson et al., 1993), further linking APP, 
or its derivatives, with regulation of neuron excitation. Surprisingly, APLP-2 KO alone does not 
produce a different phenotype from controls (Heber et al., 2000; Von Koch et al., 1997). Thus the 
picture suggests that considerable functional redundancy exists between the gene homologues, but 
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certain properties of APLP-2, which APP and APLP-1 may cover in combination, appear essential to 
early development.  
 
Interestingly, primary culture and stem cell derived neuronal models with permutations of APP/APLP-
1/APLP-2 KO do not demonstrate significant death phenotypes compared to controls (Bergmans et 
al., 2010; Heber et al., 2000), although APP/APLP-2 KO is reported to alter copper homeostasis 
(Bellingham et al., 2004). If these in vitro models reflect in vivo physiology, this may suggest that 
deleterious effects could be systemic, and perhaps involve peripheral organs such as the liver. 
Indeed, some evidence shows raised pancreatic APP and amyloid deposits in type 2 diabetes, a 
morbidity commonly associated with AD (Miklossy et al., 2010). 
 
1.4.2 Amyloid precursor protein processing 
A key focus of this thesis is improving the understanding of Aβ production in human in vitro models 
of fAD. To generate Aβ, APP undergoes a complex sequence of proteolysis as it is transported 
between cellular compartments. Sequential cleavage by a series of membrane bound proteases 
known as secretases liberate the Aβ domain from APP as a peptide. Canonically, there are two 
relevant cleavage pathways that share a reciprocal (competitive) relationship, although this 
conceptualisation is becoming outdated as new evidence reveals a much more sophisticated picture 
of proteolytic activity within and around the Aβ domain (Figure 3) (Andrew et al., 2016; Chávez-
Gutiérrez et al., 2012; Willem et al., 2015). APP isoforms appear to be processed by similar 
mechanisms in neurons, platelets and leukocytes (Li 1999). 
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1.4.2.1 α-secretase 
The non-amyloidogenic pathway consists of cleavage within the Aβ domain of APP (Lys16-Leu17 of 
A), generating a carboxylic acid terminal fragment (CTF) C83. Further proteolysis of C83 results in N-
terminally truncated p3 peptides that do not drive AD pathology (Figure 2). This pathway is thought 
to be the favoured method of APP processing in non-neuronal cells (Haass et al., 2012) and occurs 
throughout neuron development (Bergstrom et al., 2016). Members of the ‘a disintegrin and 
metalloproteinase’ (ADAM) family have been identified as α-secretases. ADAMs are zinc-dependent 
proteinases that cleave by hydrolysis. The principal α-secretase is ADAM10, and inhibition of this 
protease reduces sAPP by up to 90% (Jorissen et al., 2010; Kuhn et al., 2010). ADAM7, ADAM9, 
ADAM17, and ADAM19 also demonstrate α-secretase activity (Seals and Courtneidge, 2003). 
ADAM10 is activated by removal of the N-terminal pro-domain in the Golgi, which reveals the 
catalytic site (Endres and Deller, 2017; Seegar et al., 2017). C-terminal regions of ADAM10 function to 
guide the proteinase’s cellular localization and substrate recognition (Endres and Deller, 2017; Seegar 
et al., 2017).  
 
Other substrates of the ADAMs besides APP include NOTCH, pro-inflammatory cytokines (TNF-α and 
IL-6) and receptors (TNFRI, TNFRII, IL-6R and IL15R), cell adhesion molecules (L-selectin, Syndecan-1, 
Figure 3: A stylised diagram of the Aβ domain of APP (dark grey). Amino acids are represented by letter and colouring indicates 
charge state (blue: hydrophilic, green: amphipathic, pink: hydrophobic). Various sites of known secretase activity are depicted above, 
and AD mutations are indicated below the domain. The alternate cleavage pathways at the ε-cleavage site are highlighted.  
Figure 3: Aβ primary structure, proteolytic sites and AD mutations 
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Syndecan-4, VCAM-1, JAM-A , CXCL16), and release of CX3CL1 and VE-cadherin (overviewed in 
(Saftig and Reiss, 2011)). Interactions with PrPc and tau are particularly interesting given the 
involvement of these proteins in neurodegeneration including AD. A oligomers have been observed 
to bind directly to PrPc at the plasma membrane, resulting in activation of fyn kinase, 
phosphorylation of tau, NMDAr internalisation and increased reactive oxygen species (ROS). 
Cleavage of PrPc by ADAM10 results in its shedding from the membrane and thus limits this 
potentially toxic interaction (Jarosz-Griffiths et al., 2019). Tau is also an ADAM substrate, generating 
tau 153-441 fragment (Quinn et al., 2018). 
 
1.4.2.2 β-secretase 
The amyloidogenic pathway defines the cleavage of APP by the β-secretase activity of beta-site APP 
cleaving enzyme 1 (BACE1) at the Aβ domain N-terminus, producing sAPPβ and C99, followed by γ-
secretase cleavage of C99 at the domain C-terminus, liberating the Aβ peptide and AICD (Figure 2). 
BACE1 is a type 1 membrane-anchored aspartate protease, containing two D(T/S) G(T/S) motifs 
within its extracellular domain (Ahmed et al., 2010). BACE1 has a mostly inactive pro-protein form, 
concentrated primarily in the ER (Capell et al., 2000), although it may still be able to cleave APP 
(Creemers et al., 2001). BACE1 is matured in the golgi following glycosylation and cleavage by 
proprotein convertases (such as furin), phosphorylated by casein kinase-1, and trafficked to the 
plasma membrane. The bulk of BACE1 is rapidly reinternalized and distributed through the early and 
late endosomes, where co-localisation and low pH favour β-secretase activity, or returned to the TGN 
in a phosphorylation dependent manner (Walter et al., 2001). It is estimated that the bulk of Aβ (60-
70%) is produced in the endosomes, as this is where mature BACE1 is most concentrated (Niederst et 
al., 2015) (Figure 2).  
 
Other than cleaving prior to Asp-1 of the Aβ domain, BACE1 can also cleave APP between Tyr10 and 
Glu11, known as β’-secretase activity, which produces an N-terminally truncated peptide (C89) (Liu et 
al., 2002; Vassar et al., 1999) (Figure 3). N-terminal truncations of Aβ have also been identified at 
amino acid positions 2-x (Bayer and Wirths, 2014; Vassar et al., 1999), which may or may not be 
BACE1-dependent (Bayer and Wirths, 2014; Kummer and Heneka, 2014). It has been suggested that 
C-terminal truncation at Leu-34 may also be the work of this enzyme (Portelius et al., 2014). 
Theoretically, BACE1-BACE1’ cleavage could produce an A11 peptide (Vassar et al., 1999). There are 
conflicting reports regarding the effect of APP post-translational modification on secretase cleavage 
(Ando et al., 2001; Lee et al., 2003; Sano et al., 2006). There is the suggestion that APP695 isoform 
may be more prone to processing via the β-secretase pathway, whereas KPI-domain containing 
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isoforms (APP751 and APP770) preferentially undergo α-secretase cleavage (Belyaev et al., 2009). 
However, as APP695 is predominantly expressed in neurons whilst APP751 and APP770 are glial (Matsui 
et al., 2007; De Silva et al., 1997; Simons et al., 1996), this pattern may therefore be the result of 
cellular function rather than isoform-specific properties. It has been noted that high levels of BACE1 
are found in APP poor, plaque spared brain regions such as the striatum and thalamus. Besides APP, 
BACE1 has many other substrates which have been overviewed by Vassar et al. (Vassar et al., 2009). 
 
Other enzymes with potential -secretase-like activity are cathepsin B and meprin . Cathepsin B has 
been suggested to increase production of pyroglutamate A3-X and A11-X (where the N-terminal 
glutamate is cyclised by glutaminyl cyclase), and reduction of cathepsin B has been associated with 
reduction on amyloid pathology [X]. However, these results are not well replicated [X], and the 
enzyme does not appear to accumulate in amyloid plaques as is the case with BACE1. Meprin  is a 
zinc metalloprotease that is implicated in the production of A1-X, A2-X, and A3-X. Unlike BACE1 
meprin  activity occurs primarily at the plasma membrane, where it may directly compete with -
secretase activity. 
 
1.4.2.3 BACE2: an alternative -secretase 
Another source of β-secretase activity is BACE2, although it is sometimes considered more akin to an 
α-secretase given its tendency to cleave APP within the Aβ domain (Yan et al., 2001b), and has also 
been dubbed a θ-secretase (Sun et al., 2006). This protein shares ~75% homology with BACE1 
(Ahmed et al., 2010), and though primarily expressed within the colon, kidney and pancreas (Bennett 
et al., 2000), where its substrate cleavages influence β cell proliferation and skin pigmentation 
(Alcarraz-Vizán et al., 2017; Esterházy et al., 2011; Rochin et al., 2013; Rulifson et al., 2016), BACE2 
maturation differs from BACE1 in that maturation by removal of the pro-segment occurs by self-
cleavage (Yan et al., 2001b). 
 
Within the brain BACE2 is typically expressed in subsets of neurons, oligodendrocytes, astrocytes, 
and astrocyte-like neural stem cells (Voytyuk et al., 2018), versus the more broadly neuronal BACE1 
(Barão et al., 2016; Irizarry et al., 2001). BACE1 KO has been shown to fully ablate Aβ production in 
mouse models (Cai et al., 2001; Luo et al., 2003), and BACE1 KO does not stimulate compensatory 
upregulation of BACE2 (Luo et al., 2003). However, in vitro experiments have shown that BACE2 can 
cleave APP at the β-secretase cleavage site (Farzan et al., 2000) as well as at Phe19-Phe20, Phe20-
Ala21, and Leu34-Met35 (Abdul-Hay et al., 2012), the latter of which is thought to be its principle 
cleavage site (Figure 3). This endopeptidase-like activity may reflect the role of BACE2 as a powerful 
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Aβ degrading enzyme rather than involvement in primary production (Abdul-Hay et al., 2012), 
although the picture is further complicated by the seeming importance of BACE2 for Aβ production 
in Flemish mutant APP transfected cells (Farzan et al., 2000). Other CNS substrates of BACE2 include 
plexin domain containing 2 (PLXDC2), fibroblast growth factor receptor 1 (FGFR1), delta and notch-
like epidermal growth factor–related receptor (DNER), and vascular cell adhesion molecule 1 
(VCAM1). The latter mediates peripheral leukocyte infiltration through the blood brain barrier (BBB), 
is not a substrate shared by BACE1, and BACE2-dependent VCAM1 shedding is increased in 
inflammatory conditions both in vitro and in vivo mouse models (Voytyuk et al., 2018). 
 
Other enzymes with potential -secretase-like activity are cathepsin B and meprin . Cathepsin B has 
been suggested to increase production of pyroglutamate A3-X and A11-X (where the N-terminal 
glutamate is cyclised by glutaminyl cyclase), and manipulation of cathepsin B has been associated 
with alterations in Aβ concentration in transgenic mouse brain. However, data are not consistent, 
and the enzyme does not appear to accumulate in amyloid plaques as is the case with BACE1 
(Andrew et al., 2016). Meprin  is a zinc metalloprotease that is implicated in the production of A1-
X, A2-X, and A3-X. Unlike BACE1, meprin  activity occurs primarily at the plasma membrane, 
where it may directly compete with -secretase activity (Andrew et al., 2016). 
 
1.4.2.4 γ-Secretase 
γ-Secretase activity is responsible for the proteolysis of APP within the transmembrane domain, and 
features in both the amyloidogenic and non-amyloidogenic pathways (Haas and Selkoe 1993) (Figure 
2). This activity is performed by a protein complex, called γ-secretase, formed of four subunits: 
nicastrin, anterior pharynx defective 1a or 1b (APH-1a/b), presenilin enhancer 2 (PEN-2), and 
presenilin 1 or 2 (PSEN 1/2).  
 
The presenilins are the best studied of all the -secretase subunits, and as several PSEN1 mutations 
form a subject of interest in this thesis some additional consideration will be given to these proteins. 
PSEN1 (14q24.2) and PSEN2 (1q42.13) encode 50kDa transmembrane pro-proteins that weave 
through the membrane with nine transmembrane domains (TMDs) (Laudon et al., 2005; Spasic et al., 
2006). Either PSEN1 or PSEN2 can be present in the γ-secretase complex and act as aspartic 
proteases that function as the catalytic site (Wolfe, 2013). Aspartic acid proteases require H2O 
molecules to break a substrate’s scissile bond, so the ability of PSEN to cleave substrates within the 
hydrophobic environment of the TMD is interesting. It is suggested that TMDs six and seven, which 
incorporate the two aspartate residues, form a hydrophilic space within the membrane into which a 
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substrate is transferred (Tolia et al., 2006). Enzymatic function is activated by PEN-2 assisted auto-
endoproteolytic cleavage of the exon 9 loop (Knappenberger et al., 2004) into a 30 kDa N-terminal 
fragment and a 20 KDa C-terminal fragment (Thinakaran et al., 1996), enabling conformations 
required for aspartic acid proteolysis. It is worth noting that PSEN1 has been ascribed other ‘non-
proteolytic’ functions. PSEN1 mutations have been shown to alter Ca2+ concentrations in the ER 
(Bezprozvanny and Mattson, 2008), and it has been suggested that full-length PSEN1 may form 
membrane pores that cause calcium ‘leak channels’ (Tu et al., 2006). However, other evidence 
indicates this may be the result of its role in the activation of Ryanodine receptor (RyR) (Chan et al., 
2000; Hayrapetyan et al., 2008), inositol-3-phosphate (IP3) (Cheung et al., 2008), and 
sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pumps (Green et al., 2008), all of which are 
involved with calcium homeostasis. Another hypothesised γ-secretase independent function of 
PSEN1 affects the lysosomal degradation pathway. KO of PSEN1 was shown to reduce the ability of 
telencephalin-positive vacuoles to fuse with lysosomes in fAD PSEN1-D257A mouse model 
hippocampal neurons (Esselens et al., 2004). Both calcium homeostasis and lysosome function have 
potential relevance for AD.  
 
There are currently 246 PSEN1 mutations that have been investigated in association with AD. Of 
these, 225 are pathogenic for AD, three are not thought to be pathogenic, one is considered a risk 
factor, and 17 have uncertain pathogenicity (ALZFORUM, 2019b). Three PSEN1 mutations are 
pathogenic for CAA (ALZFORUM, 2019b). Of the 45 documented PSEN2 mutations, 16 are 
pathogenic, 12 are not pathogenic, and 17 have unclear pathogenicity for AD (ALZFORUM, 2019b). 
No PSEN2 mutations have yet been identified associated with CAA. Furthermore, and interestingly, 
neither PSEN1 nor PSEN2 are found altered in Down’s syndrome, suggesting that the AD-like 
pathology to which these individuals are vulnerable is a function of increased APP and Aβ per se, 
rather than dysregulated production. 
 
Dissociation of the γ-secretase complex by dodecyl β-D-maltoside (DDM) has revealed two major 
sub-complexes (and two minor ones) that suggest how γ-secretase may form (Fraering et al., 2004). 
Nicastrin and APH-1 bind together via multiple transmembrane domain (TMD) interactions (Chiang 
et al., 2012; Pardossi-Piquard et al., 2009). Physiologically this occurs in the endoplasmic reticulum 
(LaVoie et al., 2003). This structure recruits full-length PSEN, by the binding of PSEN C-terminal 
domain to nicastrin (Capell et al., 2003; Kaether et al., 2004), and both N-terminal and C-terminal 
domains to APH-1 (Steiner et al., 2008). Whether PSEN is recruited alone or as part of a pre-
assembled PSEN-PEN-2 complex is not actually demonstrated in the much-cited work of Fraering et 
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al. (Fraering et al., 2004). Regardless, PEN-2 binds to PSEN1 at the N-terminal domain (fourth TMD) 
of the latter, forming a structure capable of stable independence from the nicastrin-APH-1 sub-
complex (Fraering et al., 2004; Watanabe et al., 2005) Due to the existence of two alternate 
presenilins (PSEN1 and PSEN2) and APH-1 isoforms (APH-1a and APH-b), there are at least four 
physiologically possible γ-secretase structures (De Strooper, 2003). Once the complete γ-secretase 
complex has articulated, it is transported through the golgi and trans-golgi network to and from the 
cell surface. During transition, γ-secretase is matured and activated by proteolysis of presenilin and 
glycosylation of the various complex sub units (Takasugi et al., 2003). It would be reasonable to 
hypothesise that cellular mechanisms exist to regulate γ-secretase’s activation as it is transported 
through various cell compartments. Increased γ-secretase activity requires overexpression of all 
subunits (Haass et al., 2012), or activity enhancing mutation in APH-1 subunits (Qin et al., 2011). 
Complete KO in mice is embryonically lethal, whilst complete loss of function of PSEN1, Pen-2, and 
Nicastrin in humans results in acne inversa, but not neurodegeneration or AD (Wang et al., 2010). 
 
γ-secretase cleaves APP toward the C-terminal of its TMD (Figure 3). The area of cleavage activity is 
broad, spanning from at least 14-43 amino acids (Kummer and Heneka, 2014; Moore et al., 2012; 
Portelius et al., 2012), and capable of producing peptides of many different lengths, including the 
often overlooked small fragment products (3-4 amino acids) generated by the sequential nature of γ-
secretase cleavage (Takami et al., 2009). Despite some assertions (Fernandez et al., 2016), it is not 
yet definitively known at which amino acid(s) γ-secretase makes its first cut (and incidentally where 
the Aβ domain ends is therefore undefined). Cleavage at the epsilon (ε) site (amino acids Thr48 or 
Leu49 of the Aβ sequence) represents one of the earliest evidenced cleavages of APP by γ-secretase 
and is considered to define two different peptide cleavage pathways (Chavez-Gutierrez et al., 2012; 
Qi-Takahara, 2005; Takami et al., 2009) However, Takami et al. have also suggested cleavage at 
Met51 or Leu52 could precede Thr48 or Leu49 respectively (Takami et al., 2009). Regardless, point 
deletion experiments have shown that the number of amino acids between the terminal 
transmembrane sequence and ε-cleavage site does not alter the point of ε-cleavage, and therefore 
does not dictate the nature of subsequent cleavages (Fernandez et al., 2016). Rather, it appears to be 
the arrangement of amino acid side chains along the TMD helix, not the number of amino acids per 
se that guides the initial binding site and subsequent exposure of APP to the catalytic site (Fernandez 
et al., 2016). 
 
γ-Secretase is a developmentally important enzyme with many substrates beyond APP which include 
proteins involved in synaptogenesis and dendritic spine maturation (NOTCH, ErbB4, E-cadherin, N-
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cadherin, ephrin-B2) (Barthet et al., 2013), regulators of neural and glial process migration and 
adhesion (ephrin A4, CD44, netrin receptor, neuroligin), and regulators of APP trafficking (LRP1 and 
SORLA), reviewed by Carroll and Li (Carroll and Li, 2016). A particularly interesting development in 
this area of study is the identification of regulatory proteins, such as γ-secretase activating protein 
(gSAP) (Chu et al., 2015) and hypoxia-inducible factor 1α (Hif1α) (Villa et al., 2014), which facilitate γ-
secretase interaction with certain substrates over others, and may be associated with AD. 
 
1.4.2.5 The tripeptide hypothesis 
A feature of γ-secretase proteolysis of APP proteins (whether single or dimerised is a matter of 
contention (Fernandez et al., 2016; Itkin et al., 2017) is that cleavages occur in a sequential manner, 
approximately every three to four amino acids (Figure 3). This process theoretically, and to a certain 
extent demonstrably, produces a series of C-terminal tripeptides dependent on the extent of 
truncation of the Aβ domain at gamma (γ) cleavage sites, and is dubbed the ‘tripeptide hypothesis’ 
(Qi-Takahara, 2005). Though the mechanisms of how this occurs remain to be fully elucidated, recent 
studies are building a working understanding.  
 
It is understood that the substrate binding region proximal to the γ-secretase catalytic site contains 
three hydrophobic substrate binding ‘pockets’ which accommodate three substrate residues N-
terminal to the scissile amide bond, explaining the propensity for tripeptide cleavage sequence 
(Bolduc et al., 2016). Despite some initial controversy, a consensus that the APP TMD adopts an 
alpha-helical arrangement is beginning to emerge. This structure appears to be denatured by γ-
secretase into a random coil within the binding pocket region enabling proteolysis. The extent to 
which the enzyme is successful in making sequential cleavages is determined by the structural 
stability of the γ-secretase and/or APP (Chavez-Gutierrez et al., 2012; Fernandez et al., 2016). The 
kinetics of APP transfer through or release from the γ-secretase catalytic site are still mysterious, 
although the negative charge of the substrate C-terminal has been shown not to assist this 
transferral (Fernandez et al., 2016). 
 
1.4.2.6 γ-Secretase loss of function 
It was proposed that partial loss of function in the γ-secretase catalytic subunit, presenilin (PSEN), 
may underlie memory impairment and neurodegeneration in the pathogenesis of AD (Shen and 
Kelleher, 2007). However, recent work has begun to show that γ-secretase carboxypeptidase-like 
activity, rather than overall activity, is reduced in familial Alzheimer’s disease (fAD) with PSEN 
mutation involvement (Szaruga et al., 2017). In other words, ‘efficiency’ is the major determinant of 
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Aβ production. Mutant PSEN appears to be less efficient at making successive cleavages of APP, 
resulting in relative over-production of longer Aβ peptides, whilst proteolysis of other substrates is 
functionally spared. However, further experimental work is needed to properly substantiate this 
interpretation. 
 
1.4.2.7 Aβ peptides generated by γ-secretase 
Combined with the concept of an initial ε-site cleavage, the tripeptide model predicts two alternative 
Aβ peptide production pathways: Aβ49  Aβ46  Aβ43  Aβ40 or Aβ48  Aβ45  Aβ42  Aβ38 
(Chavez-Gutierrez et al., 2012) (Figure 3). Recent experiments have begun to explore and validate the 
scope of this theory, and γ-secretase-generated peptides currently identified are: Aβ43 (Almdahl et 
al., 2017; Lauridsen et al., 2017; Saito et al., 2011; Zoltowska and Maesako, 2016), Aβ42, Aβ40, Aβ39, 
Aβ38, and Aβ37 (Kukar et al., 2011; Moore et al., 2018), possibly Aβ34 and Aβ33 (Kukar et al., 2011), 
and possibly Aβ17 (Portelius et al., 2011, 2012). Whilst the existence of many of these peptides fit 
the model, certain peptides (Aβ49-Aβ44) remain to be reliably detected. Additionally, Aβ38 does not 
neatly fit within either tripeptide pathway and yet is readily detected and associated with the Aβ48 
pathway (Chavez-Gutierrez et al., 2012). γ-secretase does not have a fourth substrate binding pocket 
(Fernandez et al., 2016), and so the mechanism for Aβ38 production within a tripeptide framework 
remains unclear. How fixed are these pathways? Could there be others (as implicated in (Matsumura 
et al., 2014)? Could the ε-cleavage site extend to Aβ50 or Aβ47? Many questions surround this 
hypothesis and will require high fidelity human APP processing models as platforms to explore from. 
 
1.4.2.8 η-Secretase 
Finally, the most recent addition to the list of APP-secretases was “eta” or η-secretase, identified by 
the work of two independent groups in variety of models including transgenic mouse CSF and 
primary culture, Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) cells, and 
embryonic pluripotent stem cell (EPSC) -derived human (Wang et al., 2015; Willem et al., 2015). 
MT5-MMP, a membrane-bound matrix metalloproteinase, is implicated as a potential η-secretase 
candidate as Aη-α concentrations were partially reduced by KO of this molecule (Willem et al., 2015). 
Whatever combination of molecules contribute to η-secretase activity, it is thought to result in a 
cleavage of APP between Asp504 and Met505 (relative to the APP695 sequence) within the flexible 
extracellular juxtamembrane region, generating CTFη (Willem et al., 2015). Inhibition of lysosomal-
cathepsins results in accumulation of CTFη in cell lysates (Wang et al., 2015; Ward et al., 2017), and 
accumulation of CTFη is found localised to dystrophic neurites and amyloid plaque halos (but not 
cores) (Willem et al., 2015), suggesting involvement with neurotoxicity. Subsequent cleavage of the 
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CTFη by α-secretase, β-secretase or β’-secretase activity results in the liberation of an Aη-α, Aη-β or 
Aη-β’ peptide respectively. BACE1 proteolysis of CTFη (generating Aη-β or Aη-β’) would also be 
potentially amyloidogenic and so produce Aβ if interaction with γ-secretase were not altered. Aη-β 
has been shown to have no effect on synaptic transmission or long term potentiation (LTP) of CA1 
pyramidal primary neurons (Willem et al., 2015). Aη-α also had no effect on synaptic transmission, 
but did demonstrate a lowering effect on LTP. Aη-α has yet to be detected extra-cellularly (Ward et 
al., 2017). Interestingly, Willem et al. observed that η-secretase processing significantly exceeded 
amyloidogenic processing by 9.5 ± 1.87 times (p=0.001, Student’s t-test) (Willem et al., 2015). β-
secretase proteolysis of APP is documented to be a less frequent event than α-secretase proteolysis, 
neither of which necessarily preclude η-secretase activity, and so this finding may make sense. 
However, it is somewhat difficult to square this with the proposal that η-secretase products have 
neurotoxic function and more work is certainly required to interrogate this further, though 
unfortunately beyond the scope of this thesis. 
 
1.4.3 Amyloid Beta 
Having detailed the mechanisms by which Aβ peptides are produced, focus will now shift to the 
properties they have and the structures they form.  
 
 
 
 
Figure 4: Processes of Aβ aggregation 
Figure 4: Showing the theorised process of Aβ aggregation from monomers, to oligomers, to protofilaments, to protofibrils, mature 
fibrils and eventually the distinctive amyloid plaques, characteristic of AD. Multidirectional arrows highlight the dynamic relationship 
of the various structure as they form and devolve in solution. Phases of lag and growth are recognised in this process, with relative 
energetic barriers to aggregation usually limiting the formation rates of early oligomers, before certain conformational and 
environmental changes occur to facilitate the stability of larger fibril structures. 
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1.4.3.1 Amyloid beta: primary structure and biophysical properties 
Aβ peptides are typically polar molecules; the domain C-terminus (amino acids 30-50) is enriched 
with hydrophobic amino acids, as well as a medial clustering (amino acids 17-21), whilst the extra-
membrane projecting N-terminus (amino acids 1-16) has a comparatively higher number of 
hydrophilic and amphipathic amino acids (Figure 3) (Enache et al., 2018). These domains represent a 
key feature of Aβ conformation and therefore the extent to which they are present in the sequence 
of a given peptide determines a significant portion of its biochemistry. Furthermore, in an unfolded 
state, Aβ (peptide sequences 1-36 to 1-43) are estimated to have a pI of 5.59, and therefore a net 
negative charge at physiological pH (-2.9 at pH7.4). These intrinsic factors dictate the propensity of 
molecules to bind to surfaces, and Aβ40 has been shown to adsorb onto hydrophobic as well as 
positively charged hydrophilic surfaces (Rocha et al., 2005). Given the importance of individual amino 
acid residues to the conformational and aggregative behaviour of Aβ peptides, it is important to note 
that rodent APP in the region of Aβ domain differs from human by three N-terminal amino acids 
(Arg5 is substituted by Gly, Tyr10 by Phe and His13 by Arg) which makes rodent Ab less prone to form 
amyloid aggregates and less cytotoxic (Fraser et al., 1992). 
 
1.4.3.2 Amyloid beta: secondary and tertiary structures 
Substantial investigation of Aβ monomer secondary structures has been conducted, largely focused 
on Aβ40 and Aβ42, but inclusive of various smaller peptides. Due to a range of, and lack of 
consistency between, experimental conditions utilized, a definitive understanding has not been 
reached. However, the general consensus is that in aqueous solution at between 4-25°C and 
approximately neutral pH (pH 7-7.4), Aβ40 and Aβ42 typically adopt a random coil secondary 
structure in dynamic equilibrium with heterogeneous collapsed coil structures featuring a hairpin 
turn toward the C-terminal region (Ball et al., 2011; Riek et al., 2001; Roche et al., 2016; 
Vivekanandan et al., 2011). Many incongruences in the literature likely arise from variations in pH, 
temperature, buffer composition, peptide type (e.g. endogenous/recombinant/synthetic etc.), and 
post-translational modification between experiment conditions (Hou et al., 2004; Roche et al., 2016). 
Indeed Aβ peptides can be post-translationally modified by oxidation, phosphorylation, nitration, 
racemization, isomerization, pyroglutamylation, and glycosylation (Hou et al., 2004; Kummer and 
Heneka, 2014). These factors influence the aggregation dynamics of Aβ and seem to be of relevance 
to neurotoxicity. Indeed, this may contribute to the documented differences in aggregation 
propensity observed between recombinant or synthetic Aβ peptides and endogenous forms 
(Vandersteen et al., 2012). Although an intrinsically disordered structure is energetically favourable 
for Aβ monomers in neutral buffered solution, under certain conditions Aβ peptides readily adopt 
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defined β-sheets in aqueous solution (Nikolic et al., 2011; Schladitz et al., 1999; Serpell, 2000) and α-
helices in organic solvents or the hydrophobic environment of lipid membranes (Nerelius et al., 2009; 
Serpell, 2000; Soto et al., 1994; Wei and Shea, 2006) although each peptide form behaves uniquely 
(Wise-Scira et al., 2011). The formation of initial non-random secondary structures can be driven by 
temperature, pH, salt content, and surface interactions that change the Gibbs free energy (∆G) of the 
system to make new conformations more favourable. Although there is mounting evidence that Aβ 
monomers themselves are relatively innocuous physiologically, the properties of aggregated Aβ 
forms are consistently linked to direct and indirect neurotoxic processes (Yang et al., 2017).  
 
1.4.3.3 Amyloid beta: quaternary structures 
Initial nucleation of Aβ appears to be driven predominantly by intermolecular interactions between 
hydrophobic peptide regions, which differentiate peptides with otherwise similar properties e.g. 
Aβ40 and Aβ42 (Meisl et al., 2014; Roche et al., 2016). Aβ peptides can engage in dynamic self-
aggregation, rapidly forming structures from dimers, trimers, and tetramers, to oligomers of various 
sizes, which more gradually become fibrils of parallel β-sheets that can measure tens of nanometers 
(Serpell, 2000) (Figure 4). The composition of these aggregates is difficult to dissect, but experiment 
has shown structures of single type and cross-peptide types can occur, which may have important 
implications for physiological and pathological roles (Chakraborty and Das, 2017; Moore et al., 2018). 
Critical aggregation concentration describes the concentration at which ∆G changes abruptly in a 
manner favourable to increased interaction of a particular molecule. Above a critical aggregation 
concentration threshold, the number of aggregates of a given size increases. The critical aggregation 
concentration for Aβ40 and Aβ42 is reported to be within a nanomolar range (approximately 28-120 
nM) (Iljina et al., 2016; Novo et al., 2018), at which oligomers formed of approximately 28-88 
monomers and with hydrodynamic radii of approximately 7-11 nm are present. Lower level 
aggregation of smaller structures likely occurs at lower concentration ranges. Physiological 
concentrations of Aβ in human CSF are in the picomolar range. Measurement of physiological Aβ 
concentrations in human brain are complicated by different solubility fractions, but also appear 
(along with mice (Puzzo et al., 2008; Waters, 2010)) to be present in picomolar quantities (Lazarevic 
et al., 2017). However local fluctuations in concentration and other ∆G altering parameters such as 
temperature, pH, and surface interface properties are very likely an important factor in Aβ 
aggregation in vivo.  
 
In experimental conditions small Aβ oligomer structures form rapidly, within minutes (Banerjee et al., 
2017), but with high reversibility, leading to an extended aggregation lag phase (Arosio et al., 2015), 
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where-after larger structures have greater stability as the number of interactions becomes more 
significant (Härd, 2014; Törnquist et al., 2018) (Figure 4). It was recently shown in two independent 
studies that the initial dimer structure is formed by the hydrophobically driven interaction of two 
monomers that form a mirrored S-shaped conformation, which accumulate other dimer subunits in 
cross-β sheet motifs (Colvin et al., 2016; Wälti et al., 2016). It has been observed that a certain 
proportion of aggregates, or perhaps certain structural conformations, aggregate irreversibly (Roche 
et al., 2016) forming insoluble ‘seeds’ that catalyse aggregation when introduced to Aβ monomer 
containing solutions, and can grow to extended filaments and protofibrils. Increasing evidence 
suggests that a proportion of Aβ structures that break away from certain aggregate conformations 
retain seed templating or cross-seeding potential and further facilitate aggregation through prion-like 
mechanisms (Marzesco et al., 2016; Olsson et al., 2018; Tran et al., 2017). The initial conformations 
of small Aβ aggregate structures are thought to be important for the morphology of larger fibrils. 
Different solution and interface environments can lead to formation of different fibril morphologies 
(Wood et al., 1996), and fAD mutations have been shown to produce distinct Aβ40 fibril 
morphologies with different aggregation kinetics (Hatami et al., 2017), which likely extends to other 
Aβ peptides as well. Combined, the properties and behaviours of Aβ make the peptides highly labile 
and difficult to work with in a manner relevant to preserving disease relevant qualities from in vivo to 
ex vivo.    
 
1.4.3.4 Amyloid beta plaques 
Aβ protofibrils grow and combine to form diverse fibril structures (Han et al., 2017) and insoluble 
deposits alongside other proteins and lipids, amalgamations which can eventually become the 
relatively gigantic extracellular structures known as amyloid plaques (Figure 4). Amyloid plaques are 
a defining feature of AD, and therefore it may come as some surprise that, whilst the composition 
and distribution of these structures are well described, the process of their formation is 
understudied and controversial (D’Andrea and Nagele, 2010). Interrogation of the composition of 
amyloid plaques reveals that they are complex structures inclusive of many different protein types, 
including whole neurons and glia. Aβ is enormously enriched in these plaques (approximately 80 
times that of surrounding tissue (Liao et al., 2004)) and constitutes the principle material. Of the Aβ 
forms present, Aβ42 predominates (Masters et al., 1985). Other proteins that are enriched more 
than two-fold in plaques compared to surrounding tissue are involved in cell adhesion (collagen I, 
fibrinogen, actin binding protein, coronin), cytoskeletal (tau), trafficking and sorting (clathrin heavy 
chain, dynamin, dynein heavy chain), kinases (14-3-3 isoforms), and proteinases (ubiquitin activating 
enzyme, lysosomal ATPases, cathepsin D, antitrypsin, cystatin B and C) (Liao et al., 2004). These 
44 
 
plaques are found distributed throughout the cortex and sub-cortex in advanced stage AD, with 
notable sparing of hind brain regions (Grothe et al., 2017; Thal et al., 2002). Different plaque 
morphologies exist within the brains of the same individual. Two broad categories are commonly 
described – dense core plaques and diffuse plaques (Serrano-Pozo et al., 2011). Surprisingly, the 
cataloguing of amyloid plaques is an underdeveloped area of study, but recent indications suggest 
plaque properties may differ between AD sub-categories (Rasmussen et al., 2017), and potentially 
brain regions and cell types (D’Andrea and Nagele, 2010).  
 
1.4.3.5 Amyloid beta function 
The physiological and pathological functions of Aβ remain poorly understood. Proposed physiological 
functions of Aβ can be broadly categorised into modulation of synaptic activity and plasticity 
(Abramov et al., 2009; Charkhkar et al., 2015; Lauren et al., 2009; Parihar and Brewer, 2011), cell 
signalling and kinase regulation (Boehm, 2013; Sadigh-Eteghad et al., 2014; Tabaton et al., 2010), 
oxidation regulation (Baruch-Suchodolsky and Fischer, 2009; Koppaka and Axelsen, 2000; Nelson and 
Alkon, 2005; Zou et al., 2002), cholesterol metabolism (Beel et al., 2010; Grösgen et al., 2010; 
Hartmann, 2006; Wood et al., 2003), plasma membrane modulation (Eckert et al., 2005; Kakio et al., 
2004; Milanesi et al., 2012; Peters et al., 2009), and finally immune response (Campbell, 2001; Fiala 
et al., 2007; Halle et al., 2008). Dysregulation of these activities largely encompass the pathological 
capacities of the peptide.  
 
Synaptic loss is the strongest correlate of AD severity (DeKosky and Scheff, 1990; Scheff et al., 2007; 
Terry et al., 1991), making the role of Aβ in synaptic activity and integrity of great interest. Although 
plaque burden is not well correlated with symptom severity (Francis et al., 1999; Sperling et al., 
2009), Aβ aggregates are frequently found in proximity to dysmorphic neurons, which often contain 
aggregated P-tau, signs of disrupted cellular transport, and loss of dendritic spine density (Ferrer and 
Gullotta, 1990; Moolman et al., 2004; Serrano-Pozo et al., 2011; Spires, 2005; Woodhouse et al., 
2005). Additionally, A-containing human brain extract has been reported to exert an LTP reducing 
affect in mouse hippocampal brain slices. This was found to be due to inhibition of pre-synaptic 
release potential, which was dependent on the presence of APP (Wang et al., 2017). Furthermore, 
soluble Aβ assemblies have been found co-localised with receptors of the pre- and post-synaptic 
compartments, of which nicotinic acetylcholine receptor (nAChR) and N-methyl-D-aspartate 
receptors (NMDAr) are the best studied (Caspersen et al., 2005; Kay et al., 2013; Koffie et al., 2009; 
Takahashi et al., 2004) and to interact with a plethora of receptors and ion channels (Charkhkar et 
al., 2015; Dineley et al., 2002; Domingues et al., 2007; Dougherty et al., 2003; De Felice et al., 2007; 
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Hsieh et al., 2006; Kamenetz et al., 2003; Pearson and Peers, 2006; Puzzo et al., 2008; Rammes et al., 
2017, 2018, 2011; Shankar et al., 2007; Texidó et al., 2011; Wang et al., 2000b, 2000a). 
 
Interestingly, physiological, picomolar concentrations (~200pM) of Aβ monomers are associated 
with long term potentiation (LTP) and synaptic plasticity (Domingues et al., 2007; Kelly and Ferreira, 
2006). However, nanomolar concentrations (~200nM), particularly of oligomers that form readily in 
such conditions, are associated with long term depression (LTD) (Snyder et al., 2005), and 
cytoplasmic Ca2+ dependent dendritic spine loss (Demuro et al., 2005; Wu et al., 2010; Zempel et al., 
2010). Neuronal Aβ production is enhanced and higher concentrations are detected in the interstitial 
fluid proximal to synapses following stimulation of synaptic activity (Bero, Adam W; Cirrito, John; 
Holtzman, David; Lee, Jin-Moo; Raichle, Marvus; Roh, 2011; Cirrito et al., 2005, 2008; Kamenetz et 
al., 2003), raising probability of oligomer/fibril formation. Together, this may point to a negative 
feedback function for Aβ under normal physiological conditions. 
 
Brain regions with high metabolic activity (e.g. the hippocampus), are vulnerable to accumulation of 
Aβ in AD brains (Buckner, 2005; Gouras et al., 1997), although others (e.g. the cerebellum) are not 
greatly affected in AD despite persistent and intense activity (Grothe et al., 2017; Thal et al., 2002). 
One possibly is that this is due to fundamentally important differences in network connectivity 
(Ovsepian and O’Leary, 2015), but more work in human appropriate cell models is needed. 
Cholinergic neurons are a target of the current imperfect AD therapeutics, and may have 
involvement in earlier stages of the disease than previously thought (Mufson et al., 2008). However, 
these neuronal types only represent ~5% of basal forebrain neurons (Deurveilher and Semba, 2011). 
Whilst numbers of GABAergic neurons are estimated to be more significant (~20% (Sahara et al., 
2012)), evidence for the involvement of GABAergic neurons in AD is less clear. Rossor et al. reported 
these neurons to be relatively spared in a study of post-mortem cortical tissue from AD patients 
(Rossor et al., 1982), though some studies in transgenic rodents indicate vulnerability of 
hippocampal GABAergic neurons to A-induced toxicity (Krantic et al., 2012; Pakaski et al., 1998), as 
well as to tauopathy in APOE4 over expression models (Andrews-Zwilling et al., 2010). Cortical and 
subcortical glutamatergic neurons are well demonstrated to be severely afflicted by signalling 
disruption and degeneration in the AD brain (Butterfield and Pocernich, 2003; Vazin et al., 2014; 
Viola et al., 2008). In vitro and in vivo studies have shown that Aβ oligomers preferentially bind to 
glutamatergic neuron membranes and receptors, reducing glutamate signalling and synaptic 
plasticity (Vazin et al., 2014). The classification ‘glutamatergic’ describes a heterogeneous group of 
neurons that share the use of glutamate as an excitatory neurotransmitter, and which are generated 
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from precursors in the dorsal telencephalon (Wilson and Rubenstein, 2000). Glutamate is the major 
excitatory neurotransmitter of the CNS and glutamatergic neurons (such as pyramidal and granule 
cells) constitute the greater part of ~80% of the neocortex (Wonders and Anderson, 2006) and 
subcortical regions, such as the hippocampus (Strominger et al., 2012). Therefore, glutamatergic 
cortical neurons represent an important target for AD research. 
 
1.5 Biomarkers and Alzheimer’s disease 
Thus far, this chapter has defined and outlined Alzheimer’s disease, and given a background to A 
biology. This thesis concerns the optimisation and expanded use of A peptides as biomarkers for 
AD, and the next section will introduce the need for improved AD biomarkers before narrowing focus 
to a discussion of confounding factors in A measurement and the in vitro modelling of AD.  
 
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (Atkinson A.J. et al., 2001). In other words, a biomarker of X is anything that signals 
some aspect of the state of X in a biological system. A good biomarker must meaningfully track the 
state of its dependent process. Ideally this will be in terms of high accuracy (the degree to which 
measurement matches actual values within the target context i.e. a person’s brain). However, even if 
aspects sample acquisition cause values to diverge from those of the original context, a biomarker 
may still be useful if relative differences between different states are preserved. A good biomarker 
must also have high reproducibility. The ability to make the same measurement repeatedly with low 
error underpins assessment of accuracy and interpretation of results. Finally, in practical terms, a 
biomarker should be safe and uncomplicated to obtain, as well as cost-effective to measure. 
 
Alongside clinical examination, biomarker research is now a dominant methodology to address AD 
for case identification, disease mechanism and pathway analysis, assessment of treatment targeting 
efficacy, and assessment of treatment response endophenotypes. Biomarkers for AD pathology are 
now incorporated in revised clinical criteria for the disease (Dubois et al., 2014; McKhann et al., 
2011; Ryan et al., 2018). Biomarkers can be subdivided into two categories: diagnostic (present at all 
disease stages, though may not correlate with severity) and progression (correlates with severity, but 
may not be present at all disease stages) (Dubois et al., 2014). Biomarkers can also be classified by 
the medium of measurement. Fluid biomarkers are molecules measured within biological fluid and 
constitute the focus of this thesis.  
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1.5.1 Biofluids 
For biomarker research of CNS disease CSF has the advantage of being semi-continuous with brain 
interstitial fluid whilst being segregated from blood and other body fluids in contact with peripheral 
tissues. Low protein concentration has also made CSF an easier matrix to work with in terms of assay 
development. However, methods of extraction are lumbar puncture or ventricular shunt, which are 
invasive and high skill requirement procedures that limit ease of sample accessibility. Cerebrospinal 
fluid (CSF) is an ultrafiltrate of blood plasma. Its consistency is 99% H2O with low concentrations of 
electrolytes (Na, K, Ca, Mg, Cl), monosaccharides, and protein. CSF is produced by networks of 
ependymal cells that form the choroid plexuses lining the lateral, third and fourth ventricles of the 
brain, at an approximate rate of 500mL per day (Wright et al., 2012). CSF flows through the 
ventricles, down and back up the subarachnoid space of the spinal column and is resorbed to the 
venous blood through the arachnoid villi. It is semi-continuous with brain interstitial fluid in the 
perivascular space, and small quantities are thought to be absorbed into the glymphatic system. 
Circulation is facilitated by pulsations of the choroid plexus and the motion of ependymal cell cilia. . 
In an adult human, CSF from the lumbar region contains on average 0.15 to 0.45 mg/mL protein 
(~0.3% of plasma protein), and 0.50-0.80 mg/dmL glucose (~66% of blood glucose). These values are 
age and sampling-site dependent. Protein concentration in cisternal and ventricular CSF is lower 
(Felgenhauer, 1974; Weisner and Bernhardt, 1978). Additionally, CSF from healthy individuals 
typically contains 0-5 mononuclear cells. CSF pressure, measured at lumbar puncture (LP), is typically 
100-180mm of H2O (8-15mm Hg) with the patient lying on the side and 200-300mm H2O with the 
patient sitting up. CSF provides mechanical support to the CNS, but increasing attention is focusing 
on its role as a filtration system for CNS waste products.  
 
Until recently, blood-based biomarkers of AD have been poor or controversial, though much sought 
after. The great advantage of using blood derivatives in biomarker research is the ease, low 
invasiveness, and cost-effective nature of extraction. However, as a peripheral fluid, the blood matrix 
is complex and contains metabolites from many tissues which may obscure brain-derived biomarker 
profiles as well as molecules that may bind or degrade brain proteins of interest. Blood plasma is a 
complex matrix of proteins, fibrinogens, enzymes, glucose, amino acids, fats, cholesterol, 
phospholipids, vitamins and minerals, electrolytes, hormones and dissolved gases. Serum is plasma 
from which fibrinogens and coagulant proteins have been removed. Molecules from the brain 
interstitial fluid pass through the CSF to the blood where they are recycled or filtered as waste 
through the kidneys. Development of new ultra-sensitive protein measurement techniques (e.g. 
Single molecular array (Simoa)) have opened this medium up for investigation of brain specific 
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proteins, such as tau and neurofilament light (NFL) (Blennow, 2017). These developments did not 
become accessible until after this project had commenced and so, whilst important, do not form part 
of its scope.  
 
1.5.2 Core biomarkers of AD 
A good biomarker of AD must fundamentally be linked to some aspect of the underlying 
neuropathology and distinguish those with AD from controls and from other disease states. In 
practice this means validation in neuropathologically confirmed cases of AD (Group CW, 1998), and 
the sensitivity (ability to detect true positive) and specificity (ability to detect true negative) of 
detection should be >85% (Shaw et al., 2007). Additionally, accessibility of the biomarker is crucial to 
utility in a practical clinical context (Humpel, 2011). Finally, to be deployed in a clinical or otherwise 
professional setting, biomarker measurement must be reliable with recommended intra-assay 
coefficients of variance (CVs) of <20% (FDA, 2001; Kadavil, 2013), although no official international 
criteria exists. High structural stability, a long half-life, and low reactivity are advantageous qualities.  
 
Proteins that, on balance, approximate this criteria are known as ‘core’ biomarkers for AD. At the 
current time these include Aβ42, total tau (T-tau) and tau phosphorylated at either amino acid 181 or 
231 (P-tau181 and P-tau231 respectively). Aβ42 is found decreased in AD CSF versus non-
neurodegenerative controls, frontal temporal dementia (FTD), and Parkinson’s disease (PD). In 
contrast, T-tau and P-tau are found raised in AD CSF (Blennow and Zetterberg, 2009). Meta-analysis 
of CSF Aβ42 has shown a pooled sensitivity of 0.80 (95% CI 0.78–0.82) and a pooled specificity, 0.76 
(95% CI 0.74–0.78) for distinguishing AD and non-AD cases, although significant heterogeneity in 
concentrations were noted (Mo et al., 2015). Another analysis, which compared reports from 9949 
AD patients and 6841 controls showed a highly significant average ratio of 0.56 Aβ42 in AD CSF 
versus control CSF (Olsson et al., 2016). The same study also found an average ratio of 2.56 for AD 
CSF T-tau and a ratio of 1.88 for a composite of P-tau epitopes for distinguishing AD and non-AD 
cases, which were also highly significant (Olsson et al., 2016). These effect sizes are depicted in 
Figure 5. In combination, Aβ42, T-tau and P-tau181/231 consistently produce the highest diagnostic 
sensitivity and specificities, both versus controls and other dementias, particularly in early stages 
(Blennow et al., 2010; Ferreira et al., 2014; Hansson et al., 2006). Although not yet officially 
incorporated into the AD diagnostic criteria, a growing literature also supports the utility of ratios of 
Aβ42:40 (Anoop et al., 2010; Janelidze et al., 2016; Slemmon et al., 2015) 
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There are, as yet, no certified or ‘gold standard’ reference materials to use as a reference point for 
any AD biomarker (Mattsson et al., 2012a). The consequence of this is platform-dependent bias 
across the different assays produced. Furthermore, even when the same assay platform is used, 
variation in biomarker measurements between laboratories is often high (Lewczuk et al., 2008; Lucey 
et al., 2015; Mattsson et al., 2013; Reijn et al., 2007; Verwey et al., 2009). Between-site coefficient of 
variation percentages (%CV) for commercially available T-tau and Aβ42 assays fall on average 
between 20-30% (Mattsson et al., 2013). FDA guidelines for ligand binding assays, which are among 
the more looked to bench-marks for an industry without well-defined international regulation, 
require <20% CV in the linear range (<25% CV at the lower limit of quantification) of the calibration 
curve for bioanalytical assays to meet validation criteria (FDA, 2001; Kadavil, 2013). In AD, the 
separation of patient groups by Aβ42 and T-tau is relatively robust, but there exists a considerable 
‘grey area’ where group separation becomes unclear and improved resolution would be highly 
desirable, especially at early disease stages. By identifying novel confounding factors affecting Aβ 
measurement this thesis aims to provide evidence to inform sample storage and handling practices, 
and facilitate standardisation and measurement accuracy within the fluid biomarker field. 
 
Low concentrations of Aβ42 peptide in CSF are taken to indicate a clearance deficit from the brain as 
a result of sequestration in plaques (Fagan et al., 2006; Grimmer et al., 2009). However, as covered in 
Section 1.4 the mechanisms of Aβ production, clearance and toxicity are complex. In practical terms, 
it may be that interpreting Aβ concentration as ‘a marker for AD related-neurodegeneration’ or ‘an 
indicator of brain amyloid deposition’ is not sufficient to support the interpretative needs of 
experiment. Certainly, one wonders if the many different Aβ peptides have more to give in improving 
understanding of toxic mechanism, supporting therapeutic strategy and (hopefully) progress.  
 
Several prospective biomarkers for AD are under ongoing investigation. These are beyond the scope 
of this work, but include NFL (Olsson et al., 2016), Neurogranin (Kester et al., 2015a; Thorsell et al., 
2010; Wellington et al., 2015), SorLA (Caglayan et al., 2014; Fagan and Perrin, 2012; Paterson et al., 
2014), YKL-40 (Craig-Schapiro et al., 2010; Janelidze et al., 2015; Kester et al., 2015b; Olsson et al., 
2016), NSE, VLP-1, GFAP, MCP-1, and HFABP (Olsson et al., 2016), and TREM2 (Bekris et al., 2018; Liu 
et al., 2018), as well as albumin ratio (Skillbäck et al., 2017) and -synuclein (Korff et al., 2013; Shi et 
al., 2018) for differential diagnosis.  
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1.5.3 The biomarker challenge 
Evidence that AD follows a disease course characterised by protein misfolding, followed by 
neurodegeneration, followed by clinical symptoms of dementia is extremely well established (Jack et 
al., 2013), and has withstood testing for decades. However, virtually all therapeutics based on this 
understanding have failed. Principally, these drugs have targeted aggregated forms of Aβ, or sought 
to decrease Aβ peptide production in late stage disease with - or -secretase modulators, but other 
approaches targeting tau (Medina, 2018) and inflammation (Miguel-Avarez et al., 2015) have also yet 
to meet with success. It is worth noting that in Phase II trial the anti-A BAN2401 antibody has 
showed promising signs of A42 reduction and symptom modification (at 18 months, after reporting 
no cognitive benefit at a 12-month time point (Logovinsky et al., 2016)). However, significant 
questions surrounding the balancing of treatment and control groups persist, and further validation 
at Phase III is needed. History is not on BAN2401’s side. 
 
Figure 5: Showing the results of a meta-analysis of Aβ38/40/42, T-tau and P-tau power to identify AD. Effect size is the ratio of 
mean biomarker concentration of one condition over another e.g. AD vs control (CTRL)). The z-score is a statistic representing how 
far away the observed ratio is from the null hypothesis of no difference. The size of each circle reflects the total number of subjects 
used. Data in the public domain, courtesy of ALZBIOMARKER interactive resource and Olsson et al. 2016. 
Figure 5: Meta-analysis of AD biomarker effect size 
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The challenge, therefore, is to translate knowledge of AD biology into therapeutic success. Reasons 
attributed to failures in this regard are many and complex but can be organised into at least four 
categories: issues with trial methodology, differential diagnosis, application of intervention, and 
disease conceptualisation.  
 
In the case of trial methodology, it is often difficult for large-scale longitudinal trials to recruit and 
retain sufficient participants to meet power requirements, and design of appropriate statistical 
methods is not always straightforward.  
 
In terms of differential diagnosis, the fact AD is usually a slow progressive disease of late life means 
that identifying appropriate controls or individuals without confounding co-morbidities is not easy. 
The accuracy and precision of CSF biomarkers is crucial in grouping trial participants, diagnosis of 
patients in clinical, and interpretation of therapeutic effect. As discussed in Section 1.5.2, even the 
best biomarkers are considerably less than perfect. Initiatives to track immunoassay reliability 
routinely report that between-site coefficient of variation percentages (%CV) for commercially 
available T-tau and Aβ42 assays fall on average between 20-30% (Mattsson et al., 2013) (Figure 6).  
 
Appropriate application of treatment relies on understanding effective dose regimes in balance with 
safety, and requires high quality, human valid models. It is possible that drugs may also interfere 
with measurement of biomarkers such as A, with important consequences for data interpretation. 
Furthermore, timing of application has been much commented on. Intervention in symptomatic 
stages of AD may be too late, with cascading pathology too advanced and multifactorial to reverse 
(Mehta et al., 2017). Accurate biomarkers and detailed understanding of disease biology not only 
underpin our ability to discern who to treat, but when and how.  
 
Understanding of the pathobiology of AD has grown immensely over the past three decades. Given 
the level of organisation and time required to complete a clinical trial it is not surprising that many 
lag behind cutting edge nuances of new research. Candidate drugs are typically screened in model 
systems. Such systems often over express A in order to mimic late stage human AD brain states, 
but it may be that aggregates formed in these models have low relevance to the physiological 
disease process. Along similar lines, some A species may be more relevant than others. 
Pyroglutamate forms of A (e.g. A3(PE)-42) have been shown to have enhanced cytotoxicity 
(Nussbaum et al., 2012), whereas low concentrations of monmers, and perhaps certain peptides or 
greater protportions of C-terminally truncated peptides especially, contribute to normal 
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physiological function and thus could be considered neuroprotective (Brothers et al., 2018). A 
targeting therapeutic approaches have so far had poor discrimination for these nuances beyond the 
extent to which they engage soluble versus insoluble structures. Finally, it is important to concede 
the possibility that our conceptualisation of AD may not be correct. The weight of evidence falls in 
favour of the amyloid cascade hypothesis, but it is equally clear that pieces of the puzzle and/or its 
arrangement are missing. Pursuit of better models and robust replication of results can be the only 
recourse to these doubts. This thesis will contribute to effort to understand and treat AD by 
expanding knowledge of confounding factors affecting the measurement of A peptides and their 
production in an in vitro model of fAD.  
 
 
 
Figure 6: Summarising the results of the Alzheimer’s Association QC program for CSF biomarkers from 2001-2016. Data represents a 
collaboration of more than 100 sites measuring the same samples for Aβ42 using the INNOTEST ELISA - consistently one of the best 
performing assays. Image and data provided by the Alzheimer’s Association QC program for CSF biomarkers, used with permission. 
Figure 6: Results of Aβ1-42 measurement across multiple sites 
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1.5.4 Confounding factors and amyloid beta 
Confounding factors are conditions that artificially influence the measurement of biomarkers from 
samples. Sample storage and handling practices are an important consideration for biobanking, and 
large repositories of samples are currently being generated by many international dementia 
consortiums and independent groups (e.g. Dominantly Inherited Alzheimer’s Disease Network 
(DIAN), Alzheimer’s Disease Neuroimaging Initiative (ADNI), European Prevention of Alzheimer's 
Dementia (EPAD) Longitudinal Cohort Study, The Swedish BIOFINDER Study, UCL Dementia Research 
Centre clinical cohorts and many more). These initiatives, many of them longitudinal in design, 
represent the future of appropriately powered research on well characterised disease cohorts.  
  
Table 4: Confounding factors 
Pre-analytical 
Patient demographics 
Patient medication 
Lumbar vs ventricular CSF 
Patient fasting 
Spinal cord gradient 
Diurnal variation 
Blood contamination 
Sample matrix composition 
Sample pH 
Centrifugation settings 
Post-collection interval 
Sample mixing 
Storage temperature 
Storage vessel material 
Surface exposure 
Freeze/thaw cycles 
Analytical 
Assay calibration 
Assay reagent batch 
Assay platform 
Operator competence  
Table 4: A list summarising the known confounding factors for the measurement of proteins in biological fluid, with a focus on CSF. 
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Many confounding factors for the measurement of Aβ (primarily Aβ42 and Aβ40) in fluid biomarkers 
relevant to AD research have been identified. Pre-analytical influences include clinical variables 
(besides AD and non-AD pathology) such as age, sex, genetic risk factors (e.g. APOE genotype) and 
medication (e.g. statins (Chu et al., 2018)), AD family history (Liu and Caselli, 2018; Zuo et al., 2006), 
and study design (Crean et al., 2011), CSF collection technique (Lucey et al., 2015; Rembach et al., 
2015), diurnal collection time (Cicognola et al., 2015), contamination with blood (Bjerke et al., 2010), 
interval between collection and freezing (Le Bastard et al., 2013; Kaiser et al., 2007), temperature 
(Bibl et al., 2004; Ranganathan et al., 2006; Sancesario et al., 2010), pH (Murphy et al., 2013), 
sample matrix composition (Slemmon et al., 2012, 2015), and assay measurement variation (Ellis et 
al., 2012; Fagan et al., 2011; Lewczuk et al., 2008; Mattsson et al., 2010, 2011, 2012b, 2013; Reijn et 
al., 2007; Vos et al., 2014; Wang et al., 2012). Analytical confounding factors are related to the assay 
itself, for example, differences in technician skills and training, operating procedures, assay 
manufacturing, or batch-to-batch variations in kits (Mattsson et al., 2013). Several papers have 
presented studies providing data from assessments of multiple factors (Le Bastard et al., 2015; Bjerke 
et al., 2010; del Campo et al., 2012; Fourier et al., 2015; Schoonenboom et al., 2005). These 
confounding factors are summarised in Table 4. Further study of factors influencing the 
concentration of Aβ in CSF and other biofluids is important to improve understanding of how to 
preserve disease relevant qualities from in vivo to ex vivo, and standardising storage and handling 
practices to ensure reliable interpretation of results.  
 
The experiments of this thesis focused on the interaction of A peptides with polypropylene storage 
surfaces. Protein adsorption to solid surfaces is a field of study with a long history and an expansive 
literature. In a recent review, Rabe et al. coalesce current understanding of this phenomena with 
admirable clarity (Rabe et al., 2011). There are four forces responsible for protein adsorption onto 
solid surfaces: hydrophobic, van der Waals, electrostatic, and hydrogen-bonding interactions 
(Haggerty et al., 1991; Haynes and Norde, 1994; Lee and Ruckenstein, 1988). Factors that influence 
these forces, and therefore the nature of protein adsorption to solid surfaces can be thought of in 
three categories: external parameters, surface properties and protein properties.  
 
External parameters include temperature, pressure pH, ion, salt and dissolved gas concentration 
(Faghihnejad and Zeng, 2012). Increase in temperature is generally associated with increased 
adsorption due to a corresponding increase of system entropy and diffusion rate. pH determines the 
electrostatic state of a protein based on its isoelectric point (pI), and therefore the extent of 
attraction to the surface and other molecules. Greater ionic strength decreases opposite charge 
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attraction and increases same charge attraction as a function of the Debye length. Salts can 
influence protein precipitation as a result of sequestering H2O molecules.  
 
Important surface properties are texture, surface free energy, polarity, charge, and morphology. 
Proteins with high internal stability do not readily adsorb to hydrophilic surfaces unless there is an 
electrostatic attraction, in which instance they do not tend to alter conformation. To bind to 
hydrophobic surfaces, entropy loss must be overcome by gain of energy caused by removing 
hydrophobic residues from contact with water, accompanied by structural change. Proteins with low 
internal stability adsorb onto most surfaces irrespective of electrostatic interactions due to 
favourable conformational entropy gain that binding to the surface provides (Dill, 1990; Nakanishi et 
al., 2001; Rabe et al., 2011). Polystyrene and polypropylene, among the most common storage 
materials in medical science, are non-polar and thus hydrophobic (Faghihnejad and Zeng, 2012; Jang 
and Kim, 2016; Rocha et al., 2005; Żenkiewicz, 2001). Surface texture is highly dependent on 
manufacture conditions, and co-polymer content. 
 
The primary structure and conformational dynamics of Aβ discussed in Sections 1.4.3.1-4 make the 
peptide highly labile and difficult to work with. In addition to self-aggregation in solution, Aβ will 
bind to solid surfaces with some promiscuity. Studies have demonstrated attraction of Aβ to 
negatively charged phospholipid membranes (Ji et al., 2002; McLaurin and Chakrabartty, 1997) and 
both positive NH2 and negative COOH coated surfaces (Moores et al., 2011). A40 adsorbs on 
hydrophobic and positively charged hydrophilic surfaces, where it readily forms parallel -sheets at 
surface interfaces (Rocha et al., 2005). Furthermore, other groups have demonstrated different 
Aβ42 and Aβ40 concentrations measured from CSF stored in polystyrene, polypropylene, 
copolymers, and glass containers (Bjerke et al., 2010; Kofanova et al., 2015; Lewczuk et al., 2006a; 
Murray et al., 2013; Perret-Liaudet et al., 2012a; Vanderstichele et al., 2016). Polypropylene was 
generally found associated with higher peptide measurements. As a result, clinical practice has 
moved toward standardising the use of polypropylene for CSF storage over other materials such as 
polystyrene. Despite this, polypropylene is a non-polar material and therefore has hydrophobic 
properties which are favourable for binding hydrophobic molecules, such as Aβ. An instructive 
example is given by Murray et al., in which the authors describe how the confounding effect of A 
adsorption to their polypropylene plate wells led them to misinterpret their data (Murray et al., 
2013). 
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1.5.5 Modelling Alzheimer’s disease 
In addition to the importance of improving A measurement for clinical diagnostic and trial 
purposes, a detailed understanding of healthy biology and disease processes is required to guide 
therapeutic or prophylactic strategy. AD is a disease of the living human brain, a delicate and 
notoriously difficult organ to access for study. Post-mortem samples of human brain tissue are very 
valuable, and a great debt is owed to those who have donated their brains for examination. Work on 
these samples contributed the earliest evidence of AD pathology (Stelzmann et al., 1995) and have 
provided the ‘gold standard’ confirmation of AD presence (Scheltens and Rockwood, 2011). Due to 
the degradative processes that occur in dead tissue, other samples are better suited to examination 
of disease mechanism, particularly at earlier stages of AD. The bulk of our understanding of AD 
disease mechanisms has been afforded through the use of animal models, in particular the 
transgenic (Tg) mice, among other species comprehensively reviewed by Woodruff (Woodruff-Pak, 
2008). Other methods such as in silico computational modelling are also finding increasing use 
(Ranjan et al., 2018). 
 
1.5.5.1 Animal models: the example of the transgenic mouse 
Tg mouse models capture several major aspects observed in human AD. Overexpressing human 
mutant APP (in models such as Tg2576, PDAPP, TgAPP23) leads to the formation of extracellular 
amyloid plaques, which are structurally similar to those of the human brain, in an age and A42 
dependent manner (LaFerla and Green, 2012). Additionally, just as in human AD, cognitive decline in 
these mice tends to correlate poorly with plaque load (Terry et al., 1991), but is more strongly 
associated with concentrations of soluble A oligomers which associate with synaptic loss (Ashe and 
Zahs, 2010).  
 
However, there are notable differences between the human CNS and that of other species. At a 
structural level the absence of gyrencephalic cortex in rodents, and the arrangement and 
connectivity of basal ganglia elements (e.g. the caudate, putamen and subthalamic nuclei), as well as 
broader differences in neuronal network development, complexity, diversity, density, and 
white/grey matter ratios, represent profound differences from human anatomy (Berry et al., 2018; 
Finlay and Darlington, 1995; Hill and Walsh, 2005; Rakic, 2009). In terms of modelling AD, in humans 
amyloid and tau pathology are well established by the time clinical symptoms manifest, whilst in 
mice behavioural alterations typically precede insoluble A deposition (LaFerla and Green, 2012). 
Importantly, whilst single Tg APP and PSEN mouse models present with increased tau 
hyperphosphorylation, unlike humans they do not develop NFTs (Götz et al., 2007), or demonstrate 
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much if any AD-linked neuronal loss (Ashe and Zahs, 2010). Multi-transgenic models (incorporating 
human mutated APP, MAPT, and presenilin 1), produce mice with NFT pathology downstream of 
intra- and extracellular A deposition (Blurton-Jones and LaFerla, 2006; Oddo et al., 2003). However, 
the MAPT mutations used are derived from mutations associated with FTD rather than AD, due to 
the paucity of AD associated MAPT genetics, and so questions remain over how translatable 
pharmacological interventions guided by these models might be to humans (Berry et al., 2018; 
LaFerla and Green, 2012). Additionally, whilst rodent models do display immune response to 
aberrant AD-associated proteins, the nature and severity of the inflammation imperfectly mirror 
that seen in humans (LaFerla and Green, 2012). Indeed, laboratory mouse strains are genetically 
homogenous and immune-stress privileged in a way that human therapeutic target populations are 
not (Berry et al., 2018). Finally, there are also important differences in human liver metabolism 
compared with other species, even other primates, that may impact severity of the disease 
phenotype and the effectiveness and safety of new drugs in clinical trials (Passier et al., 2016). It has 
been suggested that putative therapeutics be screened in at least two animal models prior to human 
trial (Kieburtz and Olanow, 2007). However, this is expensive to achieve, and though in principle this 
would show that targeted pathways are conserved enough between species to have greater 
confidence of effect in humans, it does not entirely circumvent the issue. 
 
1.5.5.2 Induced pluripotent stem cell models of Alzheimer’s disease 
Induced pluripotent stem cells (iPSCs) are stem cells generated by the de-differentiation 
(reprogramming) of somatic tissues (Figure 7), which have the potential to differentiate to any cell of 
the three germlines (endoderm, mesoderm, ectoderm), falling short of totipotency only through the 
inability to derive embryos and certain extra-embryonic tissues. In their Nobel Prize winning work, 
Takahashi and Yamanaka demonstrated that reprogramming of mouse fibroblasts could be achieved 
through the expression of only four pluripotency-associated transcription factors: OCT4, Klf4, SOX2, 
and c-MYC (Takahashi and Yamanaka, 2006). Later work reproduced these results using the same 
transcription factors in human cells (hiPSCs) through a variety of reprogramming vectors (Fusaki et 
al., 2009; Takahashi et al., 2007; Warren et al., 2010; Yu et al., 2007, 2009; Zhou and Freed, 2009).  
 
hiPSC-derived neurons hold great promise as neurological disease models. Disease-relevant cell 
types with a fully human genetic background can be differentiated from reprogrammed cells that 
are highly comparable to human embryonic stem cells (hESCs) (Berry et al., 2018; Mallon et al., 
2014), and often better clinically characterised, although some differences of gene expression 
between hiPSCs and hESCs have been observed (Chin et al., 2010). Importantly, iPSC-neurons 
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develop on a physiologically relevant time-frame, and are able to form electrically functional 
synaptic networks (Shi et al., 2012a). The potential for the study of neural development, physiology, 
disease mechanisms and pharmacology on functional patient-specific cells opens exciting avenues 
for personalised, targeted, and regenerative medicine, bypassing the issues of tissue rejection and 
ethical controversy that limit ESCs. 
 
 
Induced pluripotent stem cell (iPSC) models are already proving a powerful tool for exploring APP 
processing in tissue specific cells from individuals with fAD-causing mutations (reviewed in Arber et 
al. (Arber et al., 2017)). Yagi et al. found increased levels of secreted Aβ42 in neurons with the PSEN1 
A246E and PSEN2 N141I mutations (Yagi et al., 2011). Further work on neurons bearing pathogenic 
PSEN1 mutations have shown an increased ratio of A42:40 (Mahairaki et al., 2014; Moore et al., 
2015; Ochalek et al., 2017; Sproul et al., 2014; Sun et al., 2017; Woodruff et al., 2013). Similarly, iPSC-
derived neurons with an APP V717I genotype show a raised Aβ42:40 ratio (Moore et al., 2015), as 
well as increases in Aβ42 and Aβ38 (Muratore et al., 2014). APP duplication iPSCs also exhibit high 
Figure 7: Visualising the process of reprogramming cells from adult humans back to a pluripotent stem cell state and then 
developmentally forward into any cell type of the three germ lines, such as neurons in this case. Disease specific cells can be used 
to develop pharmacological interventions for disease by improving our understanding of human biology, or directly screening 
small molecules in culture. With further development of the technology, stem cells themselves could one day be used in cell 
replacement therapy.  
Figure 7: From adults to stem cells… and back again 
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levels of A40 (Israel et al., 2012). Finally, 3D cerebral organoids provide a potentially valuable 
system for modelling neurodevelopment in 3D architecture, and possibly CSF due to the presence of 
choroid plexus tissue (Lancaster et al., 2013). Early reports suggest increased amyloid aggregation in 
3D cultures (Raja et al., 2016), as well as an ability to identify candidate proteins involved in AD 
pathogenesis (Chen et al., 2018). However, a comprehensive analysis of the full spectrum of Aβ 
peptide production across multiple different fAD mutations to explore the mechanisms proposed by 
Chávez-Gutiérrez et al. has yet to be performed in patient-derived neurons (Chavez-Gutierrez et al., 
2012).  
 
Work on sAD cell lines has been more limited, although work so far has also tended to show 
increased production of A, particularly A42, compared to controls (Israel et al., 2012; Ochalek et 
al., 2017). Kunkle et al. recently published findings implicating APP in association with late onset AD, 
which largely overlaps with sAD (Kunkle et al., 2019), although GWAS data over all weight genes 
linked with amyloid clearance rather than aberrant production in sAD (Guo et al., 2017; Shen and Jia, 
2016). It has been noted that increased A in sAD lines is not consistent, particularly compared to 
fAD cultures, and some lines do not demonstrate this tendency. It is particularly interesting that 
ochalek et al. report that whilst A42 and A40 were significantly raised versus controls in the sAD 
and fAD lines they studied, (and indeed A40 was higher in sAD than fAD), the A42:40 ratio was not 
different between sAD and controls (Ochalek et al., 2017).  
 
Despite the energy with which the research community has adopted iPSCs, this is still a young and 
relatively unrefined field, accompanied by several limitations.  
 
Firstly, although the ability to isolate specific, developmentally representative human cell types for 
study is a strength of the technology, it cannot replicate the integrated systems and behaviours of a 
complete organism. Furthermore, it is well established that neural and glia development and death 
processes are moderated by intricate inter-cellular signalling dynamics. The importance of system 
interconnection to the manifestation of AD is not currently known, but it is becoming clear that many 
different types of neuron, activation states of glia, and blood brain barrier factors have 
fundamentally important roles. However, 3D cultures such as neurospheres (Choi et al., 2013) and 
cerebral organoids (Lancaster and Knoblich, 2014), represent a step toward a more physiologically 
representative neuronal network architecture and tissue complexity, including the presence of 
human progenitor cell types and stratified cortical layers.  
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Secondly, control of genetic integrity has been a focus of initial model optimisation work. The nature 
of reprogramming exposes cells to persistent genomic integration of the vector if retrovirus or 
lentivirus are used for this purpose, although non-integrative techniques such as sendai virus and 
plasmids have been developed. Additionally, retention or loss of epigenetic factors during 
reprogramming and over passage is an object of continuing concern (Berry et al., 2018; Kim et al., 
2010), as is the efficiency of protocols for directed differentiation to produce cells of the desired type 
(Berry et al., 2018; Giorgetti et al., 2010).  
 
Thirdly, the use of pluripotent cells, and expression of carcinogenically associated transcription 
factors, represents a risk that currently restricts transplant potential (Martin, 2017). The risk posed 
by prions has not been explored in detail, but is also relevant to consider in the context of 
transplanting tissue. 
 
Finally, recognition of biomarker variability between lines from different and even the same donor, as 
well as between groups, has been low but steadily growing (Wernig, 2016). Alongside the role of 
genetic integrity in this, it is worth considering the role of culture environment. iPSCs and derivative 
cells are stably cultured in incubators at 37°C, typically with 5% CO2 and 95% humidity. However, in 
most cases cells are removed from this environment for media replenishment exposing them to 
altered atmospheric and temperature conditions for variable periods of time. Media is typically not 
stored in these same conditions and thus dissolved gas concentration take additional time to 
equilibrate after feeding. Furthermore, cells are usually maintained at atmospheric oxygen 
concentrations (~21%), considerably greater than physiological concentrations (~1-5%) (Van Der 
Sanden et al., 2010). These ‘normoxic’ conditions represents a hyperoxic environment for these cells, 
which has been linked with increased rates of spontaneous differentiation, telomere length 
alteration (with implications for genomic integrity) (Chen et al., 2014). The process of feeding cells 
(by pipetting in and out media) exposes cultures to mechanical stress, and sudden molecular and pH 
change, the effects of which have not been well studied. Finally, surface coating methods vary 
between use of various materials (mouse embryonic feeder cells, Matrigel, Geltrex, laminin etc.), and 
differences in iPSC viability have been reported to even alter with surface plastic treatment (Saha et 
al., 2011). 
 
1.6 Chapter Summary and thesis aims 
AD is an emergent global health crisis for which no prophylactic or curative treatments are available. 
Of the various forms of AD, the proportionally small number of fAD cases manifest pathology 
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representative of more common sAD forms with causal factors more amenable to study. Decades of 
experiment shows that Aβ plays a key role, particularly in the early stages of AD. Despite this, the 
lack of success in the development of effective therapeutics has created a need for better biomarkers 
and more detailed understanding of basic AD biology. This thesis seeks to address these needs by 
contributing novel data to guide the storage and handling of samples intended for Aβ measurement, 
and probe the mechanisms of Aβ production in human glutamatergic cortical neurons. 
 
To reiterate, the specific aims of this project are: 
I. Identify novel confounding factors in the storage and handling of CSF and cell culture media 
that may artificially alter detectable Aβ peptides. Factors studied include: 
 Effect of sample storage volume,  
 Effect of sample transfer between tubes, 
 Effect of Tween 20 on sample measurement variation, 
 Effect of using a spinal manometer, 
 Effect of sample transportation time and temperature in clinical context, 
II. Investigate the physiological relevance of hiPSC-neurons by comparing A peptide profiles in 
cell culture, CSF, and brain homogenate from a single patient with the APP V717I mutation. 
III. Investigate the full spectrum of A peptides produced by glutamatergic cortical neurons 
from six different fAD lines (APP V717I, PSEN1 int4del, PSEN1 Y115H, PSEN1 M139V, PSEN1 
M146I, and PSEN1 R278I) and five non-neurodegenerative controls. 
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2 Methods 
 
2.1 Enzyme Linked Immunosorbent Assay 
 
 
 
Enzyme linked immunosorbent assay is an analytical technique to quantify single (singleplex), or 
multiple (multiplex) molecules in solution. In principle, the antigen of interest is immobilised to a 
surface and bound to an enzyme which is then stimulated by application of a substrate. The 
interaction between free biotin (vitamin B7) and streptavidin (a protein purified from Streptomyces 
avidinii) is extremely strong (Kd ≈10−14 mol/L) and even outperforms that between biotin and avidin 
(Kd ≈10−15 mol/L) when biotin is conjugated to another molecule. For this reason, this protein pair 
are the predominant means of forming a conjugate antibody-enzyme complex in commercial ELISAs. 
There are several different formats of ELISA, which can be defined by the approach taken to two 
concepts: analyte capture (antigen immobilisation and antibody binding) and analyte detection 
(direct or indirect). These are depicted in Figure 8.  
 
Direct assay involves the immobilisation of antigen to the surface of a 96 well assay plate or silicone 
bead. Depending on the assay, this can be through streptavidin coating of the plate and biotinylation 
of the antigen, and direct covalent binding or adsorption of the antigen to the plate surface. The 
antigen is then bound ‘directly’ by an antibody-enzyme conjugate and detected through reaction of 
the enzyme with its substrate. The advantage of direct assay is the comparatively few number of 
steps in its application, reducing experiment time and risk of measurement error due to reliance on 
Figure 8: Diagram showing the principles of the most common forms of ELISA.  
  
Figure 8: Common forms of ELISA 
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few reagents and only one antibody (i.e. no potential for cross-reaction). The disadvantages of this 
format are lower specificity and increased background signal (all proteins in solution will bind to the 
plate), and lower sensitivity (as no secondary antibody is used for signal amplification).  
 
In indirect assay, the initial method of capture is similar to direct assay and the defining difference 
comes from the method of linking antigen presence to signal. In this format multiple secondary 
antibody-enzyme conjugates bind to the primary antibody-antigen complex, and thus ‘indirectly’ to 
the antigen. The advantage of this method is increased assay sensitivity, and offers the flexibility to 
potentially use different primary antibodies with the same secondary antibody. However, the 
disadvantages of non-specific antigen immobilisation remain, alongside more assay steps and risk of 
antibody cross-reaction.  
 
Sandwich ELISA involves the initial immobilisation of an antigen-specific antibody to the surface of a 
96 well assay plate or silicone bead, rather than the antigen itself. Depending on the assay, this can 
be through streptavidin coating of the plate and biotinylating of the antibody, and direct covalent 
binding or adsorption of the antibody to the plate surface. Prior to the addition of sample, the assay 
plate is blocked with assay buffer (containing blocking agents, common examples of which are 
albumin, milk, or Tween 20) to minimize non-specific binding of molecules to the plate surface. Upon 
introduction of sample the antigen is bound and immobilized by the capture antibodies, non-specific 
proteins are washed out leaving only the analyte of interest. Next, primary antibodies complete the 
‘sandwich’ by binding to a secondary epitope of the antigen, and this complex is then detected by an 
enzyme conjugated secondary antibody (designated detection antibodies) just as in the indirect 
assay format. The advantages of sandwich ELISA are high specificity and sensitivity with low 
background signal, at the cost of a more complicated experiment design and risk of antibody cross-
reaction. The advantages provided by this method make it the most popular format for clinical 
biomarker assay. All ELISAs used in this thesis utilized the sandwich format to measure AD 
biomarkers. 
 
Finally, direct, indirect, and sandwich ELISAs can all be adapted to a competitive assay format. In this 
method, a known quantity of antigen is immobilised to the plate, the sample (unknown quantity of 
antigen) is then introduced alongside enzyme-conjugated antibodies. The antigens of interest in 
solution bind to the antibodies and ‘compete’ with antibody binding to the immobilised antigens, 
and are then washed out. When the enzyme reaction is catalysed, this process results in a signal that 
is inversely proportional to the antigen concentration of the sample i.e. a large amount of sample 
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antigen will mean less antibody bound to the plate and generate a low signal. The advantages of this 
format are the design flexibility it enables for antigens that are not amenable to forming complexes 
with multiple antibodies. The weaknesses of indirect, direct, or sandwich ELISA are retained as 
applicable.   
 
The signal produced by the enzyme reaction is measured by a detector. Depending on the assay and 
enzyme substrates used, signal can be fluorescent, chemiluminescent, or chromogenic. Method of 
detection is dependent on the nature of the signal. Fluorescent ELISA substrates require a 
fluorometer, which utilises an electron beam to excite the fluorescent tag bound to the analyte of 
interest and measures the intensity of emitted light when electrons fall back to ground state energy. 
In chemiluminescence, light is generated from a chemically exothermic reaction between the 
enzyme tag and its substrate. A photoreceptor is used to detect this light signal, and is often 
combined with a photomultiplier that transforms photon energy to a cascading voltage and amplifies 
the signal, enabling greater sensitivity. For colorimetric-based assays, such as those used in the 
ELISAs of this thesis, the enzymatic reaction produces a visible spectrum colour change in the assay 
solution, a laser is passed through the assay solution and strikes a spectrometer. The absorption of 
energy at maximal absorbance wavelength is proportionate to the intensity of the solution colour, 
and therefore of the analyte of interest. 
 
The most common enzyme reaction employed by commercial ELISAs, and the one used by ELISAs in 
this thesis, is that between horseradish peroxidase (HRP) and 3,3’,5,5’-tetramethylbenzidine (TMB) 
(Josephy et al., 1982). HRP is a metalloenzyme found in the roots of horseradish, and is smaller, more 
stable, and less expensive to produce than alkaline phosphatase. TMB is a chromogenic substrate 
molecule, which has the advantage of being non-carcinogenic. HRP catalyses the hydrolysis of H2O2 
into H2O by oxidation of TMB, a reaction that produces a blue colour with absorbances of 370nm and 
652nm. The addition of sulphuric acid stops the ongoing reaction leaving a TMB diamine which 
produces a yellow colour with a light absorbance of 450nm. 
 
Quantification of sample antigen is achieved by reference to the signal of a series of calibrators (a 
standard curve) of known concentration ranging from low to high. Calibrator data are typically fitted 
to a 4-paramater logistic curve, which accounts for maximum and minimum values, and assumes 
symmetry around the inflection point. When sample signal is plotted, the intercept between the 
signal and the curve corresponds to the analyte concentration. Two important parameters for 
assessing ELISA reliability are precision profile and dynamic range (limits of quantification). The 
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precision profile is a plot of calibrator CV over a range of concentrations. Calculation of the precision 
profile allows for the estimation of random error across a concentration range and identification of 
working range of the assay. The dynamic range of the calibration curve are thus defined by the 
concentrations where the precision profile intersects an acceptable level of variability (typically 20% 
CV). Samples with concentrations that fall beyond this range cannot be reliably quantified, and 
measurements become less reliable toward the lower and upper limits of quantification. 
 
2.1.1 Measurement of A1-43 
Aβ42 was measured by IBL international ELISA kit (Männedorf, Switzerland), according to 
manufacturer’s instructions. Samples were added undiluted in duplicate to microplate wells coated 
with a polyclonal capture antibody (#18583) specific for Aβ43 C-terminal (epitope VVIAT, A39-43). 
The microplate wells were washed with assay wash buffer to remove unbound material. Samples 
were incubated with a biotinylated detection antibody (#10326) targeting Aβ N-terminus (epitope 
DAEFRH, A1-5). The microplate wells were washed with assay wash buffer to remove unbound 
material. The detection complex was completed with the addition of horseradish peroxidase-
labelled streptavidin. After an incubation period, tetramethylbenzidine (TMB) substrate was 
introduced. Peroxidase catalysed hydrolysis produces a colorimetric signal, the absorbance of which 
was measured using a FLUOstar Omega multi-mode microplate reader (BMG Labtech). Absorbance 
was measured at 450nm minus a reference signal of 690nm. Sample concentrations were 
extrapolated from a standard curve, fitted using a four-parameter logistic algorithm. The lower and 
upper limit of quantification range for this assay is 2.34-150 pg/mL. 
 
2.1.2 Measurement of phospho tau181 
P-tau181 was measured by Fujirebio INNOTEST ® PHOSPHO-TAU(181P) ELISA kit (Innogenetics, Ghent, 
Belgium), according to manufacturer’s instructions. Samples were added undiluted in duplicate to 
microplate wells coated with an HT7 (IgG1) monoclonal capture antibody specific for human tau 
(recognising epitope PPGQK, isoform PNS-tau476-480). The microplate wells were washed with 
assay wash buffer to remove unbound material. Samples were incubated with a biotinylated tau 
specific AT270 (IgG1) monoclonal detection antibody recognising phosphorylated at Thr181 (within 
the APKTPPS epitope, isoform PNS-tau476-480). The microplate wells were washed with assay wash 
buffer to remove unbound material. The detection complex was completed with the addition of 
horseradish peroxidase-labelled streptavidin. After an incubation period, tetramethylbenzidine 
(TMB) substrate was introduced. Peroxidase catalysed hydrolysis produces a colorimetric signal, the 
absorbance of which was measured using a FLUOstar Omega multi-mode microplate reader (BMG 
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Labtech). Absorbance was measured at 450nm minus a reference signal of 690nm. Sample 
concentrations were extrapolated from a standard curve, fitted using a four-parameter logistic 
algorithm. The lower and upper limit of quantification range for this assay is 20-199 pg/mL. 
 
2.2 Electrochemiluminescent immunosorbent assay 
 
 
 
 
 
 
 
Electrochemiluminescent immunosorbent assay was conducted using a MSD SPECTRA 6000 (Meso 
Scale Discovery, Maryland, USA). The assay follows a sandwich assay format (Figure 9). The assay 
follows a sandwich ELISA format described in Section 2.1, except in the mechanism of producing 
signal. The MSD assay plate incorporates an electrical circuit that can transmit an electrical current 
through each well. Detection antibodies are conjugated with ruthenium (Ru2+) otherwise referred to 
as MSD SULFO-TAG. For the substrate, a buffer solution containing tropopylomine (TPA) is 
introduced. When an electrical current passed through the assay plate wells Ru2+ is oxidised to Ru3+ 
Figure 9: Diagram showing the principles of ECL in the assays produced by Meso Scale Discovery, used with permission (Meso Scale 
Discovery, 2013). 
Figure 9: Principles of MSD electrochemiluminescent assay 
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by the electrical current and reduced to Ru2+ by TPA, a reaction which produces light. The emitted 
light is detected by a photo-multiplier camera and is proportional to the concentration of the target 
analyte. The photo-multiplier acts as a form of enhanced chemiluminescence enabling a wider and 
more sensitive dynamic range than for a conventional ELISA. The principles of ECL immunosorbent 
assay are illustrated in Figure 9. 
 
 
 
2.2.1 Measurement of Aβ42 singleplex 
Aβ42 was measured by electrochemiluminescence (ECL) using a Meso Scale Discovery V-PLEX Aβ42 
(6E10) kit, according to manufacturer’s instructions. The microplate wells were washed with assay 
wash buffer to block the surfaces and remove unbound material. Samples were diluted 1:2 with 
diluent 35 and added in duplicate to microplate wells coated with proprietary mouse monoclonal 
peptide specific capture antibodies for human Aβx-42. The microplate wells were washed with assay 
wash buffer to remove unbound material. Samples were incubated with anti-Aβ (epitope 
DAEFRHDSGYEVHHQK, A1-16) detection antibody (6E10 clone) conjugated with an electrically 
excitable SULFO-TAG. The microplate wells were washed with assay wash buffer to remove unbound 
material. Finally, MSD read buffer was added to each well and samples were measured immediately 
using an MSD SPECTRA 6000. Concentrations were calculated from ECL signal using a four-parameter 
logistic curve fitting method with the MSD Workbench software package. The lower and upper limit 
of detection range for this assay is 3.0-2000pg/mL. The lower and upper limit of quantification range 
for this assay is 3.0-2000pg/mL. 
 
2.2.2 Measurement of Aβ38/40/42 multiplex 
Aβ38/40/42 were measured by electrochemiluminescence (ECL) using a Meso Scale Discovery V-
PLEX Aβ peptide panel 1 (6E10) kit, according to manufacturer’s instructions. The microplate wells 
were washed with assay wash buffer to block the surfaces and remove unbound material. Samples 
were diluted 1:2 with diluent 35 and added in duplicate, alongside an anti-Aβ (epitope 
DAEFRHDSGYEVHHQK, A1-16) detection antibody (6E10 clone) conjugated with an electrically 
excitable SULFO-TAG, to microplate wells coated with proprietary mouse monoclonal capture 
antibodies specific for the C-terminal neo-epitopes for Aβx-38, Aβx-40, and Aβx-42 respectively. The 
microplate wells were washed with assay wash buffer to remove unbound material. Finally, MSD 
read buffer was added to each well and samples were measured immediately using an MSD 
SPECTRA 6000. Concentrations were calculated from ECL signal using a four-parameter logistic curve 
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fitting method with the MSD Workbench software package. The lower limit of detection and upper 
limit of detection respectively for each peptide are: A38 = 60-8480pg/mL, A40 = 50-7000pg/mL, 
A42 = 3.13-1270pg/mL. The lower limit of detection and upper limit of quantification respectively 
for each peptide are: A38 = 60-8480pg/mL, A40 = 50-7000pg/mL, A42 = 3.13-1270pg/mL. 
 
2.2.3 Measurement of total tau 
T-tau was measured by electrochemiluminescence (ECL) using a Meso Scale Discovery V-PLEX Total 
tau kit, according to manufacturer’s instructions. CSF samples were diluted 1:4 (cell media samples 
were diluted 1:100) with diluent 35 and added in duplicate to microplate wells coated with 
proprietary mouse monoclonal peptide specific capture antibodies for tau isoforms 352, 381, 383, 
410, and 441. The microplate wells were washed with assay wash buffer to remove unbound 
material. Samples were incubated with proprietary mouse monoclonal anti-tau detection antibody 
(recognising tau isoforms 352, 381, 383, 410, and 441) conjugated with an electrically excitable 
SULFO-TAG. The microplate wells were washed with assay wash buffer to remove unbound material. 
Finally, MSD read buffer was added to each well and samples were measured immediately using an 
MSD SPECTRA 6000. Concentrations were calculated from ECL signal using a four-parameter logistic 
curve fitting method with the MSD Workbench software package. The lower and upper limit of 
detection range for this assay is 3.0-2000pg/mL. 
 
2.3 Cerebrospinal fluid collection 
Unless otherwise specified, de-identified human CSF was provided by the Department of Psychiatry 
and Neurochemistry (University of Gothenburg). Use of CSF met the ethical approval criteria of the 
regional ethics board at the University of Gothenburg. The CSF samples were collected by lumbar 
puncture prior to 13:00, from between the L3/L4 or L4/L5 inter-spaces. A volume of 10mL of CSF was 
collected at ambient room temperature into a 10mL polypropylene tube (Sarstedt, Nümbrecht, 
Germany cat. 62.9924.284) directly from the needle. In the case of visible blood contamination, the 
CSF was discarded and the tap continued in a new tube once bleeding had stopped. Samples were 
centrifuged at 2200 relative centrifugal force (RCF) for ten minutes at 20°C, transferred to another 
10mL tube (Sarstedt cat. 62.9924.284) and stored at -80◦C within 1-4 hours of collection. CSF was 
transported overnight from the University of Gothenburg to University College London frozen on dry 
ice by international courier. Samples were stored, unthawed, at -80°C upon receipt. 
 
In a number of experiments CSF was divided into AD and non-AD categories. AD CSF was derived 
from a cohort of individuals with CSF biomarker profiles consistent with AD. These were defined 
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according to cut-offs that, combined, are 95% sensitive and 87% specific for AD: Aβ1-42 <530 pg/mL, 
T-tau >350 pg/mL, P-tau >60 pg/mL using Innogenetic’s INNOTEST Aβ1-42, hTau and P-tau assays 
(Hansson et al., 2006). Non-AD CSF (also referred to as CTRL CSF) was defined by a biomarker profile 
that did not meet these criteria. Hansson et al. derived these values by assessment of lumbar CSF 
taken from 137 patients with MCI and 39 controls followed clinically over a period of 3-6 years, 
during which time conversion to AD was documented. Association between altered CSF biomarkers 
and progression to Alzheimer's disease was independent of established risk factors including age, 
sex, education, APOE genotype, and plasma homocysteine assays (Hansson et al., 2006). 
 
2.4 iPSC culture 
iPSCs were grown on geltrex matrix (ThermoFisher, cat. A1413302) in six-well polystyrene culture 
plates (Nunc, cat. 158007), fed daily with 2mL Essential 8 (Thermo Fisher Scientific, cat. A1517001). 
Essential 8 was composed of DMEM F-12, L-scorbic acid, Selenium, Transferrin, NaHCO3, Insulin, 
FGF2, and TGFβ1 (quantities not provide by manufacturer). Cells were routinely passaged with 0.1% 
EDTA (Invitrogen, cat. 15575-038) approximately every two days, when iPSC colonies were ~300µm 
in diameter. Cells were cultured in a Heracell 150 incubator (Thermo Fisher Scientific, Cat. 
50116047) at 37°C, 5% CO2. Cell pluripotency was checked for each line by immunocytochemistry, 
using antibodies to stage-specific embryonic antigen 4 (SSEA4), OCT3/4, and Tra1-82 (Figure 10). 
SSEA4 and Tra1-82 are proteins expressed on the cell surface of undifferentiated, pluripotent stem 
cells. OCT3/4 is a transcription factor found in the nuclei of undifferentiated, pluripotent stem cells. 
Lines were routinely screened (weekly) for the absence of mycoplasma contamination. 
 
Karyotype screens and G-band analysis were performed on newly generated lines by the company of 
origin or Cell Guidance Systems in the case of CTRL1, SHEF6, APP V717I-2, PSEN1 int4del, and PSEN1 
R278I (Table 5).  
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Table 5: Cell Lines 
Cell line Mutation Sex 
Age of 
onset 
Age at 
biopsy 
APOE 
genotype 
Origin 
Ctrl1 Cognitively normal M - 78 3/3 Dr Tilo Kunath 
Ctrl2 
Cognitively normal 
ND41886 
M - 64 2/3 Coriel repository 
Ctrl3 
Cognitively normal 
RBi001-a 
M - 45-49 3/3 Sigma Aldrich 
Ctrl4 
Cognitively normal 
SIGi1001-a-1 
F - 20-24 3/4 Sigma Aldrich 
SHEF6 
Human embryonic 
stem cell line – no 
known mutation 
F - - 3/3 UK Stem Cell Bank 
APP V717I 1 
APP London mutation 
(2 clones) 
M 49 58 4/4 StemBancc 
APP V717I 2 
Unrelated APP London 
mutation. 
Pre-symptomatic 
(1 clone) 
F - 47 3/3 
Generated in 
house 
PSEN1 
int4del 
Intron 4 deletion in 
PSEN1 (2 clones) 
F 47 47 3/3 StemBancc 
PSEN1 
Y115H 
PSEN1 Y115H (1 clone) M 34 39 3/3 
Generated in 
house 
PSEN1 
M139V 
PSEN1 M139V 
(1 clone) 
F 34 45 2/3 StemBancc 
PSEN1 
M146I 
PSEN1 M146I 
Pre-symptomatic 
(1 clone) 
M - 38 3/3 StemBancc 
PSEN1 R278I PSEN1 R278I (1 clone) M 58 60 2/4 
Generated in 
house 
 
2.5 Differentiation of iPSCs to cortical neurons 
Differentiation to glutamatergic cortical neurons was performed according to the protocol published 
by Shi et al. (Shi et al., 2012). iPSCs were passaged with 0.1% EDTA (Invitrogen, cat. 25575-038) and 
Table 5: Showing the cell lines used in the thesis 
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re-plated at a 5:1 well ratio density, sufficient to reach 100% well confluency within 24 hours. When 
100% confluence was reached, E8 media was replaced with induction media.  
 
Neural induction was achieved via dual SMAD inhibition (dorsomorphin and SB431542). Induction 
media consisted of N2B27 media with added 1 µM dorsomorphin (Tocris, cat. 3093) and 10µM 
SB431542 (Tocris, cat. 1614). N2B27 cell culture media was composed of a 1:1 solution of 
DMEM/F12 + GlutaMax-l (1X) (Life Technologies, cat. 10565018) and Neurobasal Medium (1X) (Life 
Technologies, cat. 12348017) with the following supplements: 0.5X N2 supplement (Life 
Technologies, cat. 17502-048), 0.5X B27 supplement (Life Technologies, cat. 17504-044), 0.5X 
(100μM) MEM non-essential amino acids (Life Technologies, cat. 11140-050), 10μM 2-
mercaptoethanol (Life Technologies, cat. 31350-010), 50U/mL penicillin and 50μg/mL streptomycin 
(Life Technologies, cat. 15070063), 5μg/mL insulin (Sigma-Aldrich, cat. I9278), and 1mM-glutamine 
(Life Technologies, cat. 25030-024). Fresh N2B27 was made every seven days and stored at 4°C.    
 
 
 
 
 
Figure 10: Showing the main stages in the differentiation of iPSCs to glutamatergic cortical neurons, following the Shi protocol (Shi et 
al. 2012).  
Figure 10: Neuronal differentiation 
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The switch from E8 to induction media was considered day 0, for the purposes of tracking cell 
maturation. Induced cells were maintained in induction media for 12 days, with the media replaced 
daily, during which time they formed a compact neuroepithelial layer. On day 12 the 
neuroepithelium was passaged with 1mg/mL dispase (Thermo Fisher Scientific, cat. 1715041) and re-
plated in 1:50 laminin (Sigma-Alderich cat. L2020-1MG) in Dulbecco’s phosphate buffered saline 
solution (DPBS, Life Technologies, cat. 14190-326) coated plate wells at a ratio of 1:2 wells (6-well 
plate to 12-well plate (Nunc, cat. 150628). From this point on they were fed with N2B27 media and 
passaged to 1:100 laminin coated plates.   
 
By day 20 the neuroepithelial cells had formed neural tube-like rosette structures from which neural 
progenitor cells migrated. At day 20 cultures were passaged with 1mg/mL dispase at a ratio of 1:2 or 
1:1 wells. Between days 20-30 cultures continued to differentiate from neuroepithelium to neural 
precursors and layer VI neurons. Non-neuronal differentiation was looked for by light microscopy 
and, if detected, additional passage with 1mg/mL dispase was conducted to filter out these cells.  
 
At day 30, cultures were expanded through passage with 500μL accutase (ThermoFisher Scientific, 
cat. A1110501) at a ratio of between 1:2 and 1:4. At day 35, cells were passaged with 500μL 
accutase and re-plated at a final density of approximately 50,000 cells per cm2. At this stage the 
majority of cells were neural progenitors or deep layer neurons. Over the next 70 days, progenitors 
continued to differentiate into neurons of the six cortical layers. By day 100, cultures were 
composed of functional post-mitotic glutamatergic neurons from each of the cortical layers. Neurons 
used for the experiments in this thesis were grown by Dr. C. Arber and myself. 
 
2.6 Cultivation of 3D organoids 
Cerebral organoids were produced by Dr. C. Arber and Mr. C. Lovejoy following the protocol 
published by Lancaster et al. (Lancaster and Knoblich, 2014; Lancaster et al., 2013). iPSCs were 
cultured as described in Section 2.4. iPSC cultures were dissociated into single cells with 0.1% EDTA 
(Invitrogen, cat. 25575-038), followed by 500μL accutase. Cells were re-suspended in 0.5mL 
embryoid media (40mL DMEM/F12 + GlutaMax-l (1X) (Life Technologies, cat. 10565018), 20% 
knockout serum replacement (KOSR) (Invitrogen, cat. 10828-028), 3% ESC-Quality FBS (Gibco, cat. 
10270-106), 1X MEM non-essential amino acids (Life Technologies, cat. 11140-050), 3.5μM 2-
mercaptoethanol (Life Technologies, cat. 31350-010), 4ng/mL FGF2 (Peprotech, cat. 100-18B 1), 
50μM ROCK inhibitor (Y27632, Millipore, cat. SCM075)), and aliquoted into ultra-low adherence 96-
well ultra-low attachment U-bottom plates (Sigma, cat. CLS7007) at a density of 9000 cells per well. 
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Cells were then allowed to re-aggregate and form embryoid bodies under gravity in an incubator for 
five days, replacing the media every two days.  
 
After six days (designated day 0 for the purposes of tracking culture maturity), embryoid bodies 
were fed with organoid induction media (1:1 solution of DMEM/F12 + GlutaMax-l (1X) (Life 
Technologies, cat. 10565018), and 1X Neurobasal Medium (Life Technologies, cat. 12348017), 
100μM MEM non-essential amino acids (Life Technologies, cat. 11140-050), 50μg of 0.2μm filter 
sterilised Heparin (Sigma, cat. H3149)), and incubated with daily media changes for four days, during 
which time neuroectoderm developed. On day 12 embryoid bodies were suspended in Matrigel 
droplets (BD Biosciences, cat. 356234) to allow neuroepithelial buds and lumen filled voids to form 
with 3D structures. These embryoid bodies were transferred to a 5cm2 culture dish (VWR, cat. 734-
2318) and induction media was switched to organoid differentiation media without vitamin A (1:1 
solution of DMEM/F12 + GlutaMax-l (1X) (Life Technologies, cat. 10565018) and Neurobasal Medium 
(1X) (Life Technologies, cat. 12348017) with the following supplements: 1X N2 supplement (Life 
Technologies, cat. 17502-048), 1X B27 supplement without vitamin A (Life Technologies, cat. 
12587010), 100μM MEM non-essential amino acids (Life Technologies, cat. 11140-050), 100μM 2-
mercaptoethanol (Life Technologies, cat. 31350-010), 50U/mL penicillin and 50μg/mL streptomycin 
(Life Technologies, cat. no. 15070063), 5μg/mL insulin (Sigma-Aldrich, cat. I9278)).  
 
From day 18+, embedded embryoid bodies were fed with organoid differentiation media with 
vitamin A (1:1 solution of DMEM/F12 + GlutaMax-l (1X) (Life Technologies, cat. 10565018) and 
Neurobasal Medium (1X) (Life Technologies, cat. 12348017) with the following supplements: 1X N2 
supplement (Life Technologies, cat. 17502-048), 1X B27 supplement (Life Technologies, cat. 17504-
044), 100μM MEM non-essential amino acids (Life Technologies, cat. 11140-050), 100μM 2-
mercaptoethanol (Life Technologies, cat. 31350-010), 50U/mL penicillin and 50μg/mL streptomycin 
(Life Technologies, cat. no. 15070063), 5μg/mL insulin (Sigma-Aldrich, cat. I9278)) and maintained on 
an orbital shaker under incubator conditions. Media was replaced every three-four days. Orbital 
agitation facilitates nutrient and gaseous diffusion in support of cells deep within the growing 
organoid tissue and minimises necrosis.  
  
2.7 Cell Count 
Cell counts were conducted by Trypan blue staining. Trypan blue is a diazo dye that can only pass 
through the membranes of dead cells and does not compromise the viability of live ones. During 
passage, with cells in suspension immediately prior to re-plating, 10μL of cell solution were mixed 
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with 10μL of 0.4% Trypan blue (Gibco, cat. 15250061). This mixture was ejected into a 
haemocytometer (Marenfeld Neubaue-improved, cat. 0640010) and placed on a light microscope 
with a 10X objective. The average count of unstained cells in each of the four chamber corners was 
recorded, multiplied by the volume of the haemocytometer (10,000cm3), and then multiplied by any 
dilution factors (i.e. 2X from admixture with Trypan blue). 
 
2.8 Cell culture media collection 
Cortical neurons and 3D organoids were fed with N2B27 cell culture media, composed of a 1:1 
solution of DMEM/F12 + GlutaMax-l (1X) (Life Technologies, cat. 10565018) and Neurobasal Medium 
(1X) (Life Technologies, cat. 12348017) with the following supplements: 1X N2 supplement (Life 
Technologies, cat. 17502-048), 1X B27 supplement (Life Technologies, cat. 17504-044), 100μM MEM 
non-essential amino acids (Life Technologies, cat. 11140-050), 100μM 2-mercaptoethanol (Life 
Technologies, cat. 31350-010), 50 Units/mL penicillin and 50μg/mL streptomycin (Life Technologies, 
cat. no. 15070063), 5μg/mL insulin (Sigma-Aldrich, cat. I9278), and 1mM-glutamine (Life 
Technologies, cat. no. 25030-024). Cells were incubated in N2B27 for 48 hours prior to media 
collection. Media was collected in Greiner 15mL PP tubes (cat. T1943-1000EA), centrifuged at 2000 
RCF for five minutes at 21°C, aliquoted at 1mL into Sarstedt 2mL PP tubes (cat. 72.694.406), and 
stored at -80°C. 
 
2.9 Cell protein lysate collection 
To lyse cells for protein extraction, filter sterilised Radioimmunoprecipitation assay (RIPA) buffer 
(10mM Tris-HCl (pH 8.0) (Sigma-Aldrich, cat. 07066), 1mM EDTA (Invitrogen, cat. 25575-038), 0.5mM 
EGTA (Sigma-Aldrich, cat. E3889), 1% Triton X-100 (Sigma-Aldrich cat. X100-500ML), 0.1% sodium 
deoxycholate (Sigma-Aldrich cat. D6750), 0.1% SDS (Sigma-Aldrich cat. L3771), 140mM NaCl (Sigma-
Aldrich cat. S7653) with added 1X EDTA free cOMplete mini (Sigma-Aldrich cat. 4693159001) and 1X 
PhosStop (Sigma-Aldrich cat. 4906837001) was prepared, cell culture media was removed from the 
culture plate well and 150uL of RIPA buffer was added. Cells were incubated with RIPA buffer at 
ambient room temperature for two minutes, then transferred to a 1.5mL Eppendorf (Sigma-Aldrich 
cat. T9661-1000EA) and homogenized with ten pipette pumps. The Eppendorf was then placed on 
an orbital mixer at 4°C for one hour, after which it was snap frozen on dry ice for five minutes and 
stored at -80°C.   
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2.10 Cell RNA collection 
To isolate RNA (alongside DNA and proteins) cell culture media was removed from the culture plate 
well and 500uL of TRIzol (Life Technologies cat. 15596-026) was added. TRIzol cell lysate was 
immediately transferred to a 1.5mL Eppendorf (Sigma-Aldrich cat. T9661-1000EA) and homogenized 
with ten pipette pumps. The TRIzol cell lysate was snap frozen on dry ice for five minutes and stored 
at -80°C.   
 
2.11 Immunocytochemistry/Immunochistochemistry 
Cells for immunocytochemistry analysis were cultured as described in Section 2.5, except that the 
final passage was made onto laminin-coated glass coverslips (VWR, cat. 631-0149). After removal of 
media and washing in DPBS (Life Technologies, cat. 14190-326), these cells were fixed in 4% 
paraformaldehyde (Polysciences inc. cat: 04018-1) in 1X PBS (Thermo Fisher Scientific, cat. 
18912014) for 15 minutes. For Aβ immunofluorescence, after fixation, all samples were treated with 
formic acid for five minutes for antigen retrieval. After three washes in 0.3% triton-X-100 (Sigma-
Aldrich cat. X100-500ML) in 1X PBS (PBST), permeabilised cells were blocked in 3% bovine serum 
albumin (BSA, Sigma-Aldrich cat. A1933) in PBST. Cells were incubated in primary antibodies in 
blocking solution overnight (Table 6). After three washes in PBST, 400-600nm secondary antibodies 
(Alexafluor, Thermo Scientific) were added in blocking solution for one hour in the dark. DAPI 
(Abcam, cat. Ab228549) was added to the cells as a nuclear counterstain at 1μM and the cells were 
washed three times in PBST. Cells were mounted on ColorFrost slides (Thermo Fisher Scientific, cat. 
9951OPLUS) using DAKO mounting media or imaged in PBS. Images were captured on the Opera 
Phenix (Perkin-Elmer) or a Zeiss LSM microscope (Zeiss).  
 
Immunohistochemistry followed the same process as described for immunocytochemistry except 
that brain slices were fixed in 4% paraformaldehyde whilst thawing, and then treated with 10% 
formic acid for ten minutes for antigen retrieval prior to permeabilisation with 0.3% triton-X-100.  
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2.12 Calcium signalling 
iPSC-derived cortical neurons were cultured as described in Section 2.5, except that the final passage 
was made into eight well glass ibidi slides (Ibidi, Munich, Germany, cat. 80827) at a density of 5000 
cells per cm2. Cells were fed with 200μL of N2B27 per well every 3-4 days until the experiment. 
Cultures were transported to the laboratory of Prof. M.R. Duchen on foot in a polystyrene box. The 
ibidi chambers were sealed with parafilm (Thermo Fisher Scientific, cat. S37440) and secured to the 
box with tape alongside 50mL Greiner centrifuge tubes (Sigma-Aldrich, cat. T2318-500EA) filled with 
warm water (37°C). No atmospheric control was available, and transport took approximately 20 
minutes. Cultures were then incubated for 24 hours in a Heracell 150 incubator (Thermo Fisher 
Scientific) at 37°C, 5% CO2.  
 
Following the instruction of Dr. G. Bhosale, cells were washed with 300μL Hank’s Balanced Salt 
Solution (HBSS) at 37°C. HBSS was pH adjusted with NaOH to pH 7.4, consisted of CaCl2 (0.1396g/L), 
Table 6: Antibodies used for immunocytochemistry and western blotting 
Antigen Company Host Dilution  
DAPI Abcam (ab228549)  1:10,000 
NANOG Cell Signaling Tech 
D73G4 
Rabbit 1:500 
SSEA4 Biolegend MC-813-70 Mouse 1:500 
FOXG1 Abcam Ab18259 Rabbit 1:500 
pVimentin MBL International D076-
3S 
Mouse 1:250 
TUJ1 Biolegend 801201 and 
802001 
Mouse and Rabbit 1:10,000 
CTIP2 Abcam ab18465 Rat 1:500 
PSD95 Abcam ab2723 Mouse 1:1000 
A Dako M0872 Mouse 1:1000 
MAP2 Abcam ab5392 Chick 1:10,000 
PSEN1 C-term Millipore MAB5232 Mouse 1:1000 
PSEN1 N-term Millipore MAB1563 Rat 1:500 
 Actin Sigma Mouse 1:10,000 
Table 6: Showing the antibodies used in immunocytochemistry, immunohistochemistry, and western blot 
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MgSO4 (0.09767g/L), KCl (0.4g/L), KH2PO4 (0.06g/L), NaCl (8.0g/L), Na2HPO4 (0.04788g/L), C6H12O6 
(1.0g/L), and NaHCO3 (0.35g/L). After washing HBSS was removed and cells were incubated in 200μL 
of 5μM Fura2 solution at 37°C for 30 minutes. 5μM Fura2 solution consisted of 10uL 1mM Fura2 
(Thermo Fisher Scientific, cat. F1201) with 2μL pluronic acid in 1990μL HBSS, and was kept shielded 
from light. Fura2 is a photosensitive ratiometric fluorescent dye which binds to free intracellular 
calcium. When bound to calcium, Fura2 emits 340nm light. When not bound to calcium, Fura2 emits 
380nm light. Regardless of the presence of calcium, Fura-2 emits 510 nm light. Next, Cells were 
washed with 300μL HBSS, and then 180μL of HBSS was applied to each well as run buffer. 
 
Calcium signal measurements were obtained using an Olympus IX71 Widefield microscope with a 
40X oil immersion objective. Neither atmosphere control nor a heated stage were used. The cells 
were imaged at 340nm and 380nm with a time interval of 1 second per image. Neuron activity 
occurs in bursts of action potentials often referred to as electrical spikes, which occur over ~200 
milliseconds, with ~5 second intervals between bursts (Galtieri et al., 2017; Penn et al., 2016). 
Calcium signalling was imaged over a baseline period, then 20μL of either KCl (final concentration 
12.5mM) or glutamate (final concentration 100μM) solution were added. KCl solution consisted of 
NaCl (18.6μM), KCl (125mM), NaHCO3 (4.2mM), NaH2PO4 (1.2mM), MgCl2 (1.2mM), CaCl2 (1.2mM), 
D-Glucose (10mM), HEPES (10mM). Glutamate solution consisted of 1000μM glutamate in 1mL 
HBSS. 
 
2.13 Quantitative PCR  
RNA was harvested using TRIzol (Life Technologies cat. 15596-026) as described in Section 2.10. 2μg 
of total RNA was reverse transcribed using Superscript IV reverse transcriptase (Thermo Fisher, cat. 
18090010) using random hexamers. qPCR was performed using Power Sybr Green (Thermo Fisher, 
cat. 4402953) and an MX300P real time PCR cycler (Agilent). Primers used for qPCR are shown in 
Table 7. 
 
 
Table 7: Oligonucleotide primers used for qPCR 
Gene Forward Reverse  Amplicon 
RPL19 CCCACAACATGTACCGGGAA TCTTGGAGTCGTGGAACTGC 180bp 
TBR1 AGCAGCAAGATCAAAAGTGAGC   ATCCACAGACCCCCTCACTAG   149bp 
CTIP2 CTCCGAGCTCAGGAAAGTGTC   TCATCTTTACCTGCAATGTTCTCC   129bp 
TUBB3 CATGGACAGTGTCCGCTCAG CAGGCAGTCGCAGTTTTCAC 175bp 
Table 7: Showing the oligonucleotide primers used in the thesis 
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2.14 Collection of post-mortem brain tissue 
Frontal cortex tissue from individual P6/16 (APP V717I-1) was obtained from Queen Square Brain 
Bank. For experiments involving tissue homogenisation and extraction of Aβ fractions, tissue chips of 
right-side hemisphere frontal cortex were received frozen (-80°C). In experiments involving 
immunohistochemistry, frozen (-80°C) paraffin-fixed tissue (left-side hemisphere frontal cortex) was 
cryosectioned using a Leica sledge microtome at 7μm. 
 
2.15 Tissue extraction of amyloid beta 
Equipment was cooled to 4°C on ice prior to use. Brain tissue from the frontal cortex was stored at -
80°C and thawed on ice at 4°C. 0.25g of tissue were suspended in 10mL protease inhibitor solution 
(RIPA buffer with added 1X EDTA free cOMplete mini (Sigma-Aldrich cat. 4693159001) and 1X 
PhosStop (Sigma-Aldrich cat. 4906837001) and then homogenised with 30 strokes of a Dounce glass 
homogeniser and aliquoted into glass ultracentrifuge tubes. Tissue homogenate was centrifuged at 
100,000RCF for 60 minutes at 4°C. The supernatant, representing the soluble protein fraction, was 
aliquoted into 2mL polypropylene Eppendorf’s and stored at -80°C. The pellet, representing the 
insoluble protein fraction, was re-solubilised in 1mL 70% formic acid solution at 4°C, assisted by 100 
strokes of a polypropylene pestle. Insoluble fraction homogenate was centrifuged at 20,000RCF for 
15 minutes at 4°C. The supernatant was aliquoted into 2mL polypropylene microcentrifuge tubes 
(Star Lab, cat. S1620-2700), and 1M Tris at pH 11 was added to neutralise the formic acid. Aliquots 
were stored at -80°C.  
 
2.16 Western blot 
Cells were lysed in RIPA buffer with added 1X EDTA free cOMplete mini (Sigma-Aldrich cat. 
4693159001) and 1X PhosStop (Sigma-Aldrich cat. 4906837001). Lysates were loaded with Protein 
Orange G (Li-Cor, cat. 928-40004) and NuPAGE reducing agent (Invitrogen, cat. NP0009), then 
denatured at 95°C for five minutes. Following centrifugation at 9300RCF for three minutes at 4°C, 
electrophoresis was conducted with a NuPage 10% Bis-Tris gel (Invitrogen, cat. 10398622) in 1X 
NuPage MES SDS running buffer (Invitrogen, cat. NP0002) at 150 volts for one hour. Transfer to 
nitrocellulose membrane was conducted at 30 volts for one hour at 4°C in transfer buffer (700mL Di-
H2O, 100mL 10x Tris, 200mL methanol). The membrane was blocked in 3% BSA (Sigma-Aldrich cat. 
A1933) and incubated with primary antibody overnight (Table 6). The membrane was washed three 
times with 0.1% PBS-Tween solution and incubated in secondary antibody (Alexa Fluor 680nm 
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(Invitrogen, cat. A21058), and 800nm (Rockland, cat. 611-145-112)) for one hour, washed three 
times in 1X PBS and imaged using an Odyssey Fc (Li-Cor Biosciences). 
 
2.17 Lactase dehydrogenase assay 
Cell media samples were thawed at 21°C for one hour and assayed for lactate dehydrogenase (LDH) 
reaction using a Randox LDH P-L 401 kit (Randox, cat. LD401). LDH is an oxidoreductase that 
catalyses the conversion of pyruvate to lactic acid, with concomitant conversion of NADH to NAD+, 
in hypoxic conditions. The assay was performed on a Randox Monza (Randox) according to 
manufacturer protocol. The reaction mix was created by reconstituting lyophilised NADH (0.18 
mmol/L) in 3mL of R1a buffer/substrate (phosphate buffer (50mmol/L, pH 7.5 and pyruvate (0.6 
mmol/L)). After running a blank (de-ionised H2O), 10μL sample/quality control was diluted in 500μL 
reaction mix, vortexed for five seconds and analysed. 
 
2.18 Immunoprecipitation MALDI TOF/TOF mass 
spectrometry 
Mass spectrometry experiments were conducted by Dr. E. Portelius and Dr. E. Gkanatsiou of the 
University of Gothenburg. Aβ peptides were immunoprecipitated using Aβ-specific antibodies 
coupled to magnetic beads (Portelius et al., 2007). Briefly, 4 mg of the anti-Aβ antibodies 6E10 and 
4G8 (Signet Laboratories, Dedham, MA, USA) were separately added to 50 mL each of magnetic 
Dynabeads M-280 Sheep Anti-Mouse IgG (Invitrogen, Carlsbad, CA, USA). The 6E10 and 4G8 
antibody-coated beads were mixed and added to the samples to which 0.025% Tween 20 in 
phosphate-buffered saline (pH 7.4) had been added. After washing, using the KingFisher magnetic 
particle processor, the Aβ peptides were eluted using 100 μL 0.5% formic acid. Mass spectrometry 
measurements were performed using a Bruker Daltonics UltraFleXtreme matrix-assisted-laser-
desorption/ionization time-of-flight/time-of-flight (MALDI TOF/TOF) instrument (Bruker Daltonics, 
Bremen, Germany). All samples were analyzed in duplicate.  
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3 Confounding factor: Storage Volume 
 
3.1 Introduction 
Aβ has long been recognised as a labile and aggregation-prone peptide with importance to the 
diagnostic process of AD. As previously discussed in Section 1.5.3, the problem of measurement 
variability within and particularly between sites is widely recognised. With the advent of large-scale 
biobanking initiatives, the results from which will shape understanding of disease biology for decades 
to come, the issue of standardisation and reduction of confounding factors has never been more 
pressing.  
 
The potential for storage vessels to influence measured concentrations of Aβ and tau was recognised 
relatively early in the movement to improve biomarker standardisation in the study of 
neurodegenerative diseases (Vanderstichele et al., 2000). Tests of CSF A42, T-tau and P-tau 
concentration after exposure to polypropylene, polystyrene and glass surfaces show differences 
between materials, and the majority of studies focused on biomarker surface exposure have focused 
on these storage material differences (Kofanova et al., 2015; Lewczuk et al., 2006a; Perret-Liaudet et 
al., 2012b, 2012a). Compared to samples stored in polypropylene tubes, CSF A42 concentration is 
significantly decreased by approximately 20% when stored in polystyrene tubes (Bjerke et al., 2010; 
Perret-Liaudet et al., 2012b, 2012a). Samples stored in glass tubes also have a tendency toward 
lower A42 concentration than those stored in polypropylene, though typically to a lesser degree 
than polystyrene (Bjerke et al., 2010). Studying the differences between polypropylene, polystyrene, 
polycarbonate and polystyrene-acrylonitrile copolymer, Lewczuk et al. found that polystyrene 
significantly decreased A42, A40, and T-tau versus the other materials, whilst only the copolymer 
significantly altered the A42:40 ratio and T-tau (Lewczuk et al., 2006a). Polypropylene and 
polycarbonate had similar interactions with the biomarkers tested, with a no-significant tendency for 
lowered A in the latter. An important realisation was that the polypropylene used to manufacture 
tubes between different companies, and potentially between tube batches, is not uniform and is 
formed of different ratios of co-polymers that are often not disclosed. These differences have been 
shown to be sufficient to alter measured A42 concentrations from the same sample (Kofanova et 
al., 2015; Perret-Liaudet et al., 2012b, 2012a). 
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As a result of this work, polypropylene tubes have become widely adopted in AD research and 
clinical diagnostics. This has been possibly the most successful implementation of international pre-
analytical standardisation to date, although the field looks set to shift again toward a new design of 
‘low protein binding’ tubes in the near future (Vanderstichele et al., 2016). However, whilst the 
interaction of Aβ and tau with common storage tube materials had been relatively well documented, 
very little had been done to explore other aspects of storage vessels that could potentially confound 
biomarker measurement. One such understudied aspect was the shape of the storage vessel itself. 
With the understanding that surface adsorption was a significant factor in protein storage, a key 
question was to what extent variation in tube dimensions, and therefore size of the surface/sample 
interface, could affect the quantification of Aβ and tau. Some work suggested the standardisation of 
storage aliquot volume for the prevention of a freeze-drying effect in the event that lid seal was not 
airtight (Teunissen et al., 2009), but this had not been experimentally tested and no link to surface 
adsorption was drawn.  
 
We tested the hypothesis that differences in sample storage volume would affect the measurable 
concentration of Aβ peptides, T-tau, and P-tau in CSF and cell media as a result of surface area-
dependent protein adsorption to the storage tube surface. Additionally, we sought to validate the 
idea that the mechanism of effect was surface adsorption by including a non-ionic surfactant (0.05% 
Tween 20) to a duplicate sample series. The use of Tween 20 to increase A42 recovery had been 
previously reported (Bjerke et al., 2010; Cullen et al., 2012). 
 
3.1.1 Contributions 
The author designed and conducted all experiments, conducted the immunoassays, contributed to 
analysis of Volume Study 1 by graphically plotting data and conducted correlation of sample 
concentration with tube surface area, conducted statistical analysis of Volume Study 2, cultured iPSC 
neurons and collected media used in Volume Study 2, and wrote the scientific reports of all data. 
Volume Study 1 was co-written with RW. Paterson. 
 
Volume Study 1: 
Study conception: H. Zetterberg, NC. Fox, MP. Lunn, JM. Schott. 
Sample collection: H. Zetterberg. 
Experiment design: The author. 
Experiment: The author. 
Analysis: JM. Nicholas, RW. Paterson, the author. 
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Scientific report: The author, RW. Paterson, MP. Lunn, JM. Nicholas, NC. Fox, MD. Chapman, JM. 
Schott, H. Zetterberg. 
 
Volume Study 2: 
Study conception: H. Zetterberg, MP. Lunn, JM. Schott. 
Sample collection: H. Zetterberg, S. Wray, C. Arber, H. Wellington. 
Experiment design: The author. 
Experiment: The author. 
Analysis: The author. 
Scientific report: The author, MS. Foiani, H. Wellington, RW. Paterson, C. Arber, A. Heslegrave, MP. 
Lunn, JM. Schott, H. Zetterberg. 
 
3.2 Materials and methods 
 
3.2.1 Samples 
This study consisted of two experiments. The first tested the effect of storage volume on CSF Aβ42, T-
tau, and P-tau181, the second looked specifically at the effect of storage volume on the ratios of Aβ38, 
Aβ40, and Aβ42 in CSF and cell media from iPSC-derived cortical neurons. 
 
In the first study (Volume Study 1) CSF was collected and categorised into AD and Non-AD as 
described in Section 2.3. Due to large volume requirements, some CSF samples of the same category 
were pooled (AD n=3, Non-AD n=3) from multiple individuals as illustrated in Figure 11, whilst some 
individual samples had sufficient volume to be tested without pooling (AD n=1, Non-AD n=1). 
 
In the second study (Volume Study 2) CSF and cell media were collected and categorised as described 
in Sections 2.3 and 2.8 respectively. CSF (AD: n=3, Non-AD: n=5) was pooled as illustrated in Figure 
11. Cell media (n=6) was collected from iPSC-derived cortical neurons from lines categorised as Non-
AD (CTRL1, CTRL2, and SHEF6) aged between 80 and 100 days post-induction. 
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3.2.2 Experimental methods 
 
 
Volume Study 1 and 2 samples were prepared as illustrated in Figure 11. Patient CSF samples thawed 
at room temperature for one hour, then pooled together into a 100mL Sarstedt PP beaker (cat. 
75.1354.001) and mixed by magnetic stirrer for 30 minutes. The mixed CSF was then transferred into 
a 50mL Greiner tube and then spun at 2,750 RCF for ten minutes at 4°C. Two 10mL volume aliquots 
were then created in empty 50mL Greiner tubes. A limitation of this design was the fact that A 
concentration was not measured from tubes precursory to the final aliquot. This would have given a 
fuller picture of how well the concentrations measured reflect physiological concentration. 
 
In Volume Study 1, 5μL of Tween 20 (final concentration 0.05%) was added to one of the 10mL tubes 
as a control for protein adsorption/aggregation. The 10mL aliquots were each divided into 1mL 
aliquots (Sarstedt 2mL PP cat. 72.694.406) and CSF was divided into a series of volumes, ranging 
50μL to 1500μL in Sarstedt 2mL PP storage tubes (Sarstedt, Nümbrecht, Germany, cat. 72.694.406), 
and stored at -80°C. Prior to assay, aliquots were thawed at 21°C for one hour.  
 
In Volume Study 2, CSF and cell media were treated by the No Tween pathway only Figure 11. 
Additionally, a more limited volume series (100μL, 125μL, 250μL, 500μL, 1000μL in Sarstedt, cat. 
72.694.406 tubes) was chosen to enable more samples to be run in each assay plate and exclude the 
high and low extreme aliquots, which the results of Volume Study 1 showed to be vulnerable to 
Figure 11: Diagram showing the preparation of samples for the volume experiments. 
Figure 11: Volume experiment design 
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experimental artefacts, such as lack of dead volume. Sample aliquots were frozen at -80°C. Prior to 
assay, aliquots were thawed for one hour at 21°C.  
 
In Volume Study 1, samples were analysed for Aβ42 and T-tau by singleplex MSD ECL immunoassay 
(Section 2.2.1 and 2.2.3 respectively), and for P-tau181 by INNOTEST ELISA (Section 2.1.3). In Volume 
Study 2 Aβ38, Aβ40, and Aβ42 were measured by triplex MSD ECL immunoassay (Section 2.2.2). 
 
3.2.3 Statistical analysis 
The relationship between analyte measurement and sample treatment (volume) was assessed by 
mixed model regression analysis. Data normality was assessed by histogram, qq-plot and Shapiro-
Wilk test, linearity was assessed by scatterplot of the residual variance. All analyses set alpha at 0.05, 
and confidence intervals at 95%. The formula used for the mixed model was: 
 
lme(sample concentration ~ treatment + X, random = ~1|sample) + ε 
 
lme is the command for a linear mixed model function in R programming software. The dependent 
variable, ‘sample concentration’, was the average of duplicate concentration or ratio values of a given 
Aβ peptide in pg/mL. The fixed effect variable, ‘treatment’, was sample volume, and ‘X’ represents 
other fixed effects (such as disease status, cell type, assay plate, sample pooling status). The random 
effect variable, ‘sample’, represents variation due to unaccounted for differences between samples, 
and ‘~1|’ specifies an independent intercept for each sample. ε represents residual variation not 
accounted for by the stated parameters of the model.  
 
In Volume Study 1, analysis was conducted by Dr R.W. Paterson and Dr J. Nicholas in STATA. Graphs 
were created by myself using SPSS version 21. In Volume Study 2, analysis was conducted by myself 
in R, and graphs were composed using the ggplot2 package. 
 
3.2.4 Assay variation 
For Volume Study 1, percent CV of intra- and inter-assay variability respectively was Aβ42 (5.9%, 
6.4%), T-tau (1.7%, 21.2%), and P-tau (5.8%, 5.8%), based on comparison of calibrator 2 in each assay. 
For Volume Study 2, intra- and inter-assay variation respectively was Aβ42 (4.3%C, 9.9%), Aβ40 
(4.5%, 9.5%), and Aβ38 (1.6%, 5.3%), calculated from the concentrations of an internal control CSF 
sample included in assay plates. Intra- and inter-assay CV was calculated according to ISO 5725-2 
standards (British Standards Institution, 1994). 
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3.3 Results 
 
3.3.1 Aβ concentration is altered by storage volume 
In both AD and Non-AD CSF (no Tween 20), an approximately two-fold change Aβ42 concentration 
was observed between the largest and smallest aliquot volumes (Figure 12A). For Non-AD samples, 
regression analysis predicted a significant increase in Aβ42 concentration (0.95pg/mL [95% 
confidence interval (CI) 0.36 – 1.50, p = 0.02]) per increase of 10μL aliquot volume. A similar effect 
was seen in AD CSF: 0.60pg/mL (CI 0.23– 0.98pg/mL, p = 0.003) per 10μL aliquot volume. In CSF with 
added 0.05% Tween 20 there was no significant relationship between aliquot volume and Aβ42 
concentration in either the AD or Non-AD CSF (Figure 12B). No differences were observed between 
pooled and individual CSF. 
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Figure 12: The effect of storage volume on CSF Aβ42 concentration  
Figure 12: Showing the effect of storage volume on Aβ1-42 concentration in A) untreated CSF, and in B) CSF treated with 0.05% 
Tween 20. Samples S1-7 are of pooled CSF, S8 and S9 are CSF from unique individuals. Data are mean of replicates. Error bars 
represent standard deviation. 
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3.3.2 Tau concentration is not altered by storage volume 
In AD and Non-AD Tween CSF, there was no overall significant association between measured T-tau 
concentration and aliquot volume (Figure 13). Non-AD T-tau concentration increased by 0.17pg/mL 
per 10μL volume increase (CI − 0.53 – 0.87pg/mL, p = 0.06). AD T-tau increased by 0.05pg/mL per 
10μL volume increase (CI −1 .78– 1 .88pg/mL, p = 0.96). One sample (Non-AD 1) did demonstrate a 
significant concentration change with volume, but this was not replicated by any other samples 
tested. No differences were observed between pooled and individual CSF. The addition of Tween 20 
(Figure 13B) made no difference to the relationship between T-tau and volume.  
 
Similarly, there was no significant association between No Tween sample P-tau concentration and 
aliquot volume in AD CSF (0.03pg/mL (CI − 0.01– 0 .06pg/mL, p = 0.10) (Figure 14A). In Non-AD CSF 
samples the relationship between volume and P-tau concentration was statistically, but not clinically, 
significant (0.03pg/mL (CI 0.00 – 0.05pg/mL, p = 0.03), driven by variability at the extreme high and 
low volume measurements. Measurements at 75μL were an artefact of insufficient dead volume, as 
the assay required 75μL of sample. The cause of measurement variability at 1500μL was not 
determined. With the addition of Tween 20 (Figure 14B) any association between P-tau and volume 
disappeared. No differences were observed between pooled and individual CSF. 
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Figure 13: The effect of storage volume on CSF T-tau concentration  
Figure 13: Showing the effect of storage volume on T-tau concentration in A) untreated CSF, and in B) CSF treated with 0.05% Tween 
20. Samples S1-7 are of pooled CSF, S8 and S9 are CSF from unique individuals. Data are mean of replicates. Error bars represent 
standard deviation. 
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Figure 14: The effect of storage volume on CSF P-tau concentration  
Figure 14: Showing the effect of storage volume on T-tau concentration in A) untreated CSF, and in B) CSF treated with 0.05% Tween 
20. Samples S1-7 are of pooled CSF, S8 and S9 are CSF from unique individuals. Data are mean of replicates. Error bars represent 
standard deviation. 
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Figure 15: A) Shown against the left Y-axis (surface area) is the surface area relative to volume, to which sample is exposed at 
different storage volumes in the tubes used. Shown against the right y-axis (concentration) are average Aβ42 concentrations for 
all samples with and without 0.05% Tween 20. B) Correlation analysis of averaged Aβ42 concertation with relative tube surface 
area exposure at each volume in samples without Tween 20. C) Correlation analysis of averaged Aβ42 concertation with relative 
tube surface area exposure at each volume in samples with Tween 20. The blue lines represent linear regression of the data. The 
shaded areas represent a 95% confidence interval. 
3.3.3 Mechanism: surface adsorption 
 
 
 
 
 
 
 
 
 
Figure 15: Comparison of concentration by volume and surface area  
Relative tube surface area              Aβ42 concentration (No Tween 20)                        Aβ42 concentration (Tween 20)  
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To assist interpretation of these data, we asked ‘what proportion of Aβ42 would we expect to lose if 
it were binding to the tube surface’? To answer this, we calculated the relative internal surface area 
of the experiment tube exposed at each given volume (Figure 15) (tube dimensions were provided by 
the manufacturer). Calculations were made by adding the lateral internal surface area of a hollow 
cylinder to that of a cone, using the relevant formulas from www.aqua-calc.com. Experimental 
results from No Tween CSF closely matched the pattern that would be predicted if Aβ42 was being 
adsorbed to the tube in a surface area dependent manner (R2 = 0.912). In solution, Tween 20 
molecules concentrate at surface interfaces and increase the solubility of hydrophobic molecules, 
and therefore either out-competes Aβ for surface binding sites or interacts with Aβ in a manner to 
disrupt its binding to surfaces or forming conformations capable of masking its epitopes. These 
results weight interpretation toward disruption of surface binding.  
 
3.3.4 Effect of storage volume on Aβ ratios 
The ratios of Aβ42:40 and Aβ42:38 have been proposed as more accurate biomarkers of AD than 
Aβ42 considered alone (Anoop et al., 2010; Janelidze et al., 2016; Slemmon et al., 2015). We 
considered that use of Aβ ratios might be less vulnerable to the effect of storage volume, as it had 
previously been reported that Aβ42:40 was not significantly altered during experiments in which CSF 
was exposed to different tube materials (Lewczuk et al., 2006a). We conducted Volume Study 2 to 
investigate whether this might be a viable analytical technique for mitigating the confounding effect 
of different storage volumes. 
 
3.3.5 Aβ ratios are altered by storage volume 
Detectable A42/40/38 concentration was observed to be significantly lower (all p <0.001) in 
samples of smaller storage volumes in both CSF (Figure 16) and CM (Figure 17). Results from these 
data predict for every 10μL change in CSF storage volume a concentration change of A42: 1.1pg/mL 
(0.6%), A40: 9.2pg/mL (0.3%) and A38: 3.1pg/mL (0.2%), and for every 10μL change in CM storage 
volume a concentration change of A42: 0.5pg/mL (0.3%), A40: 2.5pg/mL (0.2%) and A38: 
0.4pg/mL (0.1%) (Table 8). Results for CSF Aβ42 are highly consistent with those previously reported 
for CTRL CSF (a change of 0.95pg/mL per 10μL) (Toombs et al., 2013). Concordantly, ratios of 
Aβ42:40 and Aβ42:38 changed significantly with storage volume. In CSF Aβ42:40 change was 0.2% of 
an initial ratio value per 10μL (p <0.001), and in CSF Aβ42:38 change was 0.3% per 10μL (p <0.001) 
(Table 8). In CM, change in the Aβ42:40 and Aβ42:38 ratios were 0.1% and 0.2% of the ratio per 10μL 
(p <0.001) respectively (Table 8). The magnitude of change per unit volume was reduced in both CSF 
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and CM ratios versus Aβ42 alone. The ratio of Aβ40:38 showed a trend toward decreased A40, 
which bordered on significance in CSF (p = 0.054), and CM (p = 0.028) (Table 1).      
 
The pattern of effect in CM Aβ42:40 and Aβ42:38 was similar to that observed in CSF, although the 
absolute values were not directly comparable (Table 8). Furthermore, CM Aβ40:38 was significantly 
reduced whereas in CSF had bordered on not significant (Table 8). This was due to a relatively smaller 
effect size of volume on CM Aβ38. 
 
 
 
 
 
 Figure 16: Showing the effect of storage volume on CSF A) Aβ42, B) Aβ40, C) Aβ38, D) Aβ42:40, E) Aβ42:38, F) Aβ40:38. 
AD  Non-AD   
Figure 16: The effect of storage volume on CSF Aβ ratios  
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Figure 17: Showing the effect of storage volume on cell media A) Aβ42, B) Aβ40, C) Aβ38, D) Aβ42:40, E) Aβ42:38, F) Aβ40:38. 
Figure 17: The effect of storage volume on cell media Aβ ratios  
CTRL1      CTRL2        SHEF6 
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Table 8: Summary of volume experiment results 
Biofluid Peptide % Change per unit p 95% confidence interval 
CSF A42 0.6% <0.001 0.403 0.707 
CSF A40 0.3% <0.001 0.202 0.435 
CSF A38 0.2% <0.001 0.168 0.322 
CSF A42:40 0.2% <0.001 0.160 0.313 
CSF A42:38 0.3% <0.001 0.205 0.415 
CSF A38:40 0.1% 0.54 -0.001 0.148 
CM A42 0.3% <0.001 0.235 0.427 
CM A40 0.2% <0.001 0.106 0.217 
CM A38 0.1% <0.001 0.053 0.156 
CM A42:40 0.2% <0.001 0.104 0.234 
CM A42:38 0.2% <0.001 0.160 0.293 
CM A38:40 0.1% <0.001 0.007 0.108 
 
 
 
3.4 Discussion 
The results of these experiments show that the storage volume of a CSF sample is potentially 
sufficient to influence whether or not its Aβ42 concentration meets a clinical AD criteria, as a change 
of 10μL volume was observed to result in a change of ~1pg/mL in concentration (or 0.6% of initial 
concentration). However, it is difficult to give a hard estimate for the amount of concentration loss 
necessary to mislead interpretation of the ratio, as this will depend on how close the individual 
peptide values are to a chosen diagnostic threshold. For example, a sample with an Aβ42 
concentration a little above an AD diagnostic cut-point could give a result below the cut-point if 
stored in small volumes. In contrast, T-tau and P-tau181 were generally unaffected by storage volume. 
Therefore, ratios of Aβ42:T-tau and Aβ42:P-tau, which have been proposed as diagnostically useful 
values (Counts et al., 2017; De Jong et al., 2006), also have the potential to mislead diagnosis if 
sample volume is not standardised. The experiment design cannot exclude other mechanisms of Aβ 
concentration change (such as aggregation in solution and adoption of epitope masking 
conformations), but the correlation of tube surface area Aβ42 concentration showed that surface 
adsorption is sufficient to explain virtually all of the observed effect.      
Table 8: Summarising the results of Volume Study 2 and the effect of storage volume on Aβ concentration and ratios in CSF and cell 
media (CM). Data from AD and non-AD samples were combined. Change per unit is the exponentiated coefficient of the mixed model 
linear regression analysis. A unit is 10μL. 
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Contrary to our initial hypothesis, Aβ peptides were not affected to the same extent when CSF 
samples were stored at different volumes in the polypropylene tubes used. Of the three peptides 
studied, Aβ42 was most prone to adsorption and thus ratios of Aβ42:40, Aβ42:38 were shown to 
decrease with lower volumes, although the size of the effect was reduced versus Aβ42 alone 
(estimated to be half that of Aβ42). Therefore, whilst Aβ ratios may mitigate the risk of misdiagnosis, 
they cannot be counted on to fully prevent it if sample handling is not standardised.  
 
The effect of storage volume on Aβ peptides in cell media was found to be very similar to CSF, with a 
differential effect on Aβ42, compared to Aβ40 and Aβ38. This is relevant to cell models in AD 
research, where Aβ measurement variability within and between cell lines presents a hindrance to 
building a convergent literature of cell biology, which use of ratios may help reduce (see Section 
8.3.4). 
 
Following on from this work, Vanderstichele et al. observed significant decreases in Aβ1-42 (–13.6%), 
Aβ1-40 (–15.5%), and Aβ1-38 (–10.6%) between CSF stored at 1500μL (Sarstedt cat. 72.706) and 
500μL (Sarstedt cat. 72.730.006) in PP tubes, but not in Eppendorf LoBind tubes (Vanderstichele et 
al., 2016). They found that the Aβ42:40 ratio was not significantly altered by the difference in 
volume, whilst Aβ42:38 was altered by 3.4%, although they did observe differences between 
peptides when exposed to surfaces of new tubes (see Section 4.4). This is in contrast to our model 
which predicts larger, significant, changes in Aβ42:40 (23.7%) and Aβ42:38 (30.9%). It is worth noting 
that the volume effect is closely related to tube dimension (Toombs et al., 2013; Willemse et al., 
2017), and our results represent the difference between 1000μL and 100μL rather than 1500μL and 
500μL, which have different relative surface area exposure to the tube. Additionally, the tubes used 
by Vanderstichele et al. for each volume were not the same (Vanderstichele et al., 2016)., and 
neither matched the tube we tested (Sarstedt cat. 72.694.007), which may reduce the direct 
comparability of results. Lewczuk et al. found a slight reduction in Aβ42:40 ratio in polystyrene-
acrylonitrile copolymer tubes compared to polycarbonate, but no difference among other tubes, 
despite an apparent tendency for decreased Aβ42:40 in polystyrene-based tubes relative to 
polypropylene (Lewczuk et al., 2006a). Therefore, the effect of storage volume on Aβ peptide ratios, 
if it is real, appears to be subtle.  
 
Subsequent reports have confirmed no, or limited, effect of tube volume on CSF T-tau concentration 
(Willemse et al., 2017), although data is not unanimous. Vanderstichele et al. reported that T-tau 
concentration could be marginally influenced by storage volume, with a 4.5% concentration decrease 
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when stored at 500μL compared to a 1.6% decrease when stored at 1500μL (Vanderstichele et al., 
2017). Although, our original results support the idea that T-tau is not vulnerable to surface 
exposure, one high concentration sample in Volume Study 1 did demonstrate a decrease in 
concentration with decreased volume, and it may be that tau proteins can be prone to surface 
exposure in particular forms or at high concentrations. Interestingly, Willemse et al. noted that CSF 
Aβ42 concentration loss was a greater (more than two-fold) when the initial concentration was 
higher (Willemse et al., 2017), and potentially this could apply to more than just Aβ. 
 
The addition of Tween 20 to CSF strongly mitigated the effect of storage volume in Aβ42. Subsequent 
experiments also demonstrated this effect on Aβ38 and Aβ40 concentration when treated to another 
method of surface exposure (discussed in Chapter 4). Tween 20 also appeared to nullify the 
anomalously variable concentration results observed at 1500μL volume in P-tau, although the 
ultimate cause of this was never determined. The storage concentration of Tween 20 used in this 
study was 0.05%, the generally accepted critical micelle concentration (CMC) for Tween 20 is 0.007%, 
although micelle formation has been shown to initiate at 0.002% (Deechongkit et al., 2009). 
Therefore the Tween 20 molecules in our samples would be expected to be in micelle arrangement 
during storage and in the initial stages of the assay as well as being in competition for tube surface 
and liquid/air interface distribution with other hydrophobic molecules. The mechanism of effect is 
thus proposed to be less favourable conditions for Aβ peptide surface binding or aggregation in 
solution in the presence of Tween 20. This work supported the findings of Pica-Mendez et al. (Pica-
Mendez et al., 2010) and was subsequently verified by other groups in the context of storage volume 
(Vanderstichele et al., 2017). Given the apparent effectiveness of adding a final concentration of 
0.05% Tween 20 to CSF to the mitigation of AD biomarker surface adsorption we proposed that the 
concept of CSF sample additives should be further explored.  
 
Despite the limitation of relatively small sample size, the broad findings in CSF have been well 
replicated by subsequent independent investigations, although some conflicts in detail remain to be 
resolved. Additionally, data in cell media continue to represent the only example in the literature at 
the present date. Additionally, this experiment could have been improved by measurement of CSF 
and cell media in all storage tubes used during processing, prior to the final aliquot. This would give 
an indication of how A concentration is affected when stored at larger volumes in larger vessels as 
well as how representative values obtained are of physiological concentrations. This is particularly 
relevant in light of the effect of transferring sample between surfaces discussed in Chapter 4A 
further limitation is the fact that the experiment method followed a ‘top down’ model that has been 
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criticised by Kastantin et al. and future work would benefit from validation of the adsorption 
mechanism with high resolution imaging techniques (Kastantin et al., 2014).  
 
3.5 Chapter summary 
The findings reported in this chapter have potentially important ramifications for the diagnostic 
process of AD, and the goal of developing standardised AD biomarker cut-points. Aβ42 considered on 
its own, or in ratio with other AD biomarkers such as T-tau, P-tau181 is vulnerable to giving false 
negative and positive results in polypropylene tubes if surface exposure is not standardised. This 
effect can be mitigated by the addition of 0.05% Tween 20 early in the sample aliquoting process, 
and standardisation of sample storage practices. The use of Aβ ratios may also mitigate storage 
volume as a confounding factor in comparison to using Aβ42 measurements alone, although these 
too may be partially vulnerable to subtle differences between peptide adsorption propensities. 
 
3.5.1 Publications arising from this work 
Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD, Schott JM, Zetterberg H. 
Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab 
Med. 2013 Dec;51(12):2311-7. doi: 10.1515/cclm-2013-0293. 
 
Toombs J, Foiani MS, Wellington H, Paterson RW, Arber C, Heslegrave A, Lunn MP, Schott JM, Wray S, 
Zetterberg H.Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an 
effect incompletely mitigated by the use of ratios. Alzheimers Dement (Amst). 2018 Mar 22;10:311-
321 
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4 Confounding factor: Serial tube 
transfer 
 
4.1 Introduction 
The results of the volume experiments had shown that the propensity of Aβ to adsorb to surfaces is 
in part dependent on surface area exposure and can be diminished in the presence of 0.05% Tween 
20. We next considered whether exposure of CSF to a new surface could affect sample Aβ 
concentration.  
 
Making aliquots of a stock sample in new tubes is a common practice when making dilutions or when 
sharing samples among collaborators, and important to the facilitation of AD research. As previously 
discussed in Section 3.1, the study of protein adsorption has a large literature in physical chemistry 
journals and across the wider biomedical field. A few studies have tested the effect of serial surface 
exposure on various proteins (Bratcher and Gaggar, 2014), and a number of analytical techniques 
actively incorporate surface depletion in their methods (Desrumaux et al., 2001; Hlady et al., 1999). 
Prior to our investigation, very little work had directly addressed the potential of this issue to 
confound biomarker measurement in the AD field. The extent of research was the description that 
iterative contact with storage tubes reduced Aβ42 concentration, though no supporting data was 
shown (Perret-Liaudet et al., 2012b, 2012a), and a brief report by Pica Mendez et al showing that 
samples incubated for 30 minutes with 0.05% Tween 20 increased measurable Aβ42 concentration in 
CSF samples stored in polypropylene tubes (Pica-Mendez et al., 2010).  
 
Based on our previous results and the implications of the literature we hypothesised that CSF and 
cell media Aβ concentration would be depleted by serial transfer between storage tubes. We were 
also interested in the effect such treatment would have on the ratios of Aβ peptides. As this study 
was conducted alongside our investigation into the effect of storage volume on Aβ ratios our initial 
hypothesis was that different Aβ peptides would be affected to a similar extent. 
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4.1.1 Contributions 
The author conceived of, designed, and conducted all experiments described in this chapter, cultured 
iPSC neurons and collected media used in Transfer Study 2 (alongside C. Arber and H. Wellington), 
conducted the statistical analyses, and wrote the scientific reports.  
 
Transfer Study 1: 
Study conception: The author. 
Sample collection: H. Zetterberg. 
Experiment design: The author. 
Experiment: The author. 
Analysis: The author. 
Scientific report: The author, RW. Paterson, JM. Schott, H. Zetterberg. 
 
Transfer Study 2: 
Study conception: The author, H. Zetterberg, MP. Lunn, JM. Schott. 
Sample collection: The author, H. Zetterberg, C. Arber, H. Wellington. 
Experiment design: The author. 
Experiment: The author. 
Analysis: The author. 
Scientific report: The author, MS. Foiani, H. Wellington, RW. Paterson, C. Arber, A. Heslegrave, MP. 
Lunn, JM. Schott, S. Wray, H. Zetterberg. 
 
4.2 Materials and methods 
 
4.2.1 Samples 
This study consisted of three experiments. The first tested the effect of serial tube transfer on CSF 
Aβ42, T-tau, and P-tau181, the second looked specifically at the effect of serial tube transfer on the 
ratios of Aβ38, Aβ40, and Aβ42 in CSF and cell media from iPSC-derived cortical neurons. The third 
experiment tested the contribution of the pipette tip to any effect on Aβ peptide concentration.  
 
In the first study, Transfer Study 1, CSF was collected and categorised into AD and Non-AD as 
described in Section 2.3. CSF samples of the same category were pooled (AD n = 2, Non-AD n = 2) 
from multiple individuals as illustrated in Figure 18. 
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In the second experiment, Transfer Study 2, CSF and cell media were collected and categorised as 
described in Sections 2.3 and 2.8 respectively. CSF (AD: n = 5, Non-AD: n = 4) was pooled as 
illustrated in Figure 18. Cell media (n = 5) was collected from iPSC-derived cortical neurons (APP 
V717I-1, PSEN int4del-4, CTRL1, CTRL2, and SHEF6) aged between 80-100 days post-induction. 
 
In the third experiment, a separate group of samples (CSF n = 2 and CM n = 2) were aliquoted into 
four different volumes (100, 250, 500, and 1000 mL). These samples were collected and categorised 
as described in Sections 2.3 and 2.8 respectively. The CSF samples used were both pooled from 
individuals with CSF with a profile consistent with AD. Cell media was collected from CTRL1 and 
CTRL2. 
 
4.2.2 Experimental method 
In Transfer Study 1 and 2 samples were prepared as illustrated in Figure 18. Patient CSF samples were 
thawed at room temperature for one hour, then pooled together into a 100mL Sarstedt PP beaker 
(cat. 75.1354.001) and mixed by magnetic stirrer for 30 minutes. The mixed CSF was then transferred 
into a 50mL Greiner tube (cat. T2068-450EA) and then spun at 1750 RCF for ten minutes at 4°C. Two 
equal volume aliquots were then created in empty 50mL Greiner tubes (cat. T2068-450EA). An 
oversight of this design was the fact that concentrations of A and tau in tubes precursory to the 
final aliquot were not measured. 
 
Transfer Study 1 consisted of a pilot experiment and a replication experiment. In the pilot, 
centrifuged samples were split into two 25mL aliquots. 12.5μL of Tween 20 (final concentration 
0.05%) was introduced to one aliquot, creating paired Tween and No Tween sample pools. From 
these pools 1mL aliquots (in Sarstedt PP 2mL storage tubes cat. 72.694.406) were derived and stored 
at -80°C. Aliquots were thawed at 21°C for one hour, and used for another experiment, the 
remaining 950μL was re-stored at -80°C. Aliquots were thawed at 21°C for one hour, and sample was 
aliquoted sequentially between tubes (Sarstedt 2mL PP cat. 72.694.406) leaving the following 
volumes in each tube:  Tube 0 = 215μL, Tube 1 = 200μL, Tube 2 = 200μL, Tube 3 = 200μL, and Tube 5 
= 110μL. Only four transfers were conducted in this experiment. 
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It was recognised that the different aliquot volumes and extra freeze/thaw cycle were a flaw in the 
experiment design. Therefore, a replication experiment was conducted. Centrifuged samples were 
split into two 10mL aliquots. 5μL of Tween 20 (final concentration 0.05%) was added to one of the 
10mL tubes. The 10mL aliquots were each divided into 1mL aliquots (Sarstedt 2mL PP cat. 
72.694.406) and stored at -80°C. Aliquots were thawed at 21°C for one hour, and sample was 
aliquoted sequentially between tubes leaving 100μL in each tube (Sarstedt 2mL PP cat. 72.694.406) 
as shown in Figure 18. The number of transfers was increased to seven in order to observe if the 
effect on concentration would be maintained or change over a greater treatment range. 
 
In Transfer Study 2, CSF and cell media were prepared by the No Tween pathway illustrated in Figure 
18. 1mL sample aliquots were frozen at -80°C and were thawed for one hour at 21°C prior to assay. A 
seven transfer series of 100μL aliquots (Sarstedt 2mL PP cat. 72.694.406) was created. In both 
Transfer Study 1 and 2 samples were assayed immediately after the transfer series had been 
completed. 
 
The third experiment tested the effect of pipetting and aspirating CSF and cell media on Aβ peptide 
concentration. Aliquots of different volumes were prepared as described in Section 3.2.2 and Figure 
Figure 18: Diagram showing preparation of samples for serial tube transfer experiments.  
Figure 18: Transfer experiment design 
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11. Immediately prior to sample dilution during assay, each volume for each sample was mixed with 
a varying number of pumps (0, 5, 10, and 20) with a pipette tip (TipOne; Starlab, Milton Keynes; cat. 
S1113-1700). Tips used for samples given the 0 pump treatment were therefore not pre-wetted. 
 
In Transfer Study 1 and the pipette experiment, samples were analysed for Aβ42 (Section 2.2.1) and 
T-tau by singleplex (Section 2.2.3) as well as Aβ38/40/42 triplex MSD ECL immunoassay (Section 
2.2.2). P-tau measurement was not included as, following the results of Volume Study 1, we did not 
anticipate it would add additional information over T-tau. In Transfer Study 2, Aβ38/40/42 were 
measured by triplex MSD ECL immunoassay (Section 2.2.2). 
 
4.2.3 Statistical analysis 
The relationship between analyte measurement and sample treatment (volume) was assessed by 
mixed model regression analysis in R. Data normality was assessed by histogram, qq-plot and 
Shapiro-Wilk test, linearity was assessed by scatterplot of the residual variance. Data did not meet 
the regression model’s assumption of linearity. To meet this requirement, average concentration was 
transformed by the natural logarithm (ln). To calculate the proportional change per treatment unit, e 
was exponentiated to the power of the model’s output coefficient.  All analyses set alpha at 0.05, 
and confidence intervals at 95%. The formula used for the mixed model was: 
 
lme(ln sample concentration ~ treatment + X, random = ~1|sample) + ε 
 
lme is the command for a linear mixed model function in R programming software. The dependent 
variable, ‘ln sample concentration’, was the average of duplicate concentration or ratio values of a 
given Aβ peptide transformed by ln. The fixed effect variable, ‘treatment’, was the number of tube 
transfers, and ‘X’ represents other fixed effects (such as disease status, cell type, assay plate, sample 
pooling status). The random effect variable, ‘sample’, represents variation due to unaccounted for 
differences between samples, and ‘~1|’ specifies an independent intercept for each sample. ε 
represents residual variation not accounted for by the stated parameters of the model. Graphs were 
created using the R package ggplot2. 
 
4.2.4 Assay variation 
For Transfer Study 1, percent CV of intra- and inter-assay variability respectively were Aβ42 singleplex 
(5.0%, 9.9%), Aβ38 (5.5%, 5.5%), Aβ40 (8.5%, 8.8%), Aβ42 triplex (12.2%, 12.2%), T-tau (5.6%, 15.6%), 
calculated from concentrations of an internal control CSF sample. For Transfer Study 2, intra- and 
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inter-assay variation respectively was Aβ42 (4.3%C, 9.9%), Aβ40 (4.5%, 9.5%), and Aβ38 (1.6%, 5.3%), 
calculated from the concentrations of an internal control CSF sample. Intra- and inter-assay CV) was 
calculated according to ISO 5725-2 standards (British Standards Institution, 1994). 
 
4.3 Results 
 
4.3.1 Aβ concentration decreases with tube transfer 
The results of Transfer Study 1 demonstrated that Aβ42 decreased significantly with successive tube 
transfers in both AD and non-AD CSF (Figure 19A). Over seven and four transfers, mixed model 
analysis of Aβ42 triplex assays estimated an average 21% concentration decrease per transfer for AD 
and non-AD CSF relative to initial concentration. Values for Aβ42 singleplex assays were highly 
comparable to those of the triplex results (Pilot = 28%, Replication = 23% concentration decrease per 
transfer) (Figure 19A-B). This effect was strongly mitigated, but not entirely prevented by Tween 20, 
which reduced the effect to approximately 5% concentration decrease per transfer in all assays 
(Figure 19A-B). 
 
Aβ peptides Aβ38 and Aβ40 were also affected by iterative sample transfer between tubes (Figure 
19C-D). Over seven transfers AD and non-AD Aβ38 decreased by 16.3% per transfer respectively, 
whilst Aβ40 decreased by 16.5% per transfer. For comparison with the Pilot experiment data, when 
limited to four transfers the model predicted decreases of 12% and 13% for Aβ38 and Aβ40 
respectively. The presence of Tween 20 strongly mitigated the treatment effect to approximately 1% 
per transfer (Figure 19C-D), which was not significant after four transfers, but became so after seven. 
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Figure 19: A) CSF A42 concentration change over serial tube transfers with and without Tween 20 as measured by the MSD 
singleplex assay. Data shown include the results of a pilot study (only four transfers) and a replication experiment (seven transfers). 
B) CSF A42 C) CSF A38 and D) CSF A40 concentration change over serial tube transfers with and without Tween 20 as measured 
by the MSD triplex assay. Samples used were the same as those used in the replication experiment in panel A. Error bars represent 
standard deviation. 
                No Tween                                                 Tween 
AD            Non-AD      AD                   Non-AD 
Figure 19: Effect of serial tube transfer on Aβ peptide concentration 
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4.3.2 T-tau concentration decreases slightly with tube transfer 
 
 
 
 
 
 
 
When T-tau was measured in the same samples, serial transfer was found to not to cause a 
significant change in concentration over four transfers in the samples of the replicate experiment. 
However, a small but significant decrease in concentration (4% per transfer) was observed in these 
samples over seven transfers (Figure 20, Table 9). In the pilot study samples (which were only treated 
with four transfers) the AD sample appeared to be more strongly affected than the other samples 
measured, but overall the model only predicted a 7% decrease per transfer, which was the same as 
for the Non-AD sample. In samples treated with Tween 20, no significant effect was observed on T-
tau concentration.  
 
Figure 20: CSF T-tau concentration change over serial tube transfers with and without Tween 20. Data shown include the results of a 
pilot study (only four transfers) and a replication experiment (seven transfers). Error bars represent standard deviation. 
Figure 20: Ttau: Effect of serial tube transfer 
                No Tween                                                 Tween 
AD            Non-AD      AD                   Non-AD 
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Table 9: Summary of Transfer Study 1 results 
  Four Transfers Seven Transfers 
  No Tween Tween 20 No Tween Tween 20 
Experiment Peptide 
% 
Change 
per 
unit 
p 
95% confidence 
interval 
% 
Change 
per 
unit 
p 
95% confidence 
interval 
% 
Change 
per 
unit 
p 
95% confidence 
interval 
% 
Change 
per 
unit 
p 
95% confidence 
interval 
Pilot 
A42 
Singleplex 
28.8% <0.001 
  
5.9% 0.009          
Pilot Ttau 7.3% 0.004 -0.120 -0.033 1.0% 0.511          
Replication 
A42 
Singleplex 
23.6% <0.001 
  
4.0% <0.001 
-0.060 -0.022 
21.4% <0.001 
-0.256 -0.226 
7.8% <0.001 
-0.097 -0.066 
Replication A42 21.2% <0.001 -0.271 -0.207 3.3% <0.001   21.5% <0.001 -0.255 -0.229 5.5% <0.001 -0.064 -0.049 
Replication A38 12.1% <0.001 -0.148 -0.110 0.5% 0.365 -0.015 0.006 16.3% <0.001 -0.191 -0.166 1.5% <0.001 -0.020 -0.011 
Replication A40 13.1% <0.001 -0.156 -0.124 0.1% 0.822 -0.008 0.006 16.5% <0.001 -0.191 -0.170 1.9% <0.001 -0.025 -0.014 
Replication A42:40 9.4% <0.001   3.3% <0.001 -0.046 -0.020 6.0% <0.001 -0.075 -0.049 3.6% <0.001 -0.043 -0.031 
Replication A42:38 10.4% <0.001 -0.146 -0.073 2.9% <0.001 -0.037 -0.021 6.2% <0.001   4.0% <0.001 -0.047 -0.036 
Replication A38:40 1% 0.167   0.4% 0.503 -0.016 0.008 0.2% 0.537 -0.005 0.009 0.4% 0.129 -0.001 0.009 
Replication T-tau 1.6% 0.068 -0.034 0.001 0.6% 0.388 -0.008 0.021 4.5% <0.001 -0.056 -0.036 0.2% 0.492 -0.009 0.004 
Table 9: Summarising the results of Transfer Study 1 and the effect of serial tube transfer on Aβ concentration and ratios in No Tween and Tween CSF. Data from AD and non-AD samples were combined. The 
model’s predictions based on four and seven transfers are shown. Change per transfer is the exponentiated coefficient of the mixed model linear regression analysis.  
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4.3.3 Amyloid beta ratios are affected by tube transfer 
Although the Aβ peptides tested all decreased with iterative exposure to new tube surfaces, Aβ42 
appeared to behave differently from Aβ40 and Aβ38 and it was decided to examine this further.  
 
Transfer Study 2 tested the tube transfer effect in additional CSF and cell media samples. The 
additional CSF data supported the findings of Transfer Study 1 for the effect on Aβ peptide 
concentrations (Figure 21, Table 10). Furthermore, the data highlighted the distinct effect on Aβ42 
relative to the shorter peptides. Aβ42:40 and Aβ42:38 were observed to decrease significantly over 
the transfer series, whilst Aβ40:38 was not significantly affected (Figure 21, Table 10). Although AD 
and Non-AD CSF was affected similarly by the treatment, it is noteworthy that the use of Aβ42:40 
and Aβ42:38 separated the two diagnostic categories better than the peptides considered 
individually. 
 
The first transfer had a notably large effect on Aβ42 in this experiment, equivalent to 39% of the total 
Aβ42 lost overall (as compared to Aβ40 = 24.1% and Aβ38 = 8.8%). When transfer 0 was removed 
from the data series, the effect of transfer on Aβ42 and Aβ40 was diminished (18.8% and 16.3% 
respectively) whilst Aβ38 remained essentially the same (16.0%) but remained significant in all cases 
(p = <0.001). The effect on Aβ42:40 and Aβ42:38 was greatly diminished (2.9% and 3.4% 
respectively) but remained significant in all cases (p = <0.001). Data from samples measured in 
Transfer Study 1 (Figure 19) showed that adding Tween 20 to samples normalised the initial loss of 
A42, and so similarly mitigated the transfer effect on the Aβ42:40 and Aβ42:38 ratios (3.6% and 
4.0%) even with the data for transfer 0 included, although overall the effect remained significant (p = 
<0.001). 
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4.3.4 Aβ concentration decreases with tube transfer in culture media  
To assess the effect of transfer on Aβ in cell media we assayed samples collected from mature 
cortical neurons from fAD and Non-AD cell lines. Aβ peptide concentrations in cell media were 
significantly affected by transfer of sample between tubes (Figure 22, Table 10). Concentrations of Aβ 
Figure 21: Effect of serial tube transfer on CSF Aβ. Results in CSF show the concentration of A) Aβ42, C) Aβ40, and E) Aβ38 
decreased with consecutive transfer of sample to new storage tubes. B) Aβ42:40 and D) Aβ42:38 ratios were decreased, 
particularly at the first transfer. F) Aβ38:40 showed a significant tendency to increase with each transfer. Error bars represent 
standard deviation. 
AD  Non-AD   
Figure 21: Effect of serial transfer on CSF Aβ ratios 
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were noticeably lower in tested cell media than in CSF, and the effect size observed reflects this. The 
effect of tube transfer on the ratio of Aβ peptides was comparable to that seen in CSF with a 
decrease of Aβ42 relative to shorter peptides (Figure 22, Table 10).  
 
 
 
 
 
 
 
AD  Non-AD   
Figure 22: Effect of serial tube transfer on cell media Aβ. Results in CSF show the concentration of A) Aβ42, C) Aβ40, and E) Aβ38 
decreased with consecutive transfer of sample to new storage tubes. B) Aβ42:40 and D) Aβ42:38 ratios were decreased, 
particularly at the first transfer. F) Aβ38:40 showed a significant tendency to increase with each transfer. Error bars represent 
standard deviation. 
Figure 22: Effect of serial transfer on cell media Aβ ratios 
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Table 10: Summary of Transfer Study 2 results 
Biofluid Peptide % Change per unit p 95% confidence interval 
CSF A42 20.0% <0.001 -0.234 -0.212 
CSF A40 16.0% <0.001 -0.181 -0.167 
CSF A38 14.5% <0.001 -0.166 -0.148 
CSF A42:40 4.8% <0.001 -0.057 -0.041 
CSF A42:38 6.4% <0.001 -0.077 -0.055 
CSF A38:40 1.7% <0.001 0.011 0.023 
CM A42 7.8% <0.001 6.993 9.219 
CM A40 4.8% <0.001 4.103 5.711 
CM A38 2.4% <0.001 1.676 3.205 
CM A42:40 3.1% <0.001 2.315 4.082 
CM A42:38 5.5% <0.001 4.532 6.799 
CM A38:40 2.4% <0.001 1.599 3.334 
 
 
 
 
4.3.5 Aβ concentration decreases with tube transfer in culture media  
To test whether exaggerated A peptide loss at first transfer may have been due to adsorption to the 
pipette tip, we conducted a pilot experiment to measure A42/40/38 peptide concentration change 
in response to a varying number of aspirations using the same tip. The number of fluid pumps had no 
effect on A peptide concentration in either CSF or CM, with the exception of small volume (<250uL) 
CSF samples treated with 15 pumps or more, in which Aβ42 concentration showed a tendency for 
decrease (Figure 23). Relevant to the experiments conducted for this thesis, paired, two-tailed t-test 
showed no significant difference between 0 pumps and 5 pumps, although it was observed that 
measurement variability was greater in the 0 pump group (Figure 23). The initial exaggerated 
decrease in A42 observed in CSF cannot therefore be attributed to adsorption to the pipette tip. 
 
 
 
Table 10: Summarising the results of Transfer Study 2 and the effect of serial tube transfer on Aβ concentration and ratios in CSF and 
cell media (CM). Data from AD and non-AD samples were combined. Change per unit is the exponentiated coefficient of the mixed 
model linear regression analysis. A unit is one transfer. 
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Samples 
CSFX 100 
CSFX 250 
CSFX 500 
CSFX 1000 
CSFY 100 
CSFY 250 
CSFY 500 
CSFY 1000 
CTRL1 100 
CTRL1 250 
CTRL1 500 
CTRL1 1000 
CTRL2 100 
CTRL2 250 
CTRL2 500 
CTRL2 1000 
 
Figure 23: Effect of mixing by pipette in CSF and cell media across different storage volumes. Results show the concentration of 
A) Aβ42, B) Aβ40, C) Aβ38 were not significantly affected by different levels of exposure to the pipette tip. Sample CSFX Aβ42 
was measured by MSD singleplex assay. Error bars represent standard deviation.  
Figure 23: Effect of pipette mixing on CSF and cell media Aβ concentrations 
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4.4 Discussion 
In summary, we demonstrated that the concentration of Aβ peptides could be profoundly affected 
simply by transferring sample to a new storage aliquot, whilst T-tau concentration was more stable. 
Inclusion of 0.05% Tween 20 greatly mitigated, but did not entirely prevent, this effect in CSF. A 
survey of four academic AD diagnostic reference centres found that 0–2 transfers are typical in the 
course of CSF collection and processing, although more can occur depending on intended use 
(Willemse et al., 2017). As such, the effect on Aβ42 after one transfer is of particular concern. 
 
The dramatic decrease in Aβ42 observed following the first transfer of CSF in some of the samples 
testing raises the question of whether sub-populations of Aβ42, for example with different N-
terminal truncations or post-translational modifications, could adsorb at different rates. The more 
linear loss of Aβ42 following initial transfers might suggest that certain isoforms could be rapidly 
depleted upon exposure to new surfaces of different material compositions. This is speculation, but 
it is interesting that Vanderstichele et al. also found a large decrease in Aβ42 (42.5%) after transfer of 
sample from a low bind tube to a PP tube (Vanderstichele et al., 2016). If this were to be the case, it 
would mean that potentially important, disease-relevant Aβ species may be underrepresented in 
clinical or research samples, and be additionally vulnerable to pre-analytical protocol variation.  
 
Interestingly, Aβ42 concentration decreased more relative to Aβ40 and Aβ38, supporting the findings 
of the volume study. This meant that the ratios of Aβ42:40 and Aβ42:38 were also altered by serial 
transfer of sample between fresh polypropylene surfaces, although the effect size was noticeably 
smaller compared to Aβ42 concentration considered alone. The use of Aβ ratios may also therefore 
be a strategy for mitigating measurement vulnerability to pre-analytical confounding factors.  
 
In follow up to these data, relative to initial concentration Vanderstichele et al. observed significantly 
lower concentrations of Aβ42 (11.0%), Aβ40 (7.3%), and Aβ38 (2.7%) in CSF collected into PP tubes 
compared to low binding tubes (Vanderstichele et al., 2016). Additionally, they report a 
concentration decrease of Aβ42 (42.5%), Aβ40 (27.8%), and Aβ38 (16.7%) after one transfer between 
PP tubes (Sarstedt 62.554.502, and either 72.706 or 72.730.006). In comparison, at the first transfer 
our results showed a similar decrease of Aβ42 (39.0%) and Aβ40 (24.1%), but smaller decrease of 
Aβ38 (8.8%). It is worth noting that low bind tubes were found to negate the effect of transfer 
between tubes (Vanderstichele et al., 2016). Pica-Mendez et al. also noted a significant decrease in 
Aβ42 concentration relative to control when CSF was transferred to a number of different 
polypropylene tubes, notably 37.9% in the tube likely to be closest in material and dimensions to the 
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one we used (Sarstedt 1.25mL Cat. 72.609.001) (Pica-Mendez et al., 2010). They also described the 
fact that 0.05% Tween 20 nullified this effect, but did not present data (Pica-Mendez et al., 2010). 
However, a subsequent report by Willemse et al. reported a 5% decrease (up to 10% in small volume 
samples) in Aβ42 and Aβ40 per transfer over four transfers between tubes, and that Aβ42:40 
therefore remained constant over transfer treatment (Willemse et al., 2017). An effect size of 5-10% 
is at odds with the Aβ42 (20%) and Aβ40 (16%) decrease per transfer that we observed over 
equivalent transfers. The tubes used by Willemse et al. (Sarstedt cat. 72.694.007) (Willemse et al., 
2017) are identical to the tubes we studied (Sarstedt cat. 72.694.406), except that cat. 72.694.406 is 
certified DNA and RNase free. Other differences in protocol or laboratory environment may also be 
involved, and a degree of inter-laboratory variation should be taken into consideration until these 
factors are identified.   
 
Repeated aspirations and ejections from the same tip did not significantly alter Aβ concentration in 
either CSF or CM. Indeed even when the tip was not pre-wetted no effect was seen, contrary to what 
others have described (Willemse et al., 2017). Therefore, this cannot account for the initial 
exaggerated decrease we observed at the first transfer step. Given this, we hypothesise the existence 
of a sub-population of Aβ42 that is more readily adsorbed to PP and rapidly depleted from solution. 
This interpretation would be consistent with the data reported by Vanderstichele et al. 
(Vanderstichele et al., 2016), but not Willemse et al. (Willemse et al., 2017). A similar, adsorption 
attributed, initial effect on fluorescein-labelled bovine serum albumin (BSA), also found in the B27 
fraction of the CM used in our study, has been reported (Natascha Weiß, 2010). It is possible that 
competition for surface binding sites by this and other proteins of the CM matrix might explain why 
the first transfer step effect was not observed in these samples, although we did not examine fluid 
protein content as a variable. 
 
In regard to effect of tube transfer on T-tau, the experiments reported in this chapter show that this 
biomarker is generally unaffected by this form of treatment. This is in line with other studies that 
have shown T-tau to be unaffected by transfer between different tube materials (Perret-Liaudet et 
al., 2012a; Willemse et al., 2017). However, one high concentration sample showed a tendency 
toward meaningful decrease, and a similar finding in the volume study (Section 3.3.3) may be 
recalled. Vanderstichele et al. recently reported a significant decrease in T-tau following transfer to 
PP storage tubes (Vanderstichele et al., 2016), and it could be that there are sample specific 
differences in T-tau isoform composition that are more or less vulnerable to surface adsorption.   
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One limitation of this study was the low number of samples used (two CSF pools), and although 
other groups have replicated the broad findings, nuances of differential A adsorption remain to be 
fully validated. A major limitation to this study was the fact that A and tau concentrations were not 
measured in all storage tubes used during processing, prior to the final aliquot. If, as we speculate, 
certain A forms are lost to the tube surface preferentially then they may have begun to be depleted 
prior to the point of measurement in this experiment format.   
 
The findings reported in this chapter have potentially important ramifications for the diagnostic 
process of AD where low concentrations of Aβ42 and high tau are a key positive marker, and for 
research practices of sharing samples between groups. Aβ42 considered on its own, or in ratio with 
other AD biomarkers, is vulnerable to giving false negative and positive results in polypropylene 
tubes if surface exposure is not standardised. This effect can be mitigated by the addition of a final 
concentration of 0.05% Tween 20 early in the sample aliquoting process. 
 
4.5 Chapter summary 
The findings reported in this chapter further demonstrate the importance of surface exposure as a 
confounding factor for biomarker research. Aβ42 considered on its own, or in ratio with other AD 
biomarkers such as T-tau and Aβ40 is increasingly vulnerable to giving false positive results for AD 
with each iteration of contact with a new storage vessel, even if that vessel is made of 
polypropylene. The effect on ratios of Aβ peptides was particularly interesting. On the one hand the 
effect of transferring sample between tubes was lessened when ratios were used, and so treatment 
of data in this way may be more reliable than measurements of individual peptides. However, the 
effect was not completely mitigated and data indicate that Aβ42 is a peptide particularly vulnerable 
to surface adsorption, which could potentially mislead results if surface exposure is not standardised. 
Adding 0.05% Tween 20 to the sample early in the sample aliquoting process, proved effective for 
mitigating the effect of serial sample transfers.  
 
4.5.1 Publications arising from this work 
Toombs J, Paterson RW, Schott JM, Zetterberg H. Amyloid-beta 42 adsorption following serial tube 
transfer. Alzheimers Res Ther. 2014 Jan 28;6(1):5. doi: 10.1186/alzrt236. eCollection 2014. 
 
Toombs J, Foiani MS, Wellington H, Paterson RW, Arber C, Heslegrave A, Lunn MP, Schott JM, Wray 
S, Zetterberg H.Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an 
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effect incompletely mitigated by the use of ratios. Alzheimers Dement (Amst). 2018 Mar 22;10:311-
321 
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5 Tween 20 and measurement 
variance 
 
5.1 Introduction 
Measurement variability within and between sites is a significant issue in the AD field and scientific 
disciplines more broadly. Over the past decade increasing attention has been devoted to 
understanding the extent and source of measurement variation in assays for AD biomarkers. The 
Alzheimer’s Association QC program for AD CSF biomarkers is the largest ongoing international 
project, tracking inter- and intra-site variation in a number of the most popular biomarker assays for 
clinical diagnostics and research at more than 80 sites (Mattsson et al., 2011, 2013). Results showed 
modest and gradual improvements between 2011 and 2013 (despite doubling the number of 
participating sites in this period) with coefficients of variance between sites shifting from 13%-36% 
(Mattsson et al., 2011) to 20%-30% (Mattsson et al., 2013), and intra-site variability ranging from 9-
19% (Mattsson et al., 2013). Aβ42, T-tau and P-tau have been the most rigorously tested biomarkers, 
and results tend to fall within a roughly similar range albeit with a tendency for slightly lower 
variation in tau (Carrillo et al., 2013). Reports from other groups, which include a mix of different 
centres and assay platforms, show broadly similar findings with inter-site variability falling mostly 
within the 20%-40% range (del Campo et al., 2012; Carrillo et al., 2013; Lewczuk et al., 2006b; 
Mattsson et al., 2012b; Verwey et al., 2009), and although some claim much more impressive 
capabilities (Bittner et al., 2016) these are not common or well replicated. Intra-assay variability is 
typically much lower (in the range of 3%-15%) (Bittner et al., 2016; Lewczuk et al., 2006b; Mattsson 
et al., 2010), although it is not always clear whether presented data represent assays conducted by 
multiple or the same operators. It is likely that the latter accounts for the lower end of the variance 
estimate.  
 
Simplistically, lowering inter-site variation is important for the establishment of standard diagnostic 
AD biomarker concentration reference ranges (cut-offs) and the development of ‘gold standard’ 
reference materials, which would enable better translation of results between sites, trials, and 
increase research power by pooling compatible data. Lowering intra-assay variation is important for 
improving diagnostic confidence in clinics linked to specific centres. Overall, between laboratory 
concordance for sample diagnosis is respectable, approximating 90% in the Alzheimer’s Association 
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QC program for the majority of the samples assessed (Mattsson et al., 2013), but can still lead to 
patient misclassification and influence clinical decision-making or clinical trial (Garciá Barrado et al., 
2015; Mo et al., 2017). The current situation is insufficient to allow global biomarker cut-offs for AD 
and other diseases to be assigned. Issues with laboratory procedure standardisation and assay 
performance have been the most frequently suggested sources of this variation.  
 
The experiments reported in Chapters 3 and 4 showed that the addition of 0.05% Tween 20 could be 
a potential strategy to mitigate pre-analytical confounding factors in CSF. Next we questioned 
whether measurement variability of CSF Aβ and tau treated in a standardised manner could be 
improved by the addition of Tween 20.  We hypothesised that the addition of 0.05% Tween 20 to CSF 
would decrease ambient measurement variance in samples stored and handled in the same 
standardised conditions. 
 
5.1.1 Contributions 
The author designed, and conducted the experiment described in this chapter, conducted the assays, 
conducted the statistical analyses with advice from JM. Nicholas and A. Petzold, and wrote the 
scientific reports.  
 
Study conception: H. Zetterberg, JM. Schott. 
Sample collection: H. Zetterberg. 
Experiment design: The author. 
Experiment: The author. 
Analysis: The author, JM. Nicholas, A. Petzold. 
Scientific report: The author, RW. Paterson, JM. Nicholas, A. Petzold, JM. Schott, H. Zetterberg. 
 
5.2 Materials and methods 
 
5.2.1 Samples 
CSF was collected as described in Methods Section 2.3. CSF samples were categorised as either 
pooled from multiple individuals (n=3) or from single subjects (n=3). 
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5.2.2 Experimental methods 
 
 
 
As shown in Figure 24, centrifuged CSF samples were transferred at a volume of 11mL into a 100mL 
Sarstedt PP beaker (cat. 75.1354.001) and mixed by magnetic stirrer for 30 minutes, forming the 
pooled group. CSF from individual subjects was treated in the same way except that it was not 
pooled with other samples. Each sample was then divided in two equal volumes (50mL Greiner tubes 
cat. T2068-450EA), and Tween 20 (final concentration 0.05%) was added to one. Tween and No 
Tween samples were then aliquoted into storage tubes (Sarstedt 2mL PP storage tubes cat. 
72.694.406) at 500μL. Sample aliquots were frozen at -80°C. Prior to assay, aliquots were thawed for 
one hour at room temperature (21°C).  
 
Samples were assayed for Aβ38/40/42 (Section 2.2.2), and T-tau by MSD by ECL immunoassay 
(Section 2.2.3), P-tau181 was measured by INNOTEST ELISA (Section 2.1.3). All assays were conducted 
by the same operator. To assess intra-plate variability, each sample were assayed in three 
duplicates. To assess inter-plate variability, the assay was repeated four times. Assays were 
conducted under double blind conditions. 
 
5.2.3 Statistical analysis 
Intra- and inter-assay CV) was calculated according to ISO 5725-2 standards (British Standards 
Institution, 1994). Results are shown in Table 11. Differences between Tween and No Tween groups 
Figure 24: Diagram showing preparation of samples for Tween variation experiments. 
  
Figure 24: Sample variation experiment design 
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were assessed by paired two-way t-test. Differences between pooled and individual CSF were 
assessed by unpaired two-way t-test. To investigate the contribution of covariates, mixed model 
analysis of data was conducted in R. To control for increasing variance as concentration increased, 
sample concentration was transformed by ln.  
 
5.3 Results 
 
5.3.1 Tween 20 decreases variability in Aβ42 measurement 
For measurements of Aβ42 in the same sample across different assays, %CVs of ‘Tween’ samples 
were significantly lower than in ‘No Tween’ samples (p = 0.04) (Table 11). Further exploration with 
the use of linear mixed model analysis revealed that this result was driven by individual subject 
samples, whilst variance in pooled samples also decreased but did not reach significance (Table 12). 
No significant differences between Tween and No Tween samples were found in Aβ40, Aβ38, T-tau or 
P-tau. However, the average degree of variability between measurements for all samples and for all 
biomarkers, whether intra- or inter-assay, was < 10%, meaning that concentration measurements can 
be considered highly repeatable regardless of Tween 20 status.  
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Table 11: AD biomarker variation: t-test analysis 
Sample 
Aβ38 Aβ40 Aβ42 T-tau P-tau 
Intra 
(%CV) 
Inter 
(%CV) 
Inter 
(%CV) 
Intra 
(%CV) 
Intra 
(%CV) 
Inter 
(%CV) 
Intra 
(%CV) 
Inter 
(%CV) 
Intra 
(%CV) 
Inter 
(%CV) 
733 2.0 7.3 3.5 4.7 2.2 6.2 6.4 8.8 4.4 9.7 
Tween 
733 
2.5 5.7 3.7 5.4 2.1 2.7 4.0 7.8 1.9 7.7 
724 3.0 5.4 3.5 3.5 1.9 3.5 5.4 8.2 1.7 5.5 
Tween 
724 
2.4 5.6 3.8 4.3 2.4 2.9 5.1 7.9 2.6 7.9 
806 2.0 5.9 2.8 5.8 2.5 8.2 6.1 6.8 2.0 5.4 
Tween 
806 
2.7 5.3 3.5 3.8 2.5 3.5 2.5 9.2 1.4 4.0 
Pool1 3.6 5.6 3.6 4.3 2.9 4.4 3.1 6.3 1.2 6.4 
Tween 
Pool1 
2.0 5.3 4.1 4.6 2.2 3.8 2.7 5.3 2.2 5.4 
Pool 2 3.2 5.5 2.1 4.7 2.1 6.4 3.9 8.9 2.4 5.1 
Tween 
Pool 2 
2.6 4.9 3.7 4.8 2.5 3.3 12.7 12.7 2.2 5.5 
Pool 3 1.9 5.3 2.8 3.9 2.0 4.7 2.9 6.5 1.6 4.3 
Tween 
Pool 3 
1.9 6.4 2.4 4.6 1.7 4.6 4.0 8.4 1.8 5.0 
Average 
No Tween 
2.62 5.83 3.05 4.48 2.27 5.57 4.63 7.58 2.22 6.07 
Average 
Tween 
2.35 5.53 3.53 4.58 2.23 4.47 5.17 8.55 2.02 5.92 
t-test 0.476 0.453 0.134 0.827 0.862 0.043 0.778 0.293 0.719 0.830 
 
 
 
 
Table 12: AD biomarker variation: mixed model analysis 
Sample 
Aβ38 Aβ40 Aβ42 T-tau P-tau 
Individual Pool Individual Pool Individual Pool Individual Pool Individual Pool 
Residual 
variance of 
Tween 
samples 
relative to No 
Tween 
-7% +4% 0.3% +19% -45% -15% +14% +11% -6% -10% 
p 0.698 0.820 0.986 0.318 0.001 0.364 0.461 0.591 0.700 0.558 
 
 
Table 11: The T-test analysis shows the mean intra- and inter-assay %CV by sample for each biomarker. This mean was calculated 
from 12 %CVs derived from each sample duplicate pair (n = 3 within each plate) across all plates (n = 4). A two-tailed, paired t-test 
compared Tween and No Tween sample versions for each biomarker. Inter-plate measurements of Aβ42 showed significant 
difference dependent on Tween status (p=0.04) with Tween samples having lower %CVs. 
 
Table 12: Results of a linear mixed model analysis showing the effect of Tween 20 on measurement variation relative to samples 
without Tween for individual or pooled subject CSF for each biomarker. Results were calculated using a linear mixed effects model on 
data transformed by ln. Addition of Tween 20 to samples tended to lower the residual variance of Aβ42. However, this was only 
significant in individual subject CSF.     
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5.4 Discussion 
Tween 20 treatment lowered the variability and detectable quantities of Aβ42, but did not have a 
significant impact on Aβ40, Aβ38, T-tau or P-tau181. Analysis also highlighted that Tween 20 in 
individual CSF samples had a stronger stabilising effect on Aβ42 concentration than did pooled CSF. 
The reason for this is unclear, and experiments previously discussed in Chapters 3 and 4 did not find 
differences between pooled and individual samples. However, the result suggests the use of Tween 
20 as an additive is relevant for clinically relevant samples. Despite this, measurement variation was 
low in all assays conducted and any beneficial effect of adding Tween 20 is unlikely to be meaningful 
over standardising storage and handling practice. Ultimately, there may not be sufficient incentive to 
treat CSF with Tween 20.  
 
Detergents, such as Tween 20, are known to affect protein solubility and interaction with potential 
implications for matrix composition, biomarker ratios, or antibody activity. Subsequent work from 
other groups has shown that 0.05% Triton-X 100 or Tween-20 does not affect sensitivity, specificity, 
diagnostic accuracy (Berge et al., 2015) or intra-assay variability for CSF Aβ42 concentration 
(Vanderstichele et al., 2016). Furthermore it was found that prewashing tubes with detergent-
containing buffers was also effective in reducing Aβ42 adsorption (Vanderstichele et al., 2016). 
However, the use of detergent even at low concentrations is a significant issue in mass spectrometry 
analysis, where detergent molecules coat columns and tubing and contaminate sample signal. Similar 
artefacts have been noted when using other sample additives, such as protease inhibitors (Simonsen 
et al., 2013). Therefore samples treated with Tween 20 early in the pre-aliquoting stages of sample 
processing, where it is likely to be most effective, would not be appropriate for such a platform. This, 
on top of the added cost in resources and procedural steps during CSF collection, as well as the 
equivalent benefits provided by low protein binding tubes (Vanderstichele et al., 2017), weigh against 
the implementation of Tween 20 as a standardised additive. 
 
This study was limited by the low number of samples assessed, and the fact that results represent a 
single-site and single-operator. Whether Tween 20 would have greater effect on the stabilisation of 
biomarker measurement between sites remains unresolved. However, due to suitably low variability 
being achieved through standardised treatment of samples alone, concerns over implementation, 
and the fact that low bind tubes have been shown to have equivalent adsorption mitigating 
properties (Vanderstichele et al., 2016), standardised use of Tween 20 as an additive would not seem 
worthwhile. 
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5.5 Chapter summary 
In summary, it was found that although adding 0.05% Tween 20 to CSF samples did decrease 
variability in Aβ42 measurements, the effect was not impressive enough to recommend its use over 
general standardisation of sample handling protocol. 
 
5.5.1 Publications arising from this work 
Toombs J, Paterson RW, Nicholas JM, Petzold A, Schott JM, Zetterberg H. The impact of Tween 20 on 
repeatability of amyloid beta and tau measurements in cerebrospinal fluid. Clinical chemistry and 
laboratory medicine. 2015;53(12):e329-32. Epub 2015/06/24 
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6 Confounding Factor: Manometer 
 
6.1 Introduction 
Having identified two relevant confounding aspects to Aβ measurement in CSF and cell media, and 
determined that the use of Tween 20 as an additive was unlikely to be practical solution, we moved 
to looking at Aβ adsorption at an earlier stage in the pre-analytical process and one more directly 
related to clinical practice.  
 
CSF is most commonly obtained by lumbar puncture (LP). This involves inserting a spinal needle 
between the spinous processes of the lumbar vertebrae (typically L3/L4 or L4/L5) (Hansson et al., 
2018), puncturing the dura mater, and entering the subarachnoid space. CSF then flows passively 
into a collection tube due to gravity and pressure difference. During the collection of CSF, a 
manometer may be used to measure CSF opening pressure (the initial pressure of the CSF in the 
subarachnoid space), when the patient is in the lateral decubitus position. High (>25 cm H2O) and 
low CSF opening pressures (<6cm H2O) (Lee and Lueck, 2014) are seen in a range of different non-
neurodegenerative conditions, and thus may inform differential diagnosis in the correct clinical 
context. 
 
Though less common in dementia clinic, CSF from non-neurodegenerative individuals is valuable and 
increasingly sample cohorts from these individuals are shared in dementia research collaborations 
(e.g.(Cunningham et al., 2018)). Additionally, it would not be unreasonable to employ manometers in 
a clinical trial setting where any confounding effect could potentially bias results to great 
consequence. Prior to our investigation, the effect of manometers on CSF biomarker concentrations 
had not been rigorously examined. Bjerke et al. had mentioned that two different catheters had no 
significant effect on Aβ42 adsorption, but did not present any data or details on the experiment 
(Bjerke et al., 2010). Another study had noticed a significant increase in Aβ42 concentration over 36 
hours with an indwelling catheter, listing the catheter as a potential, though unlikely, cause (Bateman 
et al., 2007). 
 
To test the hypothesis that contact with a manometer would decrease Aβ concentration we 
conducted a laboratory simulation in which quantities of pooled CSF were pipetted through a 
manometer or straight into a collection tube. 
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6.1.1 Contributions 
The author designed, and conducted the experiment described in this chapter, conducted the assays, 
conducted the statistical analyses, and wrote the scientific reports. MS. Foiani assisted with the 
conduct of the experiment. 
 
Study conception: H. Zetterberg, K. Blennow, MP. Lunn, NC. Fox, JM. Schott. 
Sample collection: H. Zetterberg. 
Experiment design: The author. 
Experiment: The author, MS. Foiani. 
Analysis: The author, JM. Nicholas, A. Petzold. 
Scientific report: The author, MS. Foiani, RW. Paterson, A. Heslegrave, S. Wray, JM. Schott, NC. Fox, 
MP. Lunn, K. Blennow, H. Zetterberg. 
 
6.2 Materials and methods 
 
6.2.1 Samples 
CSF was collected as described in Section 2.3. Pooled CSF samples (n=20) were divided into two 2mL 
aliquots in 25mL polypropylene (PP) collection tubes (Sarstedt, Nümbrecht, Germany, cat. 
63.9922.254), designated ‘Manometer CSF’ and ‘No Manometer CSF’ depending on whether or not 
CSF was passed through a manometer. 
 
6.2.2 Experiment method 
 
To conduct the experiment in controlled conditions, a lumbar puncture was simulated in the 
laboratory (Figure 25). Centrifuged CSF samples were thawed at room temperature for one hour, 
then pooled together into a 50mL Greiner tube (cat. T2068-450EA) and mixed on a roller for five 
minutes. Two equal volume aliquots were then created in empty Sarstedt PP 2mL storage tubes (cat. 
72.694.406). A volume of 1.5mL CSF (Manometer CSF) was manually ejected into a manometer 
made of styrene-butadiene copolymer (K-resin®) (Rocket Spinal manometer, Rocket Medical PLC, 
Washington, UK, order code:R55990, NHS SC Code: FTP002), using a 5mL pipette (Eppendorf PP 1-
5mL graduated pipette tips; (Starlab, Milton Keynes, UK, cat. I1053-000). Styrene-butadiene 
copolymer (K-resin®) has a computed formal charge of 0 and a molecular weight of 158.23956 
g/mol. This brand of manometer is stock listed by the British National Health Service and used by 
specialist clinics that perform lumbar puncture in the UK. After 60 seconds of CSF injection, the 
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manometer valve was released and the CSF allowed to drain into a 25mL collection tube (Sarstedt 
cat. 63.9922.254). The approximate inflow rate of CSF through the manometer during the 
experiment was ~0.04 cm3/s (diameter = 4mm, velocity = 21cm/minute), similar to what would be 
expected during LP with an opening pressure of 21cm H2O. Alternatively, 1.5mL CSF from the No 
Manometer CSF tube was ejected by pipette directly into a 25mL over the course of 60 seconds. 
Aliquots of 0.5mL Manometer and No Manometer CSF were created in 2mL tubes (Sarstedt cat. 
72.694.406) and stored at -80°C. Prior to assay, samples were thawed for one hour at room 
temperature (21°C). The samples were assayed for Aβ38/40/42 by MSD triplex ECL immunoassay 
(Section 2.2.2). 
 
 
 
 
 
 
6.2.3 Statistical analysis 
Data for each Aβ peptide was found to be normally distributed (D’Agostino-Pearson test, Shapiro-
Wilk test). Manometer and No Manometer results were compared by two tailed, paired t-test in 
Microsoft Excel 2010. 
 
Figure 25: Diagram showing the manometer experiment process.  
Figure 25: Manometer study experiment design 
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6.2.4 Assay variation 
Coefficient of intra-assay variability was <3% for all peptides. Inter-assay variability was Aβx-42 = 
6.7%, Aβx-40 = 9.5%, Aβx-38 = 3.8%), calculated from the concentrations of an internal control CSF 
sample. Intra- and inter-assay CV was calculated according to ISO 5725-2 standards (British Standards 
Institution, 1994). 
  
6.3 Results 
 
6.3.1 Use of a manometer reduces measurable Aβ concentration 
 
 
 
 
 
 
Relative to No Manometer CSF, Manometer CSF Aβ concentration was decreased by Aβ42: 4.3% (± 
2.4 standard error of the mean (SE)), Aβ40: 4.4% (± 1.7 SE), and Aβ38: 5.6% (± 1.5 SE) (Figure 26). A 
paired t-test showed that this was statistically significant in all peptides - Aβ42: p = 0.047, Aβ40: p = 
0.026, Aβ38: p = 0.002. Comparison of the ratios Aβ42:40, Aβ42:38, and Aβ40:38 revealed no 
significant differences between Manometer CSF and No Manometer CSF samples (Aβ42:40: p = 
0.626, Aβ42:38: p = 0.896, and Aβ40:38: p = 0.158.  
 
Figure 26: Showing the percent difference of Aβ peptide concentration in CSF pipetted through a manometer relative to the same CSF 
merely pipetted into a collection tube . All Aβ peptide concentrations tested decreased with manometer use. Error bars represent 
standard error of the mean. 
 
Figure 26: Aβ peptides: % difference of manometers CSF relative to 
no manometer CSF 
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6.4 Discussion 
During a routine LP procedure, a manometer may be employed to measure the opening pressure of 
CSF. Our findings suggest a decrease of 4–6% for A38/40/42 after CSF passes through a Rocket Spinal 
Manometer, made of styrene-butadiene copolymer (K-resin®). To our knowledge this material has 
not previously been studied in terms of its interaction with Aβ peptides. This small concentration 
change would seem unlikely, by itself, to greatly influence diagnosis of AD in individuals attending 
clinic. However, the effect may be more relevant to clinical trials for AD therapeutics, where altered 
Aβ concentration is often a secondary endpoint, as use of large datasets does not compensate for 
such forms of systematic error (Bohm and Zech, 2010). Sampling procedures in cross-sectional 
studies where the use of manometers has not been standardized may result in biased biomarker 
profiles between cohorts. For example, cognitively normal control samples continue to be 
challenging to acquire in large numbers, and AD focused collaborations may share sample cohorts 
without shared collection protocols. Furthermore, inconsistent use of manometers in longitudinal 
studies could raise levels of residual variation (statistical ‘noise’) in intra-individual biomarker data, 
which may obscure a real change, e.g., in a clinical trial; or create a bias if baseline CSF were to be 
taken without a manometer, but subsequent follow-ups used one. In either scenario, lack of 
standardization in manometer use could mislead, or obscure, therapeutic effect in the region of 5–
10% difference between comparators. These results are likely to be relevant to catheters, which are 
used in time-course studies of CSF Aβ concentration in trials assessing physiological variability or 
target engagement (Bateman et al., 2007; Den Daas et al., 2013; Lucey et al., 2015; Ooms et al., 
2014; Slats et al., 2012), though material and dimensions may alter the degree of Aβ concentration 
change. Finally, we found that the ratio of Aβ peptides was unaffected by manometer treatment, 
due to similar degree of treatment-dependent protein loss between each peptide measured. This 
provides a further reason to consider the use of Aβ ratios as diagnostic biomarkers for AD (Blennow 
et al., 2012; Janelidze et al., 2016; Struyfs et al., 2015; Terrill-Usery et al., 2016; Vanderstichele et al., 
2016). Our data supports the implication that an Aβ ratio may be useful in routine clinical diagnosis 
from the perspective of controlling for pre-analytical variation. The results of Chapters 3 and 4 also 
bear this out, albeit with the caveat that different materials, such as polypropylene, may have subtle 
effects on Aβ ratios.  
 
The experiment was a simulation of LP procedure conducted in the laboratory. An advantage of this 
was the ability to closely control the conditions of the experiment, for example removing the 
potential bias in CSF gradients from sequential tapping CSF with and without a manometer, as well 
as standardising timing and volume. However, this approach also had limitations in fully capturing 
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the circumstances of a real LP procedure. The dimensions and material of a pipette tip 
(polypropylene) differ from those of a lumbar needle (often stainless steel with a hub that can be 
made of metal or polypropylene). Additionally, CSF was stored at 21°C prior to contact with the 
manometer, while CSF collected during LP would be at approximately 37°C, pH 7.33, decreasing and 
increasing rapidly respectively, once outside the body (Muizelaar et al., 1991). Finally, the sample 
size of the study was small (n = 20), and conclusions drawn from it would benefit from independent 
replication. 
 
6.5 Chapter summary 
In summary, this study revealed a small, significant, decrease in Aβ38/40/42 when CSF was exposed 
to a spinal manometer. Ratios of Aβ peptides were unaffected. Ongoing and future trials measuring 
CSF opening pressure would be well served to consider the implications of this in study design. 
 
 
6.5.1 Publications arising from this work 
Toombs J, Foiani M, Paterson RW, Lunn M, Heslegrave A, Wray S, Schott JM, Fox NC, Lunn MP, 
Blennow K, Zetterberg H. Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β 
concentration  J Alzheimers Dis. 2017;56(3):885-891. doi: 10.3233/JAD-161126. 
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7 iPSC-neurons as a model to 
understand amyloid beta production 
in fAD 
 
7.1 Introduction 
The first phase of work concerned improvement of the reliability of Aβ as a biomarker for AD by 
identification of pre-analytical confounding factors in CSF and cell culture media, and adapting 
strategies to mitigate them. From there, the scope of work evolved into the examination of Aβ 
peptide production as part of a validation of an in vitro model of human fAD. Better understanding 
of Aβ biology will improve interpretation of it as a biomarker for AD. 
 
The relative merits of AD model technologies have been discussed in Section 1.5.5. A robust protocol 
for in vitro culture of functional glutamatergic cortical neurons has been developed by Shi et al. (Shi 
et al., 2012b, 2012a). There are four steps to the process: 1) the directed differentiation of human 
iPSCs to cortical stem and progenitor cells, including neuroepithelial ventricular zone cells, basal 
progenitor cells and outer radial glial. 2) a period of cortical neurogenesis and synaptogenesis 
consistent with a human in-utero time-frame. 3) neuronal terminal differentiation representing the 
six cortical layers, and astrocyte genesis. 4) Establishment of electrophysiological networks. 
 
The Shi protocol is one of the most widely used methods for generating glutamatergic cortical 
neurons in adherent culture (Begum et al., 2015), and makes use of SMAD inhibition. SMAD 
describes a family of signal transducing proteins for transforming growth factor beta (TGF-B) 
receptors, and is a portmanteau of mothers against decapentaplegic (MAD), a protein of the SMAD 
family originally identified in Drosophila, and small body size (SMA), a protein of the SMAD family 
originally identified in C. elegans. Neurons derived from this protocol accurately recapitulate the 
single-cell transcriptomic signature of primary human fetal cortical neurons, and express many genes 
unambiguously associated with neuronal and synaptic function (Handel et al., 2016; Patani et al., 
2012). Neuro-differentiation and development occur within a time frame analogous to in vivo, this 
has been demonstrated in both 2D and 3D culture, though with the implication that 3D cultures may 
mature slightly faster than 2D (Odawara et al., 2016; Paşca et al., 2015). Cortical neurons 
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differentiated according to this protocol eventually express the six tau isoforms present in human 
adult brain (after 365 days in culture) following an in vivo-relevant timescale (Sposito et al., 2015), 
with accelerated maturation in MAPT mutation lines (Iovino et al., 2015). One particularly interesting 
study compared transcribed protein-coding genes, long intergenic non-coding RNAs, and CpG 
methylation between iPSC-derived cortical neurons and donor-matched post mortem brain tissue (a 
cognitively normal individual with a Braak stage of 1 and a CERAD Neuritic Plaque score of 0). Results 
showed similarity between the two increased with extended time in in vitro culture (Hjelm et al., 
2013). 
 
The electrophysiological properties of cortical neurons in adherent culture derived from this method 
have been well described. Whole cell current-clamp (Gunhanlar et al., 2018; Shi et al., 2012a) 
voltage clamp (Bergstrom et al., 2016), and single cell patch clamp (Wu et al., 2016) have 
demonstrated robust electrical activity. Populations of deep layer neurons have been shown to fire 
single action potential bursts in response to current injection at day 28 (Shi et al., 2012a), as well as 
spontaneous non-synchronous activity (Haenseler et al., 2017). More complex synchronous activity 
has been observed from approximately day 65 onwards (Bergstrom et al., 2016; Gunhanlar et al., 
2018; Shi et al., 2012a). Communicative functionality has also been established in 3D culture, with 
RT-PCR experiments demonstrating that many of the major subunits of the NMDA and AMPA 
receptors are present between weeks 4 and 15 post-induction (Kirwan et al., 2015). These results 
have been supported by calcium signalling experiments showing calcium flux and spontaneous 
electrophysiological activity in co-cultures of cortical neurons with microglia (Kirwan et al., 2015; 
Nadadhur et al., 2017). Study of neuronal network data suggest that in vitro human 3D cortical 
networks have similar connectivity patterns to cortical neurons in vivo (large numbers of neurons 
with few connections, and a small number of highly connected cells that act as hubs) (Kirwan et al., 
2015). 
 
As a model of AD, glutamatergic cortical neurons derived from this protocol have shown different 
APP processing dynamics between different fAD mutation lines and versus controls (Moore et al., 
2015). Furthermore, neurons with a mutant APP genotype, but not PSEN1, have increased total tau 
and tau phosphorylation (Moore et al., 2015), a link between A and tau that has also noted in 
overexpression models (Choi et al., 2014; Muratore et al., 2014). It has also been shown that cortical 
neurons generated by this protocol internalise tau from conditioned media, where it can stimulate 
the generation of more aberrant tau in a prion-like manner (Wu et al., 2016). These cells have also 
been used for exploratory drug screening experiments. Brownjohn et al. conducted a phenotypic, 
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small-molecule screen in Down’s syndrome and fAD neurons and identified avermectins as γ-
secretase independent molecules possessing γ-secretase-like properties in the proteolysis of APP 
(Brownjohn et al., 2017). Additionally, the Shi protocol has been used as a platform for the study of 
several other diseases of the CNS, including Down’s syndrome (Shi et al., 2012c), MAPT mutations 
(Iovino et al., 2015; Sposito et al., 2015), and Huntington’s disease (Mehta et al., 2018), investigation 
of neuronal estrogen biology (Shum et al., 2015), and neuropsychological conditions such as 
schizophrenia and autism (Boissart et al., 2013; Roessler et al., 2018). 
 
Given enormous potential for a mature science of iPSC technology to interrogate AD biology, and 
facilitate therapeutic development in complement to animal models, it is important to examine Aβ 
biology and pathology in human neurons directly impacted by AD. This chapter will describe the 
characterisation of the cell lines used and contribute data to the ongoing endeavour to improve 
measurement variability in their use as AD models. 
 
7.1.1 Contributions 
The author designed the media collection protocol, cultured 2D iPSC neurons and collected media 
and lysates alongside C. Arber. Brain tissue was sectioned by T. Lashley, and homogenised by the 
author and C. Arber. Immunocytochemistry was conducted by the author and Dr Arber. 
Immunohistochemistry and Western blotting were conducted by C. Arber. Live cell calcium imaging 
was conducted by the author under the supervision of M. Duchen and G. Bosale. The author 
conducted all immunoassays, conducted the statistical analyses, and co-wrote the scientific report 
alongside C. Arber. 
 
Study conception: S. Wray, H. Zetterberg, JM. Schott, N. Fox. NS. Ryan. 
Sample collection: The author, C. Arber, C. Lovejoy, N. Willumsen, T. Lashley. 
Karyotyping: Cell Guidance Systems. 
Genotyping: C. Kun-Rodriguez, L. Darwent, and C. Arber. 
Immunocytochemistry: The author, C. Arber. 
Immunohistochemistry: C. Arber. 
Western Blots: C. Arber. 
Calcium imaging: The author, G. Bosale, M. Duchen. 
Immunoassays/LDH assay: The author. 
Analysis: The author. 
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Scientific report: C. Arber, The author, C. Lovejoy, NS. Ryan, RW. Paterson, N. Willumsen, E. 
Gkanatsiou, E. Portelius, K. Blennow, A. Heslegrave, JM. Schott, J. Hardy, T. Lashley, H. Zetterberg, S. 
Wray. 
 
7.2 Materials and methods 
 
7.2.1 Samples 
All cortical neurons used in experiments were cultured, and media collected, as described in Sections 
2.4-8. 
 
For calcium signalling experiments, iPSC-derived cortical neurons used were from the APP V717I-1.1 
(n=2), CTRL1 (n=2), and CTRL2 (n=1) lines, aged at 100 days post-induction. 
 
The cell lines used in time course experiments consisted of two iPSC-derived control lines (CTRL1 (n = 
1), and CTRL2 (n = 1)), one ESC-derived control line (SHEF6 (n = 2)), two clones of one APP mutation 
line (APP V717I-1.1 (n = 3), and APP V717I-1.3 (n = 2)), two clones of one PSEN1 mutation line 
(PSEN1 int4del.4 (n = 1), and PSEN1 int4del.6 (n = 2)). Cells were cultured by Dr C. Arber and myself.  
 
For paired sample comparison experiments, iPSC-derived cortical neuron lines used consisted of two 
clones from one APP mutation line (APP V717I-1.1 (n = 3), and APP V717I-1.3 (n = 2). Cells were 
cultured by Dr C. Arber and myself. In addition to media, cell lysates were collected as described in 
Section 2.9. Post-mortem brain tissue from the frontal cortex was collected as described in Section 
2.14 by the Queen Square Brain Bank. For immunoassay analysis of AD biomarkers tissue was 
homogenised and processed to extract different Aβ solubility fractions as described in Section 2.15 
by Dr C. Arber and myself. Samples used consisted of technical-replicates of one APP mutation brain 
(APP V717I-1). CSF was collected from the APP V717I-1 patient at the specialist cognitive disorders 
clinic (National Hospital for Neurology and Neurosurgery, in association with the Dementia Research 
Centre, UCL), referred for diagnostic LP for investigation of a suspected neurodegenerative 
condition. Ethical permission was obtained from the National Hospital for Neurology and 
Neurosurgery and the Institute of Neurology joint research ethics committee (09/H0716/64) and 
informed consent was obtained. CSF was collected by LP between 09:00 and 10:30. A volume of up 
to 20mL of CSF was collected at ambient room temperature into two 10mL polypropylene tubes 
(Sarstedt, Nümbrecht, Germany cat. 63.9922.254) directly from a 22-gauge Quincke needle, without 
manometer. In the case of visible blood contamination, the CSF was discarded and the tap continued 
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in a new tube once bleeding had stopped. Samples were centrifuged at 1750 RCF for five minutes at 
21°C, and aliquoted at 1mL into 2mL PP tubes (Sarstedt cat. 72.694.406) and frozen at -80°C within 
1-4 hours of collection.  
 
7.2.2 Experimental methods 
Cell karyotyping was conducted as described in Section 2.4. Genotyping was conducted using Sanger 
Sequencing by Drs. C. Kun-Rodriguez, L. Darwent, and C. Arber. Immunocytochemistry was 
conducted as described in Section 2.11 by Dr C. Arber and myself. 
 
Calcium signalling experiments were conducted as described in Section 2.12. Microscope image 
fields were selected on the basis of the most structurally intact network of neurons that could be 
resolved within the shortest time frame after microscope mounting.   
 
For time course experiments, cell media (N2B27) was collected from each well at three time-points 
separated by 48 hours of incubation (days 100, 102, and 104). This process of media collection was 
then repeated on the same cells at days 200, 202, and 204 post-induction.  
 
Extracellular amyloid plaques are relatively common in aged brain tissue, but also constitute a 
defining pathological feature of AD. To assess whether our in vitro 2D and 3D models capture this 
aspect of AD immunohistochemistry and immunocytochemistry were used to compare extracellular 
Aβ accumulation in brain and iPSC-derived cortical neuron tissue from the same individual 
respectively (Section 2.11). The antibodies used were Aβ (Dako, M0872), MAP2 (Abcam, ab5392), 
and DAPI (Abcam, ab228549). This work was conducted by Dr. C. Arber. 
 
Cell media and cell lysate samples, post-mortem brain tissue homogenate, as well as CSF from the 
individual APP V717I-1 were analysed for Aβ38, Aβ40, and Aβ42 by triplex MSD ECL immunoassay 
(Section 2.2.2). Ttau was measured by MSD ECL immunoassay (Section 2.2.3), and LDH by Randox 
Monza biochemistry analysis (Section 2.17). 
 
7.2.3 Statistical analysis 
For calcium signalling experiments, data was compiled using a Metafluor software package. Images 
were analysed in Image J where the pixel greyscale signal intensity of 340nm and 380nm images 
were recorded in selected regions of interest (neuronal soma, identified by gross morphology) minus 
the signal of a blank region of interest. The quantified signal ratio of 340:380nm was used to 
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determine the neuronal calcium signal response to KCl or glutamate. Graphs were created in 
Microsoft Excel. 
 
For time course experiments, mean concentrations for each biomarker were calculated from 
duplicate measurements, and variation between inductions was calculated by coefficient of 
variance. Data normality was assessed by histogram, qq-plot, and Shapiro-Wilk test. Given data non-
normality, Spearman’s rank correlation coefficient was conducted to assess the relationship 
between cell media concentrations of A or tau and LDH. For time course experiment data, variation 
between different inductions of the same line was calculated by coefficient of variance. Analysis was 
conducted in R, and graphs were composed using the ggplot2 package. 
 
For analysis of paired sample data, different sample types were generated from tissues of the same 
patient and so the sample size was limited to n=1. Statistical comparisons between different sample 
types were conducted from technical replicate measurements, and data distribution therefore 
reflects procedural variation. Statistical comparisons were conducted using Mann-Whitney U 
analysis in R, where data of each sample type was compared to that of cell media individually. In 
cases where no technical replicates were available (e.g. APP V717I-1 CSF) it was not possible to 
obtain a significance value. Analysis was conducted in R, and graphs were composed using the 
ggplot2 package. 
 
7.2.4 Assay variation 
For paired sample and time course measurements, intra- and inter-assay variation was Aβ38 (3.6%, 
6.8%), Aβ40 (5.6%, 7.4%), Aβ42 (3.8%, 10.5%), Aβ43 (7.4%, 13.2%), and Ttau (7.9%, 12.6%) 
calculated from the concentrations of an internal control CSF sample included in assay plates. Intra- 
and inter-assay CV) was calculated according to ISO 5725-2 standards (British Standards Institution, 
1994). 
 
7.3 Results 
 
7.3.1 Karyotype and genotype screen 
The process of cellular reprogramming involves the use of a vector (viral or plasmid) to alter genetic 
expression through either integrative (retrovirus, lentivirus) or non-integrative (Sendai virus, 
plasmid, synthetic mRNA) means. Use of integrative methods risk off target insertions or deletions, 
as well as unintended persistence of sequence in the nuclear DNA, and it is important to determine 
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that transformed cells do not retain these unwanted artefacts before carrying the lines forward. 
Non-invasive protocols, such as the one used in this thesis do not have these vulnerabilities, the 
trade-off being generally lower reprogramming efficiency.  
 
Never-the-less, in the artificial environment of cell culture there are many factors that can affect 
faithful cell division, not least the enzymes used in passage. It has been observed that successive 
passages increase the chance of chromosomal level anomalies (Berry et al., 2018), and so 
karyotyping of each line was performed prior to engaging in the differentiation of iPSCs to cortical 
neurons. Normal karyotype was demonstrated for each line examined (Figure 28A). Furthermore, a 
number of cell lines were from individuals with specific fAD mutations, and it was important to 
confirm that these cells retained their fAD-relevant genotype after reprogramming. Genotyping 
confirmed retention of the appropriate fAD mutations (Figure 28B). 
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 Figure 28: A) human cell lines show normal karyotypes. B) fAD mutation lines show expected genotypes. Images generated by Dr. C. 
Arber and used with permission. 
Figure 27: Results of fAD line karyotyping and genotyping 
B 
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7.3.2 Immunocytochemistry  
iPSC-derived glutamatergic cortical neurons were cultured and differentiated as described in 
Sections 2.4-8. A portion of the cells from each line examined in this thesis were plated onto glass 
coverslips at each of the major differentiation milestones, and fixed in 4% paraformaldehyde. 
Immunocytochemistry was conducted following the method described in Section 2.11, to identify 
proteins expressed by cells at each major developmental stage. 
 
Results (Figures 29-31) showed expression of pluripotency markers SSEA4, OCT3/4, and Tra1-81 in 
iPSC cultures. Following neural induction by dual SMAD inhibition neuroepithelium formed with 
characteristic rosette morphology and the expression of Ki67, PAX6, and OTX2. Neural progenitors 
and deep layer neurons (TBR1+) were present after 30 days post-induction complete with projecting 
axons (TUJ1+). Over a subsequent 70 days, mid layer (CTIP2+) and superficial layer (SATB2+ and 
BRN2+) neurons differentiated. A sub-population of astroglia (GFAP+) were also present. 
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Figure 28: Immunocytochemistry of Non-AD control iPSC lines 
Figure 29: Showing immunocytochemistry for each of the Non-AD control lines for markers of pluripotency (SSEA4, TRA1-81, OCT3/4, and Nanog), markers associated with 
neuroepithelial radial glia (PAX6 and phosphor vimentin (pVIM)), proliferating cells (Ki67 and FOXG1), and markers of the various neuronal cortical layers (TBR1, CTIP2, 
SATB2, and BRN2), as well as the axonal marker TUJ1. DAPI is a marker of nuclear protein. White asterisks indicate images provided by Dr. C. Arber, and used with 
permission.  
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Figure 29: Immunocytochemistry of fAD PSEN1 iPSC lines 
Figure 30: Showing immunocytochemistry for each of the APP V717I mutation lines for markers of pluripotency (SSEA4, TRA1-81, and OCT3/4), markers associated with neuroepithelium 
(Ki67 and PAX6), and markers of the various neuronal cortical layers (TBR1, CTIP2, SATB2, and BRN2), as well as the axonal marker TUJ1. A marker of glutamatergic synapses (PSD95) is 
shown in panel PSEN1 M146I Layer V-III, this image was taken using an Agilent Seahorse XF analyser. DAPI is a marker of nuclear protein. White asterisks indicate images provided by Dr. C. 
Arber, and used with permission. 
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Figure 31: Showing immunocytochemistry for each of the APP V717I mutation lines for markers of pluripotency (SSEA4, TRA1-81, and OCT3/4), markers associated with neuroepithelium (Ki67 and PAX6), and 
markers of the various neuronal cortical layers (TBR1, CTIP2, SATB2, and BRN2), as well as the axonal marker TUJ1. DAPI is a marker of nuclear protein. 
Figure 30: Immunocytochemistry of fAD APP V717I iPSC lines 
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7.3.3 Calcium signalling 
Neurons are specialised cells for fast and intricate communication processes. Compelling evidence 
for the function of Aβ peptides in the regulation and disruption of neuronal activity has been 
gradually building, and data point particularly to the importance of synaptic transmission to Aβ 
exocytosis (Cirrito et al., 2005, 2008) and disrupted calcium homeostasis to neurotoxicity (Abramov 
et al., 2004; Arispe et al., 1993; Berridge, 2011; Camandola and Mattson, 2011; Eckert et al., 2010). It 
is therefore important that an in vitro neuronal model of Aβ biology should demonstrate electrically 
functional properties.  
 
Neurons maintain free cytosolic Ca2+ at a concentration of ~100nM, and store excess in the ER and 
mitochondria, or export it to the extracellular space against the massive 20000-fold concentration 
gradient (Clapham, 2007). During membrane depolarisation, voltage-gated calcium channels (such 
as nAChRs and NMDArs) open allowing Ca2+ (and Na+ with much lower affinity) ions to enter the cell 
(Simons, 1988). The increase of Ca2+ above resting level within the cytosol is known as a calcium 
signal. Cytosolic Ca2+ acts as a crucial secondary messenger which binds to various proteins (e.g. 
calmodulin) causing conformational changes that expose hydrophobic regions and facilitate inter-
molecular interactions, including pre-synaptic vesicular-membrane fusion that enables 
neurotransmitter release (Jahn and Fasshauer, 2012). Therefore, demonstration of functional 
calcium signalling in response to ionic and neurotransmitter stimulation provides validation of 
neuronal functional maturity.    
 
The majority of neurons observed responded with a single calcium signal immediately following 
stimulation with 12.5mM KCl and with 100μM glutamate (Figure 32). Out of a total 127 cells 
observed, a single neuron from the CTRL1 displayed continuous, regular calcium signalling 
approximately every 30 seconds for as long as it was recorded (six minutes) (Figure 32E). In the initial 
moments of recording, the 340nm:380nm ratio signal from this cell was falling to baseline, 
potentially indicating spontaneous activity prior to stimulation. A number of other neurons 
demonstrated tiny fluctuations (340:380nm = 0.05-0.1 above baseline) in the 340nm:380nm ratio 
post-stimulation (neuron 20 (Figure 32A) and neuron 13 (Figure 32C)). It is unclear whether these 
fluctuations reflect true calcium signals, rather the fact that these neurons all eventually 
demonstrated indications of calcium toxicity (a prolonged high 340nm:380nm that either plateaued 
or continued to increase) suggests these may denote stress.  
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Figure 32: A) CTRL2 cortical neuron calcium signals in response to 12.5mM KCl administered at 106 seconds, and 100μM glutamate at 
186 seconds. B) Image of CTRL2 neurons at 50 seconds in the 340nm channel. C) fAD genotype (APP1 V717I) cortical neuron calcium 
signals in response to 12.5mM KCl administered at 46 seconds, and 100μM glutamate at 280 seconds. D) Image of (APP V717I) 
neurons at 50 seconds in the 340nm channel. E) CTRL1 cortical neuron calcium signals in response to 12.5mM KCl administered at 34 
seconds and followed over an extended time frame. Neuron 1 (E: black line, F: circled red) is noteworthy for regular calcium signals 
following KCl stimulation, and potential spontaneous activity prior to stimulation. The disturbance at 500 seconds reflects the 
microscope stage being accidentally jolted. F) Image of CTRL1 neurons at 50 seconds in the 340nm channel.   
Figure 31: Live cell calcium imaging 
A B 
C D 
E F 
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7.3.4 Variability of A peptide concentrations over time and between 
independent inductions 
The issue of cell culture variability is often discussed in terms of controlling reprogramming 
efficiency and maintaining genotypic homogeneity between culture batches (Berry et al., 2018). A 
relatively neglected aspect is the variability in protein biomarker measurements between and within 
differentiated cell lines.  
 
Environmental factors known to alter in vitro neuronal protein expression include: temperature, 
oxidation, infection, culture purity, as well as cell density, viability, maturity and electrical 
functionality. Whilst certain of these factors (e.g. temperature, oxidation, and infection) are 
relatively easy to standardise with good laboratory practice, and others (purity and electrical 
maturity) demonstrably robust, long term neuronal culture following the Shi protocol (Shi et al., 
2012a) is vulnerable to differences in culture density.  
 
The different neuronal progenitors that represent a strength of this approach differentiate at 
different rates. When the final passage is made at ~day 35 post-induction, a population of cells are 
still mitotic and continue to differentiate. Furthermore the extended time course required for the 
culture to reach a mature, terminally differentiated state provides scope for unique levels of cell 
death. We considered that the concentration of secreted Aβ peptides would broadly relate to the 
number of viable neurons within each culture. Given emerging evidence that production of different 
Aβ peptides may follow predictable and dependent patterns (Chavez-Gutierrez et al., 2012; Takami 
et al., 2009), we hypothesised that ratios of Aβ peptides might normalise for variations in cell density 
between cultures.  
 
7.3.4.1 Tau, but not Amyloid beta, correlates with cell death 
Concentrations of secreted A42, A40, A38, A43, T-tau, and LDH were quantified in 2D iPSC-
derived neuronal conditioned media from three non-AD and two fAD iPSC lines. LDH is a cytosolic 
enzyme, and its presence in the extracellular space is a marker of cytotoxic membrane disruption 
that accompanies cell death. Secreted A43, A42, A40 and A38 did not correlate with LDH 
(Figure 33A-D). In contrast, secreted tau displayed a strong positive correlation with LDH, and 
therefore to level of cell death (Figure 33E). 
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7.3.4.2 High variability of Amyloid beta peptide concentrations over time and 
between inductions 
When cell culture media concentrations of A peptides were examined longitudinally, acceptable 
measurement consistency (average CV = 8.3% ± 1.4 95% confidence interval (CI), inclusive of all 
peptides) was observed within each induction over the course of six days (Figure 34). However, a 
large degree of variability (average CV = 30.1% ± 5.7 CI) was observed over the longer time period of 
100 days (Figure 34). Furthermore, different iPSC clones of the same reprogrammed fibroblast line 
and independent inductions of the same iPSC line were highly variable, in some cases even over the 
Figure 33: Showing the correlation of LDH with A) 
A38, B) A40, C) A42, D) A43, E) T-tau in cell 
media collected at day 100. 
Figure 32: Lactate dehydrogenase correlation with Aβ and total tau 
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course of six days, with differences between inductions and clones being comparable to that 
between different cell lines (Figure 34).  
 
 
 
 
 
 
 
7.3.4.3 Amyloid beta ratios are consistent over time and between independent 
inductions 
To examine whether data normalisation might reveal more meaningful patterns, derived A 
peptides were analysed as ratios to the most abundant product, A40. Additionally, the A42:38 
ratio was investigated, as this ratio is a potential biomarker of APP processivity. When ratios of A 
peptides were used, variability over time collapsed. Over six days variation for all ratios was low 
(average CV = 5.1% ± 1.6 CI) (Figure 35). Over the longer time frame of 100 days ratios of A42:40, 
A42:38, and A38:40 demonstrated similarly low variation (average CV = 5.9% ± 1.4 CI), whilst 
A43:40 retained a relatively large degree of variation (average CV = 20.5% ± 4.3 CI), although this 
Figure 34: Longitudinal concentrations of A) A38, B) A40, C) A42, and D) A43 in cell media collected from different inductions of 
non-AD and fAD cell lines, including from different clones of APP V717I and PSEN1 int4del mutation lines. 
Figure 33: Cell media Aβ concentration over time 
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was half that of A43 alone (average CV = 40.7% ± 11.5 CI) (Figure 35). Furthermore, greater 
consistency was observed between different inductions and clones of the same line when ratios of 
A were employed. Importantly, the reduced variability over time and between inductions/clones 
highlighted distinct patterns of separation between fAD mutations and CTRL1, CTR2 and SHEF6 lines. 
Despite, representing cells from three different individuals and from both iPSC- and ESC-derived 
sources, ratios of all A peptides were all but indistinguishable between the non-AD lines. A 
phenotype of increased Aβ42:40 relative to these controls was demonstrated in both fAD mutation 
cells (Figure 35A). Furthermore, both clones of cells bearing an intron 4 deletion in PSEN1 
demonstrated raised Aβ42:38 and Aβ43:40 relative to control lines (Figure 35B-D). The ratio Aβ38:40 
appeared to distingush APP and PSEN1 mutation lines from each other as well as controls, as this 
ratio was raised versus controls in APP V717I, and slightly decreased versus controls in PSEN1 
int4del. 
 
 
 
 
 
 
Figure 35: Longitudinal ratios of A) A42:40, B) A42:38, C) A38:40, and D) A43:40 in cell media collected from different inductions 
of non-AD and fAD cell lines, including from different clones of APP V717I and PSEN1 int4del mutation lines. 
Figure 34: Cell media Aβ ratios over time 
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7.3.4.4 Ttau concentrations are high and variable over time and between 
independent inductions 
Concentrations of T-tau were extremely high in cell culture media, and samples had to be diluted 
1:100 (compared to 1:4 for CSF) in order to fit within the linear range of the assay standard curve. 
Measurements from the same induction showed considerable variability over both six-day (average 
CV = 19.4% ± 1.5 CI) and 100-day time frames (average CV = 29.2% ± 10.3 CI), and differences 
between different inductions and clones of the same line were comparable to those between 
different cell lines (Figure 36A). Additionally, a trend for T-tau concentrations to decrease after 
successive 48-hour time points was observed during both week 100 and week 200 collections.  
 
 
 
 
 
 
Different iPSC clones of the same reprogrammed fibroblast line and independent inductions of the 
same iPSC line were highly variable, even over the course of six days, with differences between 
inductions and clones being comparable to that between different cell lines (Figure 36). 
Normalisation of Ttau values in ratio to A40 did not improve interpretability of the data between 
days 100-104, although between days 200-204 the distinctions between Non-AD, APP V717I, and 
PSEN1 int4del became more defined (Figure 36B). Finally, the use of a Ttau:LDH ratio appeared to 
stabilize the successive decrease in Ttau concentration, especially between days 100-104, although 
no genotype specific pattern emerged (Figure 36C). 
 
Figure 36: Longitudinal concentrations of A) T-tau, B) Ttau:A40, and C) Ttau:LDH in cell media collected from different inductions 
of non-AD and fAD cell lines, including from different clones of APP V717I and PSEN1 int4del mutation lines. 
Figure 35: Cell media Ttau ratios over time 
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7.3.5 Comparison of amyloid beta profiles in paired biosamples 
Having characterised relevant protein expression and excitatory function in our cortical neuron 
model, as well as identifying the utility of using A ratios to investigate A production biology, we 
asked the question: how well does A production in vitro reflect patterns observed within adult 
human biofluids and tissues? One highly interesting study compared RNA transcription in iPSC-
derived neurons and glia culture with temporal tissue from the same non-neurodegenerative 
individual and observed similar CpG methylation after neuronal differentiation (Hjelm et al., 2013). 
Additionally, whilst a number of genes were up- or down-regulated in vitro, differences in down-
regulation decreased with time in culture (Hjelm et al., 2013). To contribute to this slowly emerging 
area of study, we compared relative A levels in iPSC conditioned media, iPSC-neuronal lysates, ex 
vivo lumbar CSF, and post-mortem brain tissue homogenate from the same fAD patient donor (APP 
V717I-1). 
 
7.3.5.1 iPSC-cortical neuron cultures do not generate extracellular amyloid 
plaques 
 
Experiment by immunocytochemistry and western blot demonstrated that APP was expressed in 2D, 
3D, and post-mortem tissue (Figure 37). APP expression was greater in 3D than 2D culture systems, 
due to the relative differences in cell density, which was higher in the cell dense environment of the 
organoid. However, deposition of amyloid into dense-core and diffuse plaques was only observed in 
post-mortem brain of this individual, but not in either 2D or 3D in vitro models (Figure 37).  
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7.3.5.1.1 Amyloid beta ratios in paired biosamples 
When absolute concentrations of A38/40/42 were compared in cell media, cell lysates (soluble and 
insoluble fractions), frontal cortex (soluble and insoluble fractions), and lumbar CSF from the same 
individual results showed gross differences in the quantities of A peptides present between sample 
types (Figure 38). Concentrations were universally highest in CSF (although the experiment was not 
appropriately powered to estimate significance in this case), whilst cell media A42 (Figure 38A) and 
A40 (Figure 38B) were lower, and cell lysate and brain fraction concentrations lower again. A38 
concentration also differed significantly between cell media and other sample types (Figure 38C). 
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Figure 37: Comparison of APP protein expression 
between 2D, 3D and post-mortem tissue. A) Comparison 
of APP protein expression between tissues using and 
antibody versus the APP C-terminal domain (CTF) with 
MAP2 depicting neuronal cells. Scale bar represents 
25m. B) Showing representative immunohistochemistry 
(post mortem brain panels) and immunocytochemistry 
(2D and 3D panels) for the detection of extra cellular Aβ 
in tissues derived from the same individual. C) Western 
blot comparing APP levels between APP V717I-1 and Ctrl 
1 in 2D and 3D. Work done and images produced by Dr. 
C. Arber and used with permission.   
Figure 36: APP expression in Post mortem, 2D, 
and 3D cortical neurons  
A 
B 
C 
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Additionally, there was a tendency for insoluble lysate and brain fractions to have more A38 than 
the soluble fractions (Figure 38C).  
 
Use of A ratios highlighted some interesting patterns. No significant difference in A42:40 was 
found between cell media with the soluble brain fraction, although variability between brain tissue 
extraction replicates was high (Figure 38D). However, A42:38 and A38:40 ratios were clearly 
divergent between cell media and soluble brain fraction (Figure 38E-F). A38 was very difficult to 
detect in soluble brain fraction, with only one replicate generating a signal, comparable to that 
obtained more reliably in the insoluble fraction. A42:40 and A42:38 were decreased in CSF 
relative to cell media, but the A38:40 ratio was highly comparable. This was also the case for the 
soluble cell lysate fraction. The insoluble fractions of cell lysates and brain homogenate 
demonstrated similar A ratios to each other, but in all cases distinct from cell media. This reflected 
proportionally lower Aβ42 and/or increased A40 and A38 content. 
 
 
 
 
 
   
Figure 38: showing comparative A) Aβ42, B) Aβ40, C) Aβ38, D) Aβ42:40, E) Aβ42:38, and F) Aβ3840 in cell media, cell lysates, 
homogenised frontal cortex (brain), and lumbar CSF from the same individual with an APP V717I genotype. Cell lysates and brain 
tissue were partitioned into soluble (sol) and insoluble (ins) fractions by ultracentrifugation and solubilisation in SDS and formic acid 
respectively.  
Figure 37: Comparison of Aβ peptide concentration and ratios between paired samples  
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7.4 Discussion 
The protocol for cortical neuronal differentiation devised by Shi et al. has been widely validated for 
cortical development and electrophysiology (Gunhanlar et al., 2018; Haenseler et al., 2017; Kirwan 
et al., 2015; Nadadhur et al., 2017; Shi et al., 2012a). The neurons produced in our hands showed 
normal karyotype, retained fAD mutation genotype, and followed expected development into 
glutamatergic cortical neurons and glia of the six cortical layers, as demonstrated by expression of 
neuron and cortical layer specific markers. Live calcium imaging of iPSC-derived neurons 
demonstrated that most cortical neurons examined exhibited a single transient calcium signal in 
response to KCl stimulation. This is indicative of the presence of functional ion channels in the cell 
plasma membranes, which is further attested by PSD95-positive staining demonstrated in Figure 39. 
The neurons also exhibited a transient calcium signal in response to glutamate stimulation, though 
relatively fewer than had responded to KCl. This implies that a subpopulation of neurons had 
functional glutamate receptors. Additionally, very few neurons demonstrated continuous or 
spontaneous activity suggesting that either the cells observed did not represent a fully mature 
population or that the conditions of the experiment were not optimal.  
 
There were some substantial limitations to this experiment. First was the lack of temperature and 
atmospheric control whilst the cultures were mounted on the microscope, and the time of exposure 
to these conditions during mounting and focusing the microscope on an appropriate area of interest. 
This also applies to the conditions of transportation between laboratories that, despite a 24 hour 
rehabilitation period in an incubator, were likely not ideal for culture integrity. Thus conditions did 
not faithfully reflect the physiological environment, nor the limited time exposed to ambient 
laboratory conditions during media replenishment. Secondly, glutamate response was measured 
after KCl treatment. Although this had the advantage of demonstrating response to both treatments 
in the same neurons, it is possible that conditions following KCl introduction interfered with the 
glutamate response. Finally, although a strength of this technique is the simultaneous examination 
of multiple neurons with relative efficiency, sample sizes used were small (only APP V717I, CTRL1 
and CTRL2 were observed, and replicate n = 1-2 per line). Data is too preliminary to draw any 
conclusions regarding differences between fAD and control lines in this regard. However, Aβ (and 
particularly oligomeric structures) are thought to bind to glutamatergic neuron membranes and 
synaptic receptors resulting in decreased LTP, and it would be worthwhile to investigate this further. 
 
Thus, cortical neurons produced by this protocol express proteins from each of the cortical layers, 
and manifest calcium signals in response to KCl and glutamate, complementing work by other 
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groups (Begum et al., 2015; Gunhanlar et al., 2018; Haenseler et al., 2017; Handel et al., 2016; 
Kirwan et al., 2015; Nadadhur et al., 2017; Shi et al., 2012a), with the caveats that the population of 
mature glutamatergic neurons may be small even between day 80-100, and the method of calcium 
imaging used requires further optimising. 
 
Turning to the production of A in the cell lines cultivated, the experiments that followed A and T-
tau secretion longitudinally demonstrated three important points regarding study of A and tau in 
neuronal culture media. First, the strong correlation of T-tau with LDH suggests that a significant 
proportion of the quantities of T-tau present is due to cell death rather than physiological secretion. 
In contrast there was no correlation of LDH with any of the A peptides examined, potentially due to 
rapid and constitutive secretion of A into the extracellular space by healthy cells. This suggests that 
acute levels of cell death are not likely to greatly confound interpretation of peptide concentration.  
 
The second point addresses the use of ratios to overcome inherent variability in biomarker 
concentrations between different lines and inductions. Culture density, linked with but distinct from 
cell death, is a challenging variable to control when comparing samples by quantitative 
characteristics. We observed that, although A peptide concentrations were relatively consistent 
over short periods of time within a given induction, over a longer time course and between different 
inductions variability was such that differences between lines were difficult to confidently resolve. 
As cells were free to differentiate and die for 65-165 days prior to media collection, whilst collection 
methods were otherwise well standardised, we suspected differences in culture density to be a 
major source of this variability. As the nature of APP proteolysis means that concentrations of A 
peptides are derived from the same source and are to some extent dependent, normalising A 
peptide measurements in ratio to other peptides greatly reduced variability in temporal and 
replicate parameters and revealed genotype-specific patterns. In contrast, ratios of A with tau were 
less useful. Although ratios of A38/40/42 produced very consistent results, measurements 
involving A43 were more variable. This could be due to differences in assay performance as A43 
was analysed by ELISA rather than as part of the ECL triplex. Alternatively, it has been shown that 
neurons derived from the protocol used produce increasing quantities of longer Aβ peptides as they 
mature over 100 days post-induction (Bergstrom et al., 2016). It is possible that whilst production of 
peptides up to Aβ42 may stabilise within this period, Aβ43 and longer fragments could take more 
time resulting in the generally increased Aβ43:40 ratio observed at 200 days relative to 100 days. 
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The third point concerns the nature of genotype-specific patterns. Both APP V717I and PSEN1 
int4del cell lines expressed greater Aβ42:40 than non-AD control lines, a finding which complements 
a fast solidifying body of evidence in the literature in regard to the effect of fAD mutations on APP 
processing (Mahairaki et al., 2014; Moore et al., 2015; Ochalek et al., 2017; Sproul et al., 2014; Sun 
et al., 2017; Woodruff et al., 2013). The Aβ42:38 ratio is a potential readout of -secretase 
carboxypeptidase-like cleavage efficiency (Szaruga et al., 2015) and the Aβ38:40 has been used to 
compare the theorised A49 versus A48 dependent pathways (Takami et al., 2009). The ratios 
Aβ42:38, Aβ38:40 and Aβ43:40 showed qualitative differences between APP V717I and PSEN1 
int4del cell lines, hinting at potentially disease and therapeutically relevant mechanisms underlying 
production of different Aβ peptides. For example, PSEN1 int4del cells appeared to favour the 
production of longer Aβ peptides over shorter fragments. This was not the case for APP V717I, 
where difference from non-AD control lines was only observed in the between Aβ42 and Aβ38 in 
relation to Aβ40. These data fit conceptually with two emerging hypothesis of Aβ production: the 
tripeptide hypothesis of APP proteolysis by γ-secretase (Takami et al., 2009), and the partial loss of 
function hypothesis of γ-secretase mutation (Szaruga et al., 2017). These are concepts that are 
explored further in Chapter 9. 
 
Thus, in cultured cortical neurons A production ratios appear tightly regulated within a narrow 
physiological range. This remains stable over substantial periods of time once cells have reached 
maturity around 100 days post-induction. The use of ratios in analysis overcomes experimental 
variability, allowing meaningful comparisons between fAD lines.  
 
It is important to note that neither 2D nor 3D organoid culture systems developed A plaques. High 
A production (nM range concentration) and\or low A clearance are prerequisite for the formation 
of these structures in vitro. Others have successfully generated cultures with A plaques using 
methods of A overexpression, such as co-expression of APP and PSEN1 mutations (Choi et al., 
2014). The neurons produced by our model do not produce excessive quantities of A overall, but 
alter the quality of production. Additionally, the nature of media replacement precludes A 
accumulation sufficient to form large deposits (Choi et al., 2015). However, whilst the presence of 
plaque structures are a defining AD phenotype, the cells of our model are advantaged in that they 
represent a real human fAD genotype enabling the collection of highly relevant data regarding the 
biological effect of these mutations on the quantitative and qualitative production of different A 
peptides. 
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Comparisons of iPSC-derived neurons with paired tissues and clinically relevant fluids are extremely 
rare. Analysis of A peptide ratios in cell media, cell lysates, frontal cortex brain homogenate, 
lumbar CSF revealed that cell media and soluble fraction brain homogenate contained similar ratios 
of A42:40, whilst the ratio in CSF was noticeably lower. Additionally, A42:38 was also lower in CSF 
than cell media, whilst A38:40 was highly comparable. Reduced CSF A42 is considered to reflect 
preferential deposition of A42 in amyloid plaques and/or peptide specific clearance disruption 
(Blennow, 2017), whilst A38 and A40 are not typically found altered in AD CSF. Indeed, dense-core 
and diffuse plaques were observed by immunohistochemistry in post-mortem brain of this 
individual, and together these preliminary results are consistent with A production and clearance in 
fAD. A38 was difficult to detect in the soluble brain homogenate fraction, with only one sample 
producing detectible signal. In this case soluble fraction ratios of A42:38 and A38:40 mirrored 
those of the insoluble fraction, but not cell media, conflicting with the hypothesis that cell media 
models the soluble brain environment. More work is needed to characterise the solubility of Aβ 
peptides in this context. 
 
Finally, results from cultured neuron lysates, representing intracellular and membrane bound A, 
show depletion of A42 relative to A38 and A40, suggesting an intracellular bias against A42 
retention. The two fractions differ primarily in that relative proportions of A38 were higher in the 
insoluble fraction. Study of intracellular A has been problematic due to antibody cross-reactivity 
with full length APP and dependence on non-human or non-neuronal model systems (LaFerla et al., 
2007). Despite this, it has been proposed that accumulation of A in neurons forms the seeding 
templates that precipitate the formation of amyloid plaques when the cell dies and releases its A 
into the extracellular space (D’Andrea and Nagele, 2010; LaFerla et al., 2007). This has been 
described in human post-mortem entorhinal cortex and hippocampus (D’Andrea et al., 2001), and a 
dynamic relationship between intra-cellular and extracellular A has been noted (Oddo et al., 2004, 
2006). The results presented here do not support the accumulation of intracellular A42 in 
developmentally early iPSC-derived neurons, but may direct attention toward intracellular A38. 
Further work is required to verify these results and understand the dynamics of A, particularly 
A38, in these sample types. 
 
7.5 Chapter summary 
Characterisation experiments demonstrated the genetic integrity, appropriate cortex-genesis, and 
mature functionality of the cortical neurons generated for study. Furthermore, a method of using A 
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peptide ratios was established which normalised for differences between different inductions 
enabling reliable interpretation of A secretion patterns from various fAD mutation lines. Finally, 
comparison of paired cell media, cell lysates, and lumbar CSF from the same individual revealed 
intriguing A profiles that support notions of A production and clearance in fAD. 
 
7.5.1 Publications arising from this work 
Charles Arber1§, Jamie Toombs1,2§, Christopher C. Lovejoy1, Natalie Ryan3, Ross W. Paterson3, Nanet 
Willumsen1,4, Eleni Gkanatsiou5, Erik Portelius5,6, Kaj Blennow5,6, Amanda Heslegrave1,2, Jonathan M. 
Schott3, John Hardy1,2, Tammaryn Lashley4, Nick C. Fox3, Henrik Zetterberg1,2,5,6± and Selina Wray1± 
Familial Alzheimer’s disease patient-derived neurons reveal distinct mutation-specific effects on 
amyloid-beta. Mol Psychiatry. 2019 
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8 Aβ production in fAD mutations 
 
8.1 Introduction 
Having characterised genotypic, phenotypic and functional aspects of the cell model, and identified 
interesting mutation-specific patterns in Aβ peptide production ratios, the next step was to examine 
a wider array of Aβ peptides in a larger number of fAD mutations. We expanded our investigation to 
include additional PSEN1 fAD iPSC lines and a sample set that included paired neurons generated by 
2D adherent culture and 3D cerebral organoids. Given the variability in concentrations between 
inductions and the corresponding difficulty of interpreting data, measurement of T-tau was not 
pursued. Very few studies have explored Aβ dynamics in both human neuronal models and at 
endogenous expression levels. 
 
The fAD mutations available for study were: APP V717I, PSEN1 int4del, Y115H, M139V, M146I, and 
R278I. This section will give a brief overview of the epidemiology, neuropathology, and known 
effects on A production.  
 
The APP V717I point mutation was first identified in two kindreds (English and American) with early 
onset AD (57 ± 5 years) (Crawford et al., 1991; Goate et al., 1991). There are now approximately 30 
known kindreds with this mutation worldwide, making it one of the most prevalent APP mutations. 
The neuropathology associated with this mutation is of extensive amyloid plaque and NFL positive 
lesions Crawford et al., 1991; Goate et al., 1991), although variability in non-typical features was 
noted as one individual from the English family also had mild amyloid angiopathy and cortical and 
brainstem Lewy bodies. This mutation has been observed to increase Aβ42 production with little 
effect on Aβ40 (Eckman et al., 1997; Herl et al., 2009; De Jonghe et al., 2001; Theuns et al., 2006). 
Additionally, in iPSC models, APP V717I has been reported to alter neuronal APP subcellular 
localization, Aβ38 and sAPPβ generation, and tau expression and phosphorylation (Muratore et al., 
2014). The cell lines used in this thesis were derived from two patients not previously described in 
the literature. 
 
The PSEN1 L113_I114insT (int4del) mutation was first identified in two English individuals in 1998 
(Tysoe 1998). Subsequently, at least nine kindreds with the mutation have been identified, all from 
the British isles (Janssen et al., 2003; De Jonghe et al., 1999; Rogaeva et al., 2001; Sassi et al., 2014). 
The mutation is associated with a very young onset ranging between 34-41 years. PSEN1 int4del is 
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the result of the deletion of a single nucleotide (guanine) from the intron 4 splice donor site. This 
results in altered splicing and the production of two deletion transcripts and one insertion transcript. 
The deletion transcripts produce C-terminally truncated PSEN1 proteins, whilst the insertion 
transcript produces a full-length PSEN1 with one extra amino acid (threonine) inserted between 
codons 113 and 114. De Jonghe et al. have shown that only the product of the insertion transcript 
alters Aβ production in vitro (De Jonghe et al., 1999), where overall amyloidogenic processing of APP 
is increased (~2.5 fold) (Szaruga et al., 2015) and the ratio of Aβ42:40 is increased (De Jonghe et al., 
1999; Szaruga et al., 2015). Neuropathologically, PSEN1 int4del presents with typical amyloid 
plaques and NFTs, with considerable neuronal loss in the hippocampus. The cell line used in this 
thesis was derived from a patient not previously described in the literature. 
 
The PSEN1 Y115H point mutation was first identified in a French kindred (Campion et al., 1995), and 
subsequently a few more kindreds have been found from France (Campion et al., 1999), Germany 
(Finckh et al., 2005) and Great Britain. Age of onset occurs approximately between 35-47 years if age 
(Campion et al., 1995, 1999; Finckh et al., 2005), with a very aggressive disease course. 
Neuropathological presentation is of typical AD (Finckh et al., 2005). This mutation is associated with 
an increased Aβ42:40 ratio in both extracellular and intracellular compartments (Murayama et al., 
1999; Shioi et al., 2007), but an overall decrease in Aβ production as well as Notch cleavage 
(Sannerud et al., 2016), suggestive of broad γ-secretase loss of function. The cell line used in this 
thesis was derived from a patient not previously described in the literature. 
 
The PSEN1 M139V point mutation has been reported in at least nine families from the USA and 
Europe (Boteva et al., 1996; Clark et al., 1995; Finckh et al., 2000; Gómez-Isla et al., 1999; Hanisch 
and Kolmel, 2004; Hüll et al., 1998; Hutton et al., 1996; Larner and Du Plessis, 2003; Palmer et al., 
1999; Rippon et al., 2003; Sandbrink et al., 1996b; Żekanowski et al., 2003). Age of symptom onset 
occurs approximately between 32-60 years of age. Affected individuals present with atypical AD 
symptoms. Most cases have featured myoclonus and seizures often early in the disease course 
(Finckh et al., 2000; Fox et al., 1997; Hanisch and Kolmel, 2004; Hüll et al., 1998; Kennedy et al., 
1995; Sandbrink et al., 1996b), whilst speech disruption is also common, with a link to chromosome 
14 (Boteva et al., 1996; Kennedy et al., 1995). Neuropathology is consistent with AD, and formation 
of NFTs and neuronal loss are observed to occur relatively rapidly (Gómez-Isla et al., 1999). However, 
atypical plaque deposition has been described in at least one case, where plaques were prevalent in 
the occipital cortex and cerebellum in addition to the more typical temporal, parietal, frontal 
cortices (Larner and Du Plessis, 2003). Surprisingly, symptoms did not include myoclonus spastic 
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paraparesis, cerebellar signs, or gait disturbance in this case (Larner and Du Plessis, 2003). 
Biochemically, the mutation alters the carboxypeptidase-like activity of -secretase (Chávez-
Gutiérrez et al., 2012). The consequence of this is reported to be lowered production of A40 and 
A38 and increased A42 in several different cell models, (Chávez-Gutiérrez et al., 2012; Houlden et 
al., 2000; Murayama et al., 1999; Shioi et al., 2007). The cell line used in this thesis was derived from 
a patient not previously described in the literature. 
 
The PSEN1 M146I point mutations have been identified in a small number of British and Danish 
kindreds (Janssen et al., 2003; Jørgensen et al., 2008; Li et al., 2016; Lindquist et al., 2009). Two 
codon variants have been reported for the PSEN1 M146I missense point mutation (G>C (Lindquist et 
al., 2009), and G>A (Janssen et al., 2003). The average age of symptom onset range is given as 38-57 
years of age (Jørgensen et al., 2008; Lindquist et al., 2009). Neuropathology information is limited, 
but the mutation appears to manifest a typical EOAD phenotype (Goate et al., 1991; Lindquist et al., 
2009). In vitro cortical neurons of this genotype exhibit increased Aβ42/Aβ40 ratios (Moore et al., 
2015), as well as size, number and clustering of lysosomes, associated with increased concentrations 
of LAMP1 and a decrease in bidirectional lysosome motility (Hung and Livesey, 2018). The cell line 
used in this thesis was derived from a patient not previously described in the literature. 
 
The PSEN1 R278I point mutation was first identified in two members of a kindred with the onset of 
atypical AD symptoms occurring between 48-51 years of age (Godbolt et al., 2004). Symptoms were 
characterized by early language impairment, and relative preservation of episodic memory, MRI 
showed white matter lesions, but minimal atrophy, and clinical criteria for AD was not met. This 
mutation has been observed to impair the maturation of PSEN1, with decreased concentrations of 
the N-terminal fragment (NTF) and C-terminal fragment (CTF) (Saito et al., 2011). In vitro studies 
have shown that the carboxypeptidase-like activity of -secretase is uniquely impaired, resulting in 
favoured production of longer A peptides (Szaruga et al., 2015), especially A43 (Nakaya et al., 
2005; Saito et al., 2011) Some evidence suggests that AICD production may also be slightly impaired 
(Szaruga et al., 2015). The cell line used in this thesis was derived from a patient not previously 
described in the literature. 
 
This selection of fAD mutations represents a relatively large number in comparison with other 
studies that have investigated AD biomarkers in fAD patient cell lines, and reflects a mix of AD 
causing genotypes, with a weighting toward PSEN1 mutations. 
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8.1.1 Contributions 
The author designed the media collection protocol, cultured 2D iPSC neurons, collected cell media, 
cell lysates, conducted all immunoassays, conducted all statistical analyses and co-wrote the 
scientific report alongside C. Arber. Culture of 3D organoids and collection of media and lysates of 
these was conducted by C. Arber and C. Lovejoy. C. Arber conducted Western blotting, qPCR, and 
immunocytochemistry. E. Portelius and E. Gkanatsiou conducted IP MALDI TOF/TOF. 
 
Study conception: S. Wray, H. Zetterberg, JM. Schott, N. Fox. NS. Ryan. 
Sample collection: The author, C. Arber, C. Lovejoy, N. Willumsen. 
Experiment design: The author, C. Arber, S. Wray. 
Experiment: The author, C. Arber, E. Gkanatsiou, E. Portelius. 
Analysis: The author, C. Arber. 
Scientific report: C. Arber, The author, C. Lovejoy, NS. Ryan, RW. Paterson, N. Willumsen, E. 
Gkanatsiou, E. Portelius, K. Blennow, A. Heslegrave, JM. Schott, J. Hardy, T. Lashley, H. Zetterberg, S. 
Wray. 
 
8.2 Materials and methods 
 
8.2.1 Samples 
iPSC-derived cortical neurons used in these experiments were cultured for 100 days post-induction 
as described in Section 2.5. The cell lines used consisted of five control lines (CTRL1-4 and SHEF6), 
two APP V717I patient lines (APP V717I-1 and V717I-2), and five PSEN1 mutations with one patient 
line each (PSEN1 int4del, Y115H, M139V, M146I, R278I). APP V717I-1 and PSEN1 int4del each had 
two clones (APP V717I-1.1 and APP V717I-1.3, and PSEN1 int4del.4, PSEN1 int4del.6). Information 
for each cell line can be found in Table 5. 2D cell cultures were by myself and Dr C. Arber, and as 3D 
cerebral organoids by Dr C. Arber and Mr C. Lovejoy. 
 
8.2.2 Experimental methods 
Cell lines were characterised for neuronal markers by immunocytochemistry as described in Section 
2.11 and qPCR as described in Section 2.13. Primers used for qPCR are shown in Table 7. 
 
Cell media (N2B27) was collected from each well after 48 hours of incubation, centrifuged and 
aliquoted as described in Section 2.8. Immediately after the aspiration of media, cell lysates and RNA 
were collected from representative wells as described in Sections 2.9 and 2.10 respectively. At least 
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three inductions, representing biological replicates, were generated for each cell line. Cell media 
samples were analysed for Aβ38, Aβ40, and Aβ42 were measured by triplex MSD ECL immunoassay 
(Section 2.2.2). Analysis for the full spectrum of Aβ peptides was conducted by immunoprecipitation 
MADLI TOF/TOF by Dr E. Gkanatsiou and Dr E. Portelius (Section 2.18).  
 
APP expression, generation of APP proteolysis products, and PSEN1 protein expression in the cell 
lines were investigated by western blot (Section 2.16). 
 
8.2.3 Statistical analysis 
The use of seven fAD lines, together with five controls, represents sufficient statistical power for a 
false discovery rate of 0.2 (Germain and Testa, 2017). Data normality was assessed by histogram, qq-
plot and Shapiro-Wilk test. Spearman's rank correlation coefficient was conducted to assess the 
relationship between A ratios and age of onset, and Non-AD and fAD line A peptide spectra. Tests 
for significance were conducted by Mann Whitney U. Analysis was conducted in R, and graphs were 
composed using the ggplot2 package. 
 
8.2.4 Assay Variation 
Percent CV of intra- and inter-assay variability respectively were Aβ38 (4.7%, 13.3%), Aβ40 (5.9%, 
9.4%), Aβ42 (4.7%, 12.6%), Aβ43 (7.4%, 13.2%), T-tau (7.9%, 12.6%), calculated from concentrations 
of an internal control CSF sample. Intra- and inter-assay CV was calculated according to ISO 5725-2 
standards (British Standards Institution, 1994). 
 
8.3 Results 
 
8.3.1 Comparison of 2D and 3D model neurons 
Characterisation of iPSCs from both 2D and 3D cell lines confirmed expression of pluripotency 
markers (NANOG and SSEA4) in stem cell cultures (Figure 39A). 2D cultures expressed forebrain 
regional marker FOXG1 and radial glial marker pVIM at day 25 post-induction and expression of 
synaptic marker PSD95, cortical layer V marker CTIP2 and pan-neuronal marker TUJ1 at day 100 
post-induction (Figure 39A). Cerebral organoids were also confirmed to display forebrain 
specification via FOXG1 and neuronal commitment via TUJ1 at day 40 post induction (Figure 39A). It 
was not possible to maintain PSEN1 M139V to day 100 in 3D culture, and so 3D cell media is not 
represented in this analysis. Furthermore, Expression levels of cortical layer markers TBR1 and CTIP2 
and neuronal marker TUBB3 were quantified by qPCR for 2D lines (Figure 39B). Comparison of APP 
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protein expression between 2D, 3D and post-mortem tissue by western blotting, showed 
comparable expression of APP, with 3D organoids showing increased variability likely due to the 
increased cellular diversity and heterogeneity of this system. (Figure 39C).  
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Figure 38: Immunocytochemistry and protein expression in 2D and 3D cell lines 
Figure 39: A) Showing immunocytochemistry for each line used in comparison of an expanded set of Aβ peptide ratios between fAD genotypes and controls. NANOG and SSEA4 are markers of pluripotency, and 
denote undifferentiated stem cells. FOXG1 is a transcription factors that promote proliferation of the neuroectoderm and phosphor vimentin (pVIM) is a marker of mitotic m-phase radial glia. PSD95 is a 
synaptic protein of glutamatergic neurons. CTIP2 is a marker of layer V-III cortical neurons, and TUJ1 is an axonal marker. DAPI is a marker of nuclear protein. B) Expression levels of cortical layer markers TBR1 
and CTIP2 and neuronal marker TUBB3 quantified by qPCR. Number of independent neural inductions for each line is displayed in the histogram. C) Relative quantities of APP in 3D versus 2D cultures for each 
line. Numbers within histogram bars represent sample n. Work in 2D conducted by Dr C. Arber. Work in 3D conducted by Mr. C. Lovejoy. Images produced by Dr. C. Arber and used with permission.   
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8.3.2 Mutation-specific effects on APP cleavage, highlighting relative 
increments in A42 and A43 
When cell media was analysed for Aβ peptides by ECL and ELISA, 3D cultures closely followed the 
results of their 2D counterparts in the fAD lines, although greater variability between 3D and 2D 
control lines was observed. In both 2D and 3D cultures, A42:40 was increased in all fAD mutations, 
to approximately twice that of controls for most fAD lines (Figure 41A). The PSEN1 R278I mutation 
displayed the smallest increase in A42:40.  
 
A42:38, a putative biomarker for -secretase cleavage efficiency, was significantly increased in all 
PSEN1 mutation lines versus non-AD (Figure 41B). Specifically, PSEN1 int4del and PSEN1 Y115H 
demonstrated similar A42:38, whereas PSEN1 M139V, PSEN1 M146I and PSEN1 R278I exhibited 
decreasing changes versus non-AD. APP V717I mutant neurons also showed a small, yet significant, 
increase in A42:38.  
 
A38:40 is a proposed marker of -secretase cleavage pathway. Interestingly, this ratio was able to 
distinguish neuronal lines based on mutation status (Figures 41C and 35C). Compared to non-AD 
cells A38:40 was significantly increased in APP V717I, whilst in PSEN1 mutations the ratio was 
unchanged versus non-AD in PSEN1 Y115H, PSEN1 M146I and PSEN1 R278I, and decreased in PSEN1 
int4del, PSEN1 M139V. Once more results from 3D cultures closely aligned with those of 2D.  
 
Ratios of A43 to other A peptides have rarely been described in the literature. Results showed 
that in comparison to non-AD, all PSEN1 mutations, except PSEN1 M146I, demonstrated increased 
A43:40 (Figure 41D). The magnitude of increase in PSEN1 R278I is particularly noteworthy given the 
comparatively small degree of change in the A42:40 ratio we observed in this line, and the previous 
reports of elevated A43 in this mutation (Saito et al., 2011; Veugelen et al., 2016). APP V717I was 
not observed to differ from non-AD. Results for A42:43 and A38:43 generally mirror results for 
A38:40. These ratios compare products on the two cleavage product pathways (Figure 41C, E and F, 
see also Figure 3) where ratios were raised in APP V717I versus non-AD. This was not the case for 
PSEN1 mutations, where changes in A production pathway shift are not supported (Figure 41C, E 
and F).  
 
When A peptide ratios were compared with age of onset for each genotype, the A42:40 ratio 
showed negative correlation (Figure 40), depicting younger at of onset with higher A42:40 ratios. 
A43:40 showed a weak positive correlation (Figure 40), suggesting that A43 is less well correlated 
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to age of onset. Combining A42 and A43 relative to A40 and A38 did not enhance correlation, 
suggesting A42 shows the strongest link with age of onset. 
 
In summary, our panel of fAD iPSC-derived neurons display a series of mutation-specific alterations 
in the relative production of different A peptides, highlighting varied size and scale of changes in -
secretase endopeptidase and carboxypeptidase-like cleavage of APP. The APP V717I mutation 
specifically alters the endopeptidase cleavage pathway, with A38:40 and A42:43 results 
reinforcing the proposed shift in product lineages (Chávez-Gutiérrez et al., 2012). PSEN1 mutations 
lead to higher relative proportions of either A42 or A43 via reduced carboxypeptidase-like 
activity, and may implicate a role for A43 in AD pathogenesis. 
 
 
 
 
 
 
 
Figure 39: Correlation between age of onset and Aβ ratios in fAD neurons 
Figure 40: Analysis of age of onset correlation to Aβ ratios and Aβ secretome analysis by mass spectrometry infers mutation-specific 
differences of β/α/γ-secretase relative contribution. A-D) Mean ratio data for Aβ42:40 and Aβ43:40 were correlated with age of onset 
for each genotype. No statistical correlation is achieved with this sample size. 
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Figure 40: fAD neurons display mutation-specific A profile differences 
Figure 41: Conditioned media was collected at 100 days post-neuronal induction for analysis. Results from the ratios A) Aβ42:40, B) Aβ42:38, C) Aβ38:40, D) Aβ43:40, E) Aβ42:43, F) Aβ38:43 are displayed. 2D 
data was generated from multiple inductions per line, specifically APP V717I-1 clone 1 (n=7), APP V717I-1 clone 3 (n=3), APP V717I-2 (n=2), PSEN1 Int4del clone 4 (n=5), PSEN1 Int4del clone 6 (n=5), PSEN1 
Y115H (n=6), PSEN1 M139V (n=6), PSEN1 M146I (n=3), PSEN1 R278I (n=6).  Control data was generated from the following inductions: Ctrl 1 (n=5), Ctrl2 (n=6), Ctrl3 (n=7), Ctrl4 (n=6), and SHEF6 (n=4). 3D data 
consisted of two inductions of each line, except APP V717I-1 clone 3, SHEF6, and M139V for which no data is available. Significance levels: * = <0.05, ** = <0.01, *** = <0.001. 
2D Culture 3D Culture 
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8.3.3 Mass spectrometry highlights varied reduction in -secretase activity 
relative to other secretases as a result of fAD mutations  
To investigate the secretome of A peptides and to infer different activities of the -, - and -
secretases, MALDI TOF/TOF mass spectrometry was performed on A peptides immunoprecipitated 
from 2D iPSC-neuronal supernatants. Given that A profiles were consistent in 2D and 3D cultures, 
only media from 2D cultures were analysed. As demonstrated in Figure 35, using ratios of A 
peptides to A40 acts as an internal normalisation to represent the data, and therefore was utilised 
to probe the mass spectrometry data.  
 
Mass spectrometry confirmed the broad findings for relative amounts of A38/40/42 generated 
using the MSD immunoassay previously described, although A43 was not detectable with this 
method of analysis. A42:40 was significantly raised in all fAD mutations except PSEN1 R278I (Figure 
42A), which had been the mutation where this ratio was least altered in the immunoassay. A42:38 
was significantly increased versus non-AD in all PSEN1 mutations except PSEN1 Y115H (although a 
clear tendency for increase, proportional to the immunoassay results, was observed) and R278I 
where the level of significance in the immunoassay had once again been weak (Figure 42B). A38:40 
was significantly increased in the APP V717I line versus non-AD, unchanged versus non-AD in PSEN1 
Y115H, PSEN1 M146I and PSEN1 R278I, and decreased in PSEN1 int4del and M139V (Figure 42C), 
mirroring the immunoassay results.  
 
Moving beyond A38/40/42, mass spectrometry highlighted several interesting patterns among less 
well studied peptides. A39 ratios displayed a similar, though not identical, pattern to A38 whereby 
specifically APP V717I showed increased A39:40 relative to non-AD and PSEN1 mutant neurons 
(Figure 42D). A38 is often used as the final fragment in the A48>45>42>38 pathway, although 
A39 is reported as an alternative fragment generated from A42 (Matsumura et al., 2014). Aβ42:39 
was found to be raised significantly in a subset of PSEN1 mutant neurons as well as APP V717I versus 
non-AD (Figure 42E), complementing findings of A42:38 by MSD.  
 
No differences in Aβ37:40 were observed between non-AD and any fAD mutation (Figure 42F), 
indicating that the disease mechanism that results in impaired -secretase carboxypeptidase-like 
efficiency mainly affects the processing of longer A peptides, which is in line with the proposed 
mechanistic model for fAD (Szaruga et al., 2017). 
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Relative to the -secretase-dependent peptide A40, PSEN1 int4del neurons exhibited significantly 
raised levels of BACE1-BACE2 products (A19/20) and BACE1-BACE1/BACE2 products (A34) (Figure 
42G-I) (Yan et al., 2001; Shi et al., 2003; Bergstrom et al., 2016), as well as a non-significant skew 
toward increased - secretase products (A15/16) (Figure 42K-L), and A17, attributed to either -
secretase cleavage (Portelius et al., 2011) or endothelin-converting enzyme cleavage (Eckman et al., 
2001) (Figure 42J). Similarly, PSEN1 Y115H significantly increased BACE1--secretase products and 
displayed a tendency for increased BACE1-BACE2 products (Figure 42G-L). These effects were not 
evident in other fAD neurons, which displayed grossly similar secretomes to non-AD samples (Figure 
41).  
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Figure 42: Results from mass spectrometric analysis of cell media for Aβ peptides generated by A-F) BACE1 and γ-secretase activity G-I), BACE1 and BACE2 activity, and J-L) BACE1 and α-secretase activity 
normalised as ratios. Mean data was generated at day 100 from multiple independent inductions per line, specifically non-AD (n=10) consisting of pooled data of Ctrl1 (n=2), Ctrl2 (n=2), Ctrl3 (n=2), Ctrl4 (n=2) 
and Shef6 (n=2). fAD data was generated from the following, APP V717I-1 clone 1 (n=5), APP V717I-1 clone 3 (n=2), PSEN1 int4del clone 4 (n=2), PSEN1 int4del clone 6 (n=2), PSEN1 Y115H (n=2), PSEN1 M139V 
(n=2), PSEN1 M146I (n=2) and PSEN1 R278I (n=2). Significance levels: * = <0.05, ** = <0.01, *** = <0.001. 
Figure 41: Mutation specific differences of A secretomes from multiple proteolytic pathways 
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Figure 42: Mass spectrometry analysis of N-terminally truncated Aβ peptides 
Figure 43: Results from mass spectrometric analysis of cell media for N-terminally truncated Aβ 
peptides in ratio to Aβ40 A) Aβ2-40 generated by an alternative β-secretase cleavage. B-G) Aβ peptides 
N-terminally cleaved at Phe4 by unknown secretase activity. H-K) Aβ peptides N-terminally cleaved at 
Arg5 by unknown secretase activity L-Q) Ratios of peptides produced by β’-site cleavage followed by γ-
secretase cleavage. R) Ratio of Aβ11-42 and Aβ11-40, both produced by β’-site cleavage. Mean data 
was generated at day 100 from multiple independent inductions per line, specifically non-AD (n=10) 
consisting of pooled data of Ctrl1 (n=2), Ctrl2 (n=2), Ctrl3 (n=2), Ctrl4 (n=2) and Shef6 (n=2). fAD data 
was generated from the following, APP V717I-1 clone 1 (n=5), APP V717I-1 clone 3 (n=2), PSEN1 int4del 
clone 4 (n=2), PSEN1 int4del clone 6 (n=2), PSEN1 Y115H (n=2), PSEN1 M139V (n=2), PSEN1 M146I 
(n=2) and PSEN1 R278I (n=2). Significance levels: * = <0.05, ** = <0.01, *** = <0.001. 
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Finally, few results for N-terminally truncated A peptides ratios in fAD cell lines showed significant 
differences from non-AD. The exceptions to this were the APP V717I and PSEN1 M139V lines, which 
displayed increased A2-40:40 (p=0.01 and p=0.04 respectively), as well as decrease in A11-40:40 
(p=0.03) in PSEN1 M139V alone (Figure 43). In general, similar mutation-specific effects were seen 
for A11-x (generated by cleavage of APP at the Aβ’ site) as for the A1-x peptides that have so far 
been described e.g. a tendency for increased Aβ11-42:11-40 in the fAD lines were measurements 
were available (Figure 43R). This ratio has been previously reported to be increased in fAD, and it is 
speculated that such N-terminally truncated forms may be potently cytotoxic (Siegel et al., 2017). 
Why mutations directly affecting γ-secretase activity should influence β-secretase activity is unclear 
and further investigation of N-terminal truncations at the Aβ’ site with larger sample numbers would 
be desirable. 
 
Together these data show fAD mutation-dependent effects on APP proteolysis. Mass spectrometry 
data reinforce the findings that APP mutations alter endopeptidase cleavage and that PSEN1 
mutations reduce -secretase carboxypeptidase-like activity and. Additionally PSEN1 int4del and 
Y115H mutations appear to display a greater deficiency in -secretase activity than other PSEN1-
mutation bearing neurons, shown by an increase in - and -secretase-dependent products relative 
to -secretase-dependent peptides.  
 
8.3.4 -Secretase protein levels are altered in a subset of PSEN1 mutant 
lines 
PSEN1 mutations have been shown to alter -secretase stability (Szaruga et al., 2017; Wanngren et 
al., 2014), and so investigation of total PSEN1 protein levels was conducted using western blotting 
(Figure 44). Neurons harbouring the PSEN1 mutation R278I displayed a band at 40 kDa; relating to 
full length PSEN1 that has not undergone autocatalysis and maturation (Saito et al., 2011; Szaruga et 
al., 2015; Veugelen et al., 2016). As a result, this line exhibited reduced mature PSEN1 levels (Figure 
44B). Despite proper maturation, the PSEN1 mutations M139V and M146I showed a high degree of 
variability in PSEN1 protein levels. In a subset of neural inductions, PSEN1 levels were considerably 
lower than control neurons, however, this was inconsistent (Figure 44). PSEN1 int4del and Y115H 
lines showed consistent PSEN1 protein levels that were similar to APP V717I mutant neurons and 
non-AD lines (Figure 44A). 
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These data suggest that mature PSEN1 protein levels are variably altered when harbouring M139V, 
M146I or R278I amino acid substitutions. These lines showed A profiles that were most similar to 
control secretomes (Figure 42 and 43). The PSEN1 mutant lines that showed greatest reduction in -
secretase-dependent A peptides, int4del and Y115H, displayed PSEN1 protein levels similar to 
controls. These data suggest three alternative mechanisms behind PSEN1 partial loss of function, 
lack of PSEN1 protein maturation, lack of PSEN1 stability and reduced catalytic activity of -
secretase. 
 
8.4 Discussion 
In this study, we systematically investigated the production of A species using in vitro, patient-
derived stem cell models of fAD. The main finding was that different fAD mutations have 
qualitatively distinct effects on APP processing and A production by -secretase; affecting APP ε-
cleavage pathway and carboxypeptidase-like activity in different ways. Additionally, these results 
represent the first investigations into A43 and smaller A peptides in hiPSC neuronal models 
without overexpression. Finally, fAD mutation effects were shown to be consistent between 2D 
cortical neurons and 3D cerebral organoids. 
 
Figure 44: A) Representative western blot of 3 control neuron lysates and 6 fAD lysates. The asterisk depicts immature, full length 
PSEN1 protein at 40 kDa. Image produced by Dr C. Arber. B) Quantification of independent neuronal lysates, replicates are depicted 
by numbers within histogram. 
Figure 43: PSEN1 protein levels are variably altered in a subset of PSEN1 mutant neurons 
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The data presented offer a human neuronal validation of two hypotheses advocated by Chavez-
Gutierrez et al. (Chávez-Gutiérrez et al., 2012). Firstly, that pathogenic APP mutations favour 
increased -secretase A48>45>42>38 ε-cleavage. The concomitant increases in A38:40, A42:40, 
and A42:43 observed in APP V717I cells are consistent with this idea. Interestingly, this pattern 
extended to A39:40, A39 being the true tripeptide postcedent of A42 (Matsumura et al., 2014). 
Study of A39 has been largely limited to models of oligomerisation (Anand et al., 2008; Cloe et al., 
2011) and further investigation is called for. 
 
The second tenet substantiated by our data is that mutations in PSEN1 lead to inefficient -secretase 
carboxypeptidase activity. This predisposes neurons to the accumulation of longer A fragments, 
demonstrated by consistently increased A42:40 alongside increased A42:38 in PSEN1 mutation 
cell lines. The observed increase in A43:40 reinforces the idea of reduced carboxypeptidase 
efficiency on the A49>46>43>40 pathway, and it is interesting that different mutations seem to 
specifically effect one pathway or both. Reduced carboxypeptidase activity can be further explained 
by three distinct mechanisms. Firstly, reduced -secretase activity is suggested for PSEN1 int4del and 
Y115H lines, potentially due to their location near the substrate docking domain (Somavarapu and 
Kepp, 2016; Takagi-Niidome et al., 2015). Secondly, incomplete maturation of PSEN1 protein with 
R278I mutations leads to reduced levels of mature protein (Saito et al., 2011; Veugelen et al., 2016). 
Finally, PSEN1 M139V and M146I mutations lead to variably altered PSEN1 levels, consistent with 
altered protein stability (Szaruga et al., 2017; Wanngren et al., 2014) and supported by studies of 
PSEN1 abundance in brain tissue of early onset AD patients (Mathews et al., 2000; Verdile et al., 
2004). This variability in PSEN1 protein levels is likely to reduce the pool of functional -secretase 
enzyme. This finding demonstrates the advantage of using a more physiological model, such as iPSC-
derived neurons, as protein instability could explain why the pathogenic M139V protein shows close 
to wild-type biochemical enzyme kinetics (Chávez-Gutiérrez et al., 2012). Reduced carboxypeptidase 
activity is especially relevant given the recent suggestion that shorter A peptides may be 
protective, meaning reductions in A38 and A40 could lie behind certain PSEN1-associated 
pathology (Moore et al., 2018). It remains unclear why PSEN1 mutations affect the 
carboxypeptidase-like activity of -secretase without an apparent change to endopeptidase activity, 
but can be explained due to enzyme-substrate interaction destabilisation as proposed by Szaruga et. 
al. (2017). 
 
Three findings described by the data add to the complexities of the tripeptide hypothesis. Firstly, 
PSEN1 int4del and M139V mutations reduce A38:40, potentially suggesting alterations to the ε-
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cleavage pathway. It is important to note that altered -secretase efficiency between the two 
tripeptide pathways can also explain these findings. Secondly, APP V717I mutations may lead to 
small yet significant increases in A42:38 and A42:39, suggesting reduced carboxypeptidase activity 
in these neurons. Thirdly, A37:40 ratios were not significantly altered where this might have been 
expected in the PSEN1 lines, suggesting either that the effect of reduced -secretase 
carboxypeptidase-like efficiency may diminish beyond a focal point in the APP C-terminal sequence 
or that A37 is -secretase independent.  
 
Given the divergence of different phenotypes in different lines, the use of additional PSEN1 and APP 
lines in future work will provide added validation and potentially highlight further details. Larger 
studies may make it possible to correlate the functional outcome of the different APP processing 
defects to clinical symptoms. For example, whether mutations pre- and post-codon 200 of PSEN1 
could predict age of onset (Ryan et al., 2016). Despite limitations on patient numbers, our study 
represents one of the largest series of fAD lines, allowing a unique comparison of the effects of 
different mutations on the A secretome. 
 
8.5 Chapter summary 
Five control iPSC lines and seven iPSC lines generated from fAD patients were used to investigate the 
effects of mutation on the Aβ secretome of human neurons generated in 2D and 3D. All fAD 
mutation lines demonstrated an increased Aβ42:40 ratio relative to controls, yet displayed varied 
signatures for ratios of Aβ43, Aβ38 and short Aβ fragments. Four qualitatively distinct mechanisms 
behind raised Aβ42:40 are proposed. 1) APP V717I mutation alters γ-secretase ε-cleavage site 
preference. Whereas, distinct PSEN1 mutations lead to either 2) reduced γ-secretase activity, 3) 
altered protein stability or 4) reduced PSEN1 maturation, all culminating in reduced γ-secretase 
carboxypeptidase-like activity. These data support Aβ mechanistic tenets in a human physiological 
model and substantiate iPSC-neurons for modelling fAD. 
 
8.5.1 Publications arising from this work 
Charles Arber1§, Jamie Toombs1,2§, Christopher C. Lovejoy1, Natalie Ryan3, Ross W. Paterson3, Nanet 
Willumsen1,4, Eleni Gkanatsiou5, Erik Portelius5,6, Kaj Blennow5,6, Amanda Heslegrave1,2, Jonathan M. 
Schott3, John Hardy1,2, Tammaryn Lashley4, Nick C. Fox3, Henrik Zetterberg1,2,5,6± and Selina Wray1± 
Familial Alzheimer’s disease patient-derived neurons reveal distinct mutation-specific effects on 
amyloid-beta. Mol Psychiatry. 2019. 
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9 Discussion 
 
9.1 General overview 
The first chapter introduced the pathology of AD with focus on the molecular biology of Aβ. Aβ, 
alongside tau, has served as an important biomarker for the clinical diagnosis of AD, and the tenets 
of the amyloid cascade hypothesis have played a major role in guiding therapeutic development 
over the last two decades. Ultimately, drug trial successes have been few, and whilst progress has 
been made in biomarker-based identification of early AD pathology, issues in pre-analytical 
standardisation hold this methodology back from its potential. The overarching aim of this thesis 
was to improve the utility of Aβ as a biomarker of AD by identifying pre-analytical confounding 
factors affecting its measurement and investigating the production of different Aβ peptides in an in 
vitro fAD model.  
 
Taken together, work identified Aβ peptide surface absorption as a major pre-analytical confounding 
factor, specifically in terms of sample storage volume and the transfer of sample between different 
vessels. Aβ42 was particularly vulnerable to these variables, and the different propensities for 
different Aβ peptides to bind to certain surface materials was a key finding with important 
implications for clinical adoption of Aβ ratios. Strategies to mitigate these confounding factors 
identified the addition of 0.05% Tween 20 to samples and the standardisation of surface exposure as 
likely to be effective, with the latter being recommended. In the second phase of work, well-
established iPSC-derived glutamatergic cortical neuron models of fAD were used to investigate Aβ 
peptide production. Results identified the use of Aβ ratios as a strategy for overcoming between-
batch variability and assisting data interpretation. In a cohort of one of the largest range of fAD 
mutations to date, different fAD genotypes were shown to produce distinct ratios of Aβ peptides, 
supporting a growing understanding of APP proteolysis mechanisms that will inform dissection of 
past drug failure and future drug development. 
 
This chapter will summarise and discuss the data for each of the thesis aims.  
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9.2 Aim 1: Identify novel confounding factors in the storage 
and handling of CSF and cell culture media that may 
artificially alter detectable Aβ peptides 
In this thesis the following pre-analytical confounding factors were investigated in human lumbar 
CSF and cell culture media: sample storage volume, sample transfer between storage tubes, sample 
transfer through a manometer and pipette tips, sample pre-storage temperature, and sample 
transport method.  
 
The greatest effects, and therefore those most likely to bias Aβ biomarker measurement, were 
observed in factors where surface exposure was a common element. Prior to these experiments the 
effect of surface exposure on measurable Aβ concentration had received little attention beyond the 
impact of storage vessel material differences (Bjerke et al., 2010; Kofanova et al., 2015; Lewczuk et 
al., 2006a; Perret-Liaudet et al., 2012b, 2012a). Results showed that Aβ42 concentration decreased 
by approximately 1pg/mL for every 10μL decrease in sample storage volume in polypropylene tubes, 
potentially sufficient to mislead clinical diagnosis if Aβ42 concentrations border AD diagnostic cut-
points or if low volume samples were to be used. Furthermore, transfer of sample between 
sequential polypropylene storage tubes, in simulation of sample processing for storage or aliquoting 
for collaborative sharing, decreased Aβ42 concentration by approximately 20% of the initial 
concentration per iteration. This was also true of CSF Aβ passed through a K-resin manometer, 
although the effect size was considerably smaller (~5%). T-tau and P-tau concentrations were 
generally not affected by these conditions, and in polypropylene the effect on Aβ38 and Aβ40 was 
proportionally less than on Aβ42. These findings are of particular importance as ratios of Aβ42 to 
these other biomarkers are becoming increasingly relied on in diagnostic and research settings. 
Subsequent replication of these experiments by other groups verified the principle findings, 
although with a certain degree of variation in the details such as the effect size on different Aβ 
peptide ratios (Pica-Mendez et al., 2010; Vanderstichele et al., 2017; Willemse et al., 2017).  
 
One of the most interesting implications raised by these results is the possible effect different 
ratios/conformational seeds of Aβ may have on Aβ surface adsorption dynamics in fluid matrix. 
Combining data presented in this thesis showing different adsorption propensities of certain Aβ 
peptides, fAD genotype-dependent Aβ ratio profiles, and work from others presenting potential 
formation of genotype-biased fibril structures (Törnquist et al., 2018; Vandersteen et al., 2012), 
there may be important disease relevant Aβ peptide profiles or structures within samples that we 
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could be, but are not, detecting. Although still not well understood, Aβ monomers, oligomers, and 
fibrils adopt a range of conformations in solution, and indeed current models highlight the 
importance of C-terminal sequence for multimer stability and predict the presence of a laterally 
exposed hydrophobic ‘patch’ unique to certain Aβ42 fibrils  (Colvin et al., 2016; Wälti et al., 2016). 
These properties may contribute to differences observed in Aβ42 versus Aβ40 nucleation rate 
constants (Esbjörner et al., 2014; Meisl et al., 2014) and the range of adsorption dynamics at 
different polymer surfaces (Moores et al., 2011; Rocha et al., 2005). Assays capable of identifying 
concentrations of a wider range of Aβ peptides and aggregate structures could be valuable for 
identifying the nature of underlying disruption to APP proteolysis and so inform personalised 
treatment strategies for future patients.  
 
Strategies tested to mitigate the confounding effects of surface exposure were the addition of 0.05% 
Tween 20 to samples and protocol standardisation. Both approaches were found to be effective at 
reducing the impact of surface exposure on biomarker measurement in pre-analytical storage and 
handling. However, inclusion of non-ionic surfactant in samples in the early stages of collection and 
processing is undesirable in terms of potential interference with certain analytical techniques (e.g. 
mass spectrometry), and also for increasing the complexity to routine collection logistics. Use of 
Tween 20 as a sample additive was not found to provide additional benefit over careful 
standardisation of sample treatment. Furthermore, recent studies make a compelling case for the 
use of low bind storage tubes, which rely on surface texturing and hydrophilic polymer mixes to 
reduce protein binding to comparable effect without the same limitations. 
 
The effect of temperature and collection-storage interval on measurable concentrations of Aβ and 
tau in CSF have received considerable attention as part of the movement to improve sample 
handling practices in AD research temperature (Bibl et al., 2004; Bjerke et al., 2010; Ranganathan et 
al., 2006; Sancesario et al., 2010). In a ‘live’ clinical setting data presented in this thesis showed no 
significant difference between transporting samples at 4°C and ambient temperature in terms of 
Aβ42, T-tau, and P-tau concentration. Although the literature remains conflicted on this issue, these 
results converge with the work of  (Le Bastard et al., 2015; Bjerke et al., 2010; Simonsen et al., 2013) 
and support the appropriateness of current practices in a clinical biomarker setting. Furthermore, 
collection of cell media for the measurement of Aβ peptides does not appear to require any more 
stringent temperature control, though standardisation remains highly desirable. 
 
177 
 
Over the last 20 years, the investigation of pre-analytical confounding factors has developed into a 
credible subfield in AD biomarker research. Many aspects of the pre-analytical process have been 
identified as having the potential to influence biomarker measurement, and Aβ has been among the 
most vulnerable and best studied proteins. Hansson et al. recently published a proposal for the “gold 
standard” of CSF collection to be fresh CSF collected straight from the LP needle into a low binding 
tube, and analysed within 4 hours (stored at 20–25°C) without any further handling (Hansson et al., 
2018). This procedure limits the number of processing steps, while the use of low binding tubes 
mitigates binding of proteins to the tube walls in accordance with, and citing, the work presented 
here. It should be noted that a potential weakness of this is the lack of a centrifugation step to 
remove contaminating cell debris. Greater emphasis on mid-flow, low cell count CSF might be 
desirable, but this ultimately serves to highlight the difficulty in balancing known factors and the 
challenge of implementing best practice methods that still lies ahead. Finally, as new technologies 
develop to improve biomarker detection it is inevitable that new variables will arise to confound 
measurements and the need for data to guide standardisation seems unlikely to diminish.    
9.3 Aim 2: Investigate the physiological relevance of iPSC-
neurons by comparing Aβ peptide profiles in cell culture, 
CSF, and brain homogenate from a single patient with the 
APP V717I mutation. 
iPSC-derived cell types are an exciting technology for the understanding and therapeutics of disease. 
At the time of writing, and despite an explosion of work developing, characterising, and 
interrogating various cell types, the field is still in its infancy with only the merest scratch being made 
to the depth of its potential. However, the cash-value of this technology is the degree to which cells 
produced accurately model relevant in vivo systems and processes. To this end, much effort has 
been devoted to the molecular genetic and epigenetic control of the reprogramming and 
differentiation process, but hard comparisons between the model and the aspect of the living 
system it attempts to reflect have been extremely rare, especially in regard to the human brain. To 
date only one study has reported on the comparability of paired human neuronal culture and brain 
tissue, and concluded that differences in gene expression decreased as cultured neurons were 
matured in a non-neurodegenerative individual (Hjelm et al., 2013). This thesis presented a case 
study comparing Aβ peptide profiles in cortical neuron-, CSF-, and frontal cortex tissue-derived 
samples from the same individual with an APP V717I mutation.    
 
Results showed that soluble fraction ratios of Aβ42:40 secreted into culture media by iPSC-derived 
cortical neurons were similar to those found in the post-mortem brain homogenate of the same 
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individual. This is a promising suggestion that in vitro Aβ production usefully reflects that which 
occurs in vivo in a diseased state. That such a phenotype occurs in both developmentally young 
cultured neurons and aged neurons from an elderly individual is interesting, and further evidence 
that the symptomatic pathology of AD likely requires additional factors beyond the dysregulation of 
Aβ production. Aβ42:40 and Aβ42:38 were lower in the CSF than in the cell media, whilst Aβ38:40 
ratios were comparable. This data fit with the hypothesis that cultured neurons produce in vivo 
relevant ratios of Aβ peptides, but that Aβ42 in particular is sequestered in the brain parenchyma 
(attested by immunocytochemistry in this individual) and not efficiently cleared to the CSF. The 
available measurement of Aβ38:40 in soluble fraction brain homogenate did not match cell culture 
media and does not fit the interpretation presented above. There were limitations to the 
measurement of Aβ38 in this fraction that will require further work to address. Additionally, the 
insoluble brain fraction did not yield an expected high Aβ42:40 ratio, and it is possible that Aβ 
solubilisation was incomplete in these fractions. Thus results, though initially promising, should be 
treated as preliminary until Aβ extraction and solubilisation technique can be optimised. 
9.4 Aim 3: Investigate the full spectrum of Aβ peptides 
produced by glutamatergic cortical neurons from six 
different fAD lines and five non-neurodegenerative 
controls 
Sporadic and familial forms of AD share great pathological similarity, and better understanding of Aβ 
production, its modulation and impact on cell physiology in fAD is a promising route toward finding 
methods to control the disease. To this end, A peptide production was compared between iPSC-
derived cortical neurons from individuals with APP V717I, five PSEN1 mutations, and non-
neurodegenerative controls. An important finding was the ability of Aβ ratios to normalise variability 
over time and between different inductions of the same line. This enabled more robust 
interpretation of Aβ production in the different genotypes studied. Results were highly consistent 
with those reported for the same mutations by other groups (Chávez-Gutiérrez et al., 2012; Houlden 
et al., 2000; Moore et al., 2015; Muratore et al., 2014; Murayama et al., 1999; Nakaya et al., 2005; 
Saito et al., 2011; Shioi et al., 2007; Szaruga et al., 2015). Furthermore, investigation of a large panel 
of Aβ peptides by immunoassay and mass spectrometry identified production patterns that shed 
more light on the mechanisms behind AD-related APP proteolysis. Both APP V717I cell lines 
demonstrated a bias toward Aβ42 and Aβ38 relative to Aβ43 and Aβ40, consistent with a proposed 
dual pathway model of -secretase proteolysis termed the tripeptide hypothesis (Bolduc et al., 2016; 
Chávez-Gutiérrez et al., 2012; Matsumura et al., 2014; Takami et al., 2009). Study of additional 
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peptides suggested that Aβ39 may be on the Aβ48 pathway, but C-terminal cleavage pathway 
distinctions broke down at Aβ37. PSEN1 mutations shared some Aβ peptide profile similarities but 
differed in certain other aspects (e.g. degree of Aβ43 over-production in PSEN1 R278I). These 
mutations all decreased -secretase activity, resulting in over-production of C-terminally longer 
peptides relative to more C-terminally truncated peptides, and consistent with a partial loss of 
function paradigm for -secretase in fAD (Chávez-Gutiérrez et al., 2012; Szaruga et al., 2015; 
Woodruff et al., 2013). Together these results offer evidence to support a burgeoning model of APP 
proteolysis mechanisms and suggest new understanding of Aβ peptide ratio profiles as biomarkers 
for y-secretase activity, which could have utility if y-secretase modulator therapy is pharmaceutically 
revisited. Finally, these data provide a platform to support exciting new work testing the hypothesis 
that nuances in the relationship between the presence of different Aβ peptides combinations may 
be more or less toxic and guide more effective therapeutics for AD (Moore et al., 2018).  
 
9.5 Future directions 
Over the course of work, it became clear that certain lines of enquiry would benefit from further 
exploration beyond the limits of the project, and a number of tangential questions were also raised.  
One question that emerged from the method standardisation phase of the project was: can surface 
adsorption be used to identify toxic Aβ structures and kinetics? Work demonstrated differential 
propensity for certain Aβ peptides to bind to storage vessel surfaces, and an extensive literature 
documents the variety and disease relevance of certain oligomeric and fibrillar Aβ forms. Despite the 
improvements to Aβ measurement lo-bind tubes provide, it might prove interesting to examine 
surface adsorbed Aβ from CSF and blood in the context of distinguishing AD patient categories. 
 
Regarding Aβ biomarker development in vitro, although the number of fAD mutations studied in 
vitro was comparatively large in the context of the current literature, to validate findings further it 
would be desirable to include others, particularly more APP mutations and sAD lines, and increase 
the number of individuals of each genotype. A comprehensive catalogue of Aβ production profiles by 
genotype could help identify common patterns between mutations that could guide therapeutic 
strategy, and delineate how Aβ production and clearance mechanisms differ between fAD lines and 
sAD lines. 
 
A further step in this line of enquiry is to explore the relationship between Aβ production ratios and 
the physiological function, and dysfunction, in human neuronal culture. Building on groundwork laid 
in this thesis, a key experiment to conduct in this vein is the comparison of electrophysiology and 
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calcium signalling between fAD, sAD, and control neurons. Furthermore, testing the effect of Aβ 
profile ‘correction’ by -secretase modulators or peptide specific antibodies on these functional 
readouts would be of great interest. 
 
Along similar lines, adding to the number of individuals with paired biomaterials would be extremely 
valuable for assessing the wider validity of our case study’s results. Optimisation of the Aβ 
solubilisation procedure is also needed. A major limitation was the lack of a positive control for 
insoluble Aβ recovery. Future experiments will require this to ensure complete Aβ solubility is 
achieved.  
 
9.6 Conclusion 
The principle conclusion of this work is that Aβ peptides have great potential as biomarkers in the 
basic science and diagnostic settings of neurodegenerative disease research, particularly that of AD. 
This thesis contributed to the improved use of Aβ as a diagnostic biomarker for AD. Aβ peptides, 
more so than tau, are vulnerable to a number of pre-analytical variables which can influence its use 
and quality as a biomarker for AD. Innate biophysical properties predispose Aβ peptides to 
adsorption to various surfaces at unequal rates, which is likely to be a highly pertinent consideration 
for biobanking and trial initiatives, and can be mitigated by specific treatment and standardisation of 
storage surfaces. Additionally, this thesis contributed to knowledge of Aβ peptide production in 
different fAD mutations and proposed the expanded understanding of Aβ as a biomarker for γ-
secretase activity. The use of Aβ peptide ratios were identified as a practical method for overcoming 
issues of variability in an in vitro culture model of fAD. Furthermore, Aβ production in this model was 
found to have interesting comparability with Aβ from other anatomical compartments of the same 
subject. 
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